US11053243B2 - Inhibitors of hepatitis C virus replication - Google Patents

Inhibitors of hepatitis C virus replication Download PDF

Info

Publication number
US11053243B2
US11053243B2 US16/829,878 US202016829878A US11053243B2 US 11053243 B2 US11053243 B2 US 11053243B2 US 202016829878 A US202016829878 A US 202016829878A US 11053243 B2 US11053243 B2 US 11053243B2
Authority
US
United States
Prior art keywords
group
alkyl
independently chosen
mmol
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/829,878
Other versions
US20200262836A1 (en
Inventor
Craig A. Coburn
Steven W. Ludmerer
Kun Liu
Hao Wu
Richard Soil
Bin Zhong
Jian Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Apptec Shanghai Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/028653 external-priority patent/WO2010111483A1/en
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Priority to US16/829,878 priority Critical patent/US11053243B2/en
Assigned to MERCK SHARP & DOHME CORP reassignment MERCK SHARP & DOHME CORP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WUXI APPTEC (SHANGHAI) CO., LTD.
Assigned to WUXI APPTEC (SHANGHAI) CO., LTD. reassignment WUXI APPTEC (SHANGHAI) CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLL, RICHARD, WU, HAO, ZHONG, BIN, ZHU, JIAN
Assigned to MERCK SHARP & DOHME CORP reassignment MERCK SHARP & DOHME CORP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, KUN, LUDMERER, STEVEN W., COBURN, CRAIG A.
Publication of US20200262836A1 publication Critical patent/US20200262836A1/en
Priority to US17/324,799 priority patent/US20220356182A1/en
Publication of US11053243B2 publication Critical patent/US11053243B2/en
Application granted granted Critical
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to antiviral compounds that are useful as inhibitors of hepatitis C virus (HCV) replication.
  • the compounds are expected to act on HCV NS5A (non-structural 5A) protein.
  • Compositions comprising such compounds, the use of such compounds for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, methods for inhibiting the function of the NS5A non-structural protein, and methods for inhibiting HCV viral replication and/or viral production are also provided.
  • HCV infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals.
  • Current treatments for HCV infection include immunotherapy with recombinant interferon- ⁇ alone or in combination with the nucleoside-analog ribavirin.
  • RNA-dependent RNA polymerase RNA-dependent RNA polymerase
  • HCV NS5A non-structural protein which is described, for example, in Seng-Lai Tan & Michael G. Katze, How Hepatitis C Virus Counteracts the Interferon Response: The Jury Is Still Out on NS 5 A, 284 V IROLOGY 1-12 (2001); and in Kyu-Jin Park et al., Hepatitis C Virus NS 5 A Protein Modulates c - Jun N - terminal Kinase through Interaction with Tumor Necrosis Factor Receptor - associated Factor 2, 278(33) J. B IO . C HEM . 30711 (2003).
  • a non-structural protein, NS5A is an essential component for viral replication and assembly.
  • the present disclosure relates to novel compounds of formula (I) and/or pharmaceutically acceptable salts, hydrates, solvates, prodrugs or isomers thereof. These compounds are useful, either as compounds or their pharmaceutically acceptable salts (when appropriate), in the inhibition of HCV (hepatitis C virus) NS5A (non-structural 5A) protein, the prevention or treatment of one or more of the symptoms of HCV infection, the inhibition of HCV viral replication and/or HCV viral production, and/or as pharmaceutical composition ingredients.
  • HCV hepatitis C virus
  • NS5A non-structural 5A
  • these compounds which includes reference to hydrates and solvates of such compounds, and their salts may be the primary active therapeutic agent, and, when appropriate, may be combined with other therapeutic agents including but not limited to other HCV antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
  • R 1 and R 2 may be taken together with
  • each D is a group independently chosen from the group consisting of:
  • each G is independently chosen from the group consisting of:
  • the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
  • the present invention further includes methods of treating or reducing the likelihood or severity of HCV infection, methods for inhibiting the function of the NS5A protein, and methods for inhibiting HCV viral replication and/or viral production.
  • the present invention includes compounds of formula (I) above, and pharmaceutically acceptable salts thereof.
  • the compounds of formula (I) are HCV NS5A inhibitors.
  • a first embodiment of the invention relates to compounds having structural formula (I):
  • R 1 and R 2 may be taken together with
  • each E is a group independently chosen from the group consisting of:
  • each G is independently chosen from the group consisting of:
  • each R 1 is independently chosen from the group consisting of hydrogen, halogen, —OR 3a , —CN, —C(O)R 3 , —CO 2 R 3a , —C(O)N(R 3a ) 2 , —SR 3a , —S(O)R 3a , —S(O 2 )R 3a , —(CH 2 ) 0-6 N(R 3a ) 2 , —N(R 3a )SO 2 R 3a , —N(R 3a )CO 2 R 3a , —N(R 3a )C(O)R 3 , —N(R 3a )COR 3a , —N(R 3a )C(O)N(R 3a ), C 1-6 alkyl, C 3-8 carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C 1-6 alkyl, C 3-8 carbocycle and phen
  • R′ is substituted by from 0 to 3 additional R′, which are as provided above.
  • R 1 is substituted by from 0 to 3 additional R 1 , which are as provided above.
  • R 1 is substituted by from 0 to 3 additional R 1 , which are as provided above.
  • each R 1 is chosen from the group consisting of hydrogen, halogen, —CN and C 1-6 alkyl.
  • each R 1 is chosen from the group consisting of hydrogen, fluorine and —CN.
  • each R 2 is independently chosen from the group consisting of hydrogen, halogen, —OR 4a , —CN, —CO 2 R 4a , —C(O)N(R 4a ) 2 , —N(R 4a ) 2 , —N(R 4a )CO 2 R 4a , —SR 4a , —S(O)R 4a , —S(O 2 )R 4a , —N(R 4a )SO 2 R 4a , —N(R 4a )CO 2 R 4a , —N(R 4a )CO 2 R 4a , —C ⁇ C—, phenyl, pyridinyl, pyrazinyl, pyrimidyl, 1,2,4-triazinyl, pyridazinyl, thiazyl and 9-membered bicyclic ring systems that contain from 1 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
  • each R 2 is independently chosen from the group consisting of fluorine, chlorine, —OH, —CH 3 , —OCH 3 and —CN.
  • all other groups are as provided in the general formula above and/or in the first or second embodiments.
  • W is chosen from the group consisting of —(CH 2 ) 1-3 —, —(CH 2 ) 0-2 NH(CH 2 ) 0-2 —, —(CH 2 ) 0-2 N(C 1-6 alkyl)(CH 2 ) 0-2 —, —(CH 2 ) 0-2 O(CH 2 ) 0-2 — and —(CH 2 ) 0-2 C(O)(CH 2 ) 0-2 —, where W is substituted by from 0 to 4 R w , where each R w is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; and V is chosen from the group consisting of —C(O)— and —CH 2 —, and where V is —CH 2 —, V is substituted by from 0 to 2 R v , where each R v is independently selected from the group consisting of C 1-6 alkyl and C 3-8 cycloalkyl.
  • W is chosen from the group consisting of —CH 2 —, —NH—, —N(C 1-6 alkyl)-, —C(O)—, —CH 2 NH—, —CH 2 N(C 1-6 alkyl)-, —CH 2 CH 2 —, —C(O)CH 2 —, —CH 2 C(O)—, —CH 2 O—, —CH 2 CH 2 CH 2 —, —C(O)CH 2 CH 2 —, —CH 2 C(O)CH 2 —, —CH 2 OCH 2 —, —CH 2 CH 2 C(O)—, —CH 2 CH 2 O—, —CH 2 CH 2 NH—, —CH 2 CH 2 N(C 1-6 alkyl)-, —CH 2 NHCH 2 —, —CH 2 N(C 1-6 alkyl)CH 2 —, —NHCH 2 CH 2 —, and ——CH 2 CH 2 NH—, —CH 2 CH 2
  • each D is independently chosen from the group consisting of a single bond, —C(O)N(R 5 )—, —NR 5 C(O)—,
  • R 5 is independently chosen from the group consisting of hydrogen, halogen —OR 6 , —CN, —CO 2 R 6 , —C(O)N(R 6 ) 2 , —N(R 6 ) 2 , —N(R 6 )COR 6 , —SR 6 , —S(O)R 6 , —S(O 2 )R 6 , —N(R 6 )SO 2 R 6 , —NCO 2 R 6 , —NC(O)N(R 6 ) 2 , C 1-6 alkyl substituted by from 0 to 3 substituents R 6 and C 3-8 cycloalkyl substituted by from 0 to 3 substituents R 6 , and each R 6 is independently chosen from the group consisting of hydrogen, C 1-6 alkyl and C 3-8 cycloalkyl.
  • each D is independently chosen from the group consisting of hydrogen, C 1-6 alkyl and C 3-8 cycloalkyl.
  • each D is independently chosen
  • each E is independently chosen from the group consisting of a single bond, —CH 2 NHC(O)—, —CH 2 N(CH 3 )C(O)—, —C(CH 3 )HNHC(O)—, —C(CH 3 )HN(CH 3 )C(O)—, —C(CH 3 ) 2 NHC(O)—, —C(CH 3 ) 2 N(CH 3 )C(O)—, —CH 2 NHC(O)O—, —CH 2 N(CH 3 )C(O)O—, —C(CH 3 )HNHC(O)O—, —C(CH 3 )HN(CH 3 )C(O)O—, —C(CH 3 ) 2 NHC(O)O—, —C(CH 3 ) 2 NHC(O)O—, —C(CH 3 ) 2 NHC(O)O—, —C(CH 3 ) 2 NHC(O)O—,
  • each E is independently chosen from the group consisting of a single bond
  • adjacent D and E groups each may be selected to be a single bond.
  • D and E are combined to be one single bond, and all other groups are as provided in the general formula above and/or in the first, second, third and fourth embodiments. That is, where D is a single bond and the adjacent E is a single bond,
  • each G is independently chosen from the group consisting of:
  • G is independently chosen from the group consisting of C 1-4 alkyl having 1 to 2 substituents R 11 , wherein each R 11 is independently chosen from the group consisting of —OH, —NH 2 , —NCH 3 H, —N(CH 3 ) 2 , —N(CH 2 CH 3 ) 2 , —C(O)OCH 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl.
  • G is chosen such that stable compounds result.
  • all other groups are as provided in the general formula above and/or in the first through sixth embodiments.
  • each R 1 is independently chosen from the group consisting of hydrogen, halogen, —OR 3a , —CN, —C(O)R 3 , —CO 2 R 3a , —C(O)N(R 3a ) 2 , —SR 3a , —S(O)R 3a , —S(O 2 )R 3a , —(CH 2 ) 0-6 N(R 3a ) 2 , —N(R 3a )SO 2 R 3a , —N(Z 3a )CO 2 R 3a , —N(Z 3a )C(O)R 3 , —N(R 3a )COR 3a , —N(R 3a )C(O)N(R 3a ), C 1-6 alkyl, C 3-8 carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C 1-6 alkyl, C 3-8 carbocycle and phen
  • each R 3a is independently chosen from the group consisting of hydrogen, C 1-6 alkyl and C 3-8 cycloalkyl;
  • —C ⁇ C— phenyl, pyridinyl, pyrazinyl, pyrimidyl, 1,2,4-triazinyl, pyridazinyl, thiazyl and 9-membered bicyclic ring systems that contain from 1 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
  • each R 2 is independently chosen from the group consisting of hydrogen, halogen, —OR 4a , —CN, —CO 2 R 4a , —C(O)N(R 4a ) 2 , —N(R 4a ) 2 , —N(R 4a )CO 2 R 4a , —SR 4a , —S(O)R 4a , —S(O 2 )R 4a , —N(R 4a )SO 2 R 4a , —N(R 4a )CO 2 R 4a , —N(R 4a )C(O)N(R 4a ), C 1-6 alkyl substituted by from 0 to 4 R 4 and C 3-8 cycloalkyl substituted by from 0 to 4 R 4 ,
  • each R 4 is independently chosen from the group consisting of hydrogen, —OH, C 1-6 alkyl and C 3-8 cycloalkyl, and
  • each R 4a is independently chosen from the group consisting of hydrogen, C 1-6 alkyl and C 3-8 cycloalkyl;
  • each D is independently chosen from the group consisting of a single bond, —C(O)N(R 5 )—, —NR 5 C(O)—,
  • each G is independently chosen from the group consisting of
  • aryl ring systems G′ chosen from the group consisting of: phenyl, pyridinyl and 9-membered bicyclic ring systems containing from 0 to 2 heteroatoms independently chosen from the group consisting of N and O.
  • all other groups are as provided in the general formula above.
  • R 1 is substituted by from 0 to 3 additional R 1 ;
  • each E is independently chosen from the group consisting of a single bond
  • the compound having structural formula (Ia) is a compound having structural formula (Ib):
  • Y is selected from the group consisting of O and NR 1 .
  • the compound having structural formula (Ia) is a compound having structural formula (Ib):
  • V is —CH 2 —
  • W is —(CH 2 ) 0-2 O(CH 2 ) 0-2 —
  • R 1 is fluorine
  • both instances of G are
  • W is chosen from the group consisting of —(CH 2 ) 1-3 —, —(CH 2 ) 0-2 NH(CH 2 ) 0-2 —, —(CH 2 ) 0-2 N(C 1-6 alkyl)(CH 2 ) 0-2 —, —(CH 2 ) 0-2 O(CH 2 ) 0-2 — and —(CH 2 ) 0-2 C(O)(CH 2 ) 0-2 —, where W is substituted by from 0 to 4 R w , where each R w is independently selected from C 1-6 alkyl and C 3-8 cycloalkyl; and
  • V is chosen from the group consisting of —C(O)— and —CH 2 —, and where V is —CH 2 —, V is substituted by from 0 to 2 R v , where each R v is independently selected from the group consisting of C 1-6 alkyl and C 3-8 cycloalkyl;
  • each R 2 is independently chosen from the group consisting of hydrogen, halogen, —OR 4a , —CN, —CO 2 R 4a , —C(O)N(R 4a ) 2 , —N(R 4a ) 2 , —N(R 4a )CO 2 R 4a , —SR 4a , —S(O)R 4a , —S(O 2 )R 4a , —N(R 4a )SO 2 R 4a , —N(R 4a )CO 2 R 4a , —N(R 4a )C(O)N(R 4a ), C 1-6 alkyl substituted by from 0 to 4 R 4 and C 3-8 cycloalkyl substituted by from 0 to 4 R 4 ,
  • aryl ring systems G′ chosen from the group consisting of: phenyl, pyridinyl and 9-membered bicyclic ring systems containing from 0 to 2 heteroatoms independently chosen from the group consisting of N and O.
  • all other groups are as provided in the general formula above.
  • the compound of the invention is selected from the exemplary species depicted in Examples 1 through 215 shown below, or pharmaceutically acceptable salts thereof.
  • composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.
  • HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
  • HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
  • HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
  • a method of inhibiting HCV NS5A activity in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
  • the present invention also includes a compound of the present invention for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inhibiting HCV NS5A activity, or (b) treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, or (c) inhibiting HCV viral replication and/or HCV viral production in a cell-based system, or (d) use in medicine.
  • the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(o) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above.
  • the compound may optionally be used in the form of a pharmaceutically acceptable salt, or may be present in the form of a solvate or hydrate as appropriate.
  • alkyl refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range.
  • C 1-6 alkyl refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl and methyl.
  • C 1-4 alkyl refers to n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl and methyl.
  • halogenated refers to a group or molecule in which a hydrogen atom has been replaced by a halogen.
  • haloalkyl refers to a halogenated alkyl group.
  • halogen refers to atoms of fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo), preferably fluorine.
  • Aryl ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached. Unless otherwise indicated, substituents to the aryl ring systems can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.
  • carrier refers to (i) a C 5 to C 7 monocyclic, saturated or unsaturated ring, or (ii) a C 8 to C 10 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated. Carbocycle groups may be substituted as indicated. When the carbocycles contain one or more heteroatoms independently chosen from N, O and S, the carbocycles may also be referred to as “heterocycles,” as defined below.
  • heterocycle broadly refers to (i) a stable 5- to 7-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 8- to 10-membered bicyclic ring system, wherein each ring in (ii) is independent of, or fused to, the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) independently selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the bicyclic ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quatern
  • heteroaryl ring system refers to aryl ring systems, as defined above, that include from 1 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S.
  • heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl and benzo-1,3-dioxolyl.
  • alkyl, cycloalkyl, and aryl groups are not substituted. If substituted, preferred substituents are selected from the group that includes, but is not limited to, halo, C 1 -C 20 alkyl, —CF 3 , —NH 2 , —N(C 1 -C 6 alkyl) 2 , —NO 2 , oxo, —CN, —N 3 , —OH, —O(C 1 -C 6 alkyl), C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 alkyl) S(O) 0-2 —, aryl-S(O) 0-2 —, (C 0 -C 6 alkyl)S(O) 0-2 (C 0 -C 6 alkyl)C(O)NH
  • heteroaryl ring described as containing from “0 to 3 heteroatoms” means the ring can contain 0, 1, 2, or 3 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. The oxidized forms of the heteroatoms N and S are also included within the scope of the present invention.
  • any variable for example, R 1 or R 3
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a “stable” compound is a compound that can be prepared and isolated and that has a structure and properties that remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
  • Isotopically-enriched compounds within generic formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
  • certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
  • a reference to a compound of formula (I) is a reference to the compound per se, or to any one of its tautomers per se, or to mixtures of two or more tautomers.
  • the compounds of the present invention may be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt that possesses the effectiveness of the parent compound and that is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • administration and variants thereof (e.g., “administering” a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment.
  • administration and its variants are each understood to include concurrent and sequential provision of the compound or salt (or hydrate) and other agents.
  • composition is intended to encompass a product comprising the specified ingredients, as well as any product that results, directly or indirectly, from combining the specified ingredients.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • the term also includes herein the amount of active compound sufficient to inhibit HCV NS5A and thereby elicit the response being sought (i.e., an “inhibition effective amount”).
  • an “inhibition effective amount” When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for identifying resistant HCV replicon cell lines harboring mutations within NS5A, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to the HCV replicase.
  • the compounds of the present invention can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by one or more conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the compounds of the invention can, for example, be administered by one or more of the following: orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation (such as in a spray form), or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
  • Liquid preparations suitable for oral administration e.g., suspensions, syrups, elixirs and the like
  • Solid preparations suitable for oral administration can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like.
  • Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids.
  • injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 18 th edition (ed. A. R. Gennaro, Mack Publishing Co., 1990).
  • the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
  • mammal e.g., human
  • One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
  • Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
  • the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the present invention also relates to a method of inhibiting HCV replicon activity, inhibiting HCV viral replication and/or HCV viral production, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent.
  • Such therapeutic agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha-1, R7025 (an enhanced interferon (Roche)), interferon- ⁇ , interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
  • the combination of peginterferon- ⁇ and ribaviron represents the current Standard of Care for HCV treatment.
  • Interferon- ⁇ includes, but is not limited to, recombinant interferon- ⁇ 2a (such as R OFERON interferon), pegylated interferon- ⁇ 2a (P EGASYS ), interferon- ⁇ 2b (such as I NTRON -A interferon), pegylated interferon- ⁇ 2b (P EG I NTRON ), a recombinant consensus interferon (such as interferon alphacon-1), albuferon (interferon- ⁇ bound to human serum albumin (Human Genome Sciences)), and a purified interferon- ⁇ product.
  • interferon- ⁇ 2a such as R OFERON interferon
  • P EGASYS pegylated interferon- ⁇ 2a
  • interferon- ⁇ 2b such as I NTRON -A interferon
  • P EG I NTRON pegylated interferon- ⁇ 2b
  • a recombinant consensus interferon such as interferon alpha
  • Amgen's recombinant consensus interferon has the brand name I NFERGEN .
  • Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin.
  • Viramidine represents an analog of ribavirin disclosed in International Patent Application Publication WO 01/60379.
  • the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH).
  • IMPDH inosine monophosphate dehydrogenase
  • Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH.
  • inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication.
  • the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as those disclosed in International Patent Application Publications WO 97/41211, WO 01/00622 and WO 00/25780; or mycophenolate mofetil. See Anthony C. Allison and Elsie M. Eugui, Immunosuppressive and Other Anti - Rheumetic Activities of Mychophenolate Mofetil, 44 (S UPPL .) A GENTS A CTION 165 (1993).
  • an inhibitor of IMPDH such as those disclosed in International Patent Application Publications WO 97/41211, WO 01/00622 and WO 00/25780; or mycophenolate mofetil. See Anthony C. Allison and Elsie M. Eugui, Immunosuppressive and Other Anti - Rheumetic Activities of Mychophenolate Mofetil, 44 (S UPPL .) A GENTS A CTION 165 (1993).
  • the compounds of the present invention may also be administered in combination with the antiviral agent polymerase inhibitor R7128 (Roche).
  • the compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 2′-C-branched ribonucleosides disclosed in Rogers E. Harry-O'Kuru et al., A Short, Flexible Route to 2′- C - Branched Ribonucleosides, 62 J. O RG . C HEM . 1754-59 (1997); Michael S. Wolfe and Rogers E. Harry-O'Kuru, A Consise Synthesis of 2′- C - Methylribonucleosides, 36 T ET . L ETT . 7611-14 (1995); U.S. Pat. No.
  • Such 2′-C-branched ribonucleosides include, but are not limited to, 2′-C-methyl-cytidine, 2′-C-methyl-uridine, 2′-C-methyl-adenosine, 2′-C-methyl-guanosine, and 9-(2-C-methyl- ⁇ -D-ribofuranosyl)-2,6-diaminopurine, and the corresponding amino acid ester of the ribose C-2′, C-3′, and C-5′ hydroxyls and the corresponding optionally substituted cyclic 1,3-propanediol esters of the 5′-phosphate derivatives.
  • the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease.
  • HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication.
  • Exemplary substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in International Patent Application Publications WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, WO 02/48116, WO 02/48172, WO 2008/057208 and WO 2008/057209, in British Patent No. GB 2 337 262, and in U.S. Pat. Nos.
  • the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NSSB polymerase.
  • HCV NSSB polymerase inhibitors that may be used as combination therapy include, but are not limited to, those disclosed in International Patent Application Publications WO 02/057287, WO 02/057425, WO 03/068244, WO 2004/000858, WO 04/003138 and WO 2004/007512; U.S. Pat. Nos. 6,777,392, 7,105,499, 7,125,855, 7,202,224 and U.S. Patent Application Publications US 2004/0067901 and US 2004/0110717; the content of each is incorporated herein by reference in its entirety.
  • Other such HCV polymerase inhibitors include, but are not limited to, valopicitabine (NM-283; Idenix) and 2′-F-2′-beta-methylcytidine (see also WO 2005/003147).
  • the compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in U.S. Patent Application Publications US 2006/0100262 and US 2009-0048239; International Patent Application Publications WO 01/77091, WO 01/47883, WO 02/04425, WO 02/06246, WO 02/20497, WO 2005/016927 (in particular JTK003), WO 2004/041201, WO 2006/066079, WO 2006/066080, WO 2008/075103, WO 2009/010783 and WO 2009/010785; the content of each is incorporated herein by reference in its entirety.
  • non-nucleoside HCV NSSB polymerase inhibitors that are used in combination with the present HCV NS5A inhibitors are selected from the following compounds: 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-(2-morpholin-4-ylethyl)-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-3-methoxy-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-3
  • HCV replicons and NS5A inhibitory activity of the present compounds may be tested using assays known in the art.
  • HCV inhibitors such as those described in the Examples herein have activities in genotype 1b, 2a and 1a replicon assays of from about 1 pM to about 1 ⁇ M.
  • the assay is performed by incubating a replicon harboring cell-line in the presence of inhibitor for a set period of time and measuring the effect of the inhibitor on HCV replicon replication either directly by quantifying replicon RNA level, or indirectly by measuring enzymatic activity of a co-encoded reporter enzyme such as luciferase or ⁇ -lactamase.
  • a co-encoded reporter enzyme such as luciferase or ⁇ -lactamase.
  • the effective inhibitory concentration of the inhibitor (EC 50 or EC 90 ) is determined. See Jan M. Vrolijk et al., A replicons - based bioassay for the measurement of interferons in patients with chronic hepatitis C, 110 J. V IROLOGICAL M ETHODS 201 (2003). Such assays may also be run in an automated format for high through-put screening. See Paul Zuck et al., A cell - based ⁇ - lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication, 334 A NALYTICAL B IOCHEMISTRY 344 (2004).
  • the synthesis of analogs containing the 4-azaindole core can be accomplished starting from a suitably protected 2-amino-5-nitropyridine 2, which can then be reduced by catalytic hydrogenation in order to convert the resulting free amino group to its hydrazine by the action of NaNO 2 and SnCl 2 .
  • the resulting pyridylhydrazine can be condensed with a ketone then subjected to Fisher indole cyclization conditions to afford the indole 6.
  • Acidic deprotection of the acetyl groups can be accomplished by using a strong acid to liberate the diamine, which can be selectively coupled on the more reactive aniline nitrogen using standard coupling agents, such as HATU.
  • the aminopyridine group can then be acylated with a reagent, such as acetyl chloride or a carboxylic acid, in the presence of an amide bond-forming reagent.
  • 2-Bromo-3-aminopyridines can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 5, which can undergo TFAA-mediated cyclization to provide the 4-azaindole compounds 6.
  • Protecting groups can be removed with a strong acid, such as aqueous HCl, and the resulting amine can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU.
  • scaffolds B containing a 6-azaindole core can be accomplished by the metallation of the 4-methylpyridine analog 2 with a strong base, such as BuLi, and quenching the resulting anion with the acylating agent, such as 3.
  • Intermediate 4 can be globally deprotected by the action of a strong acid, such as HBr, to give the diamino azaindole structure 5.
  • Both amino groups can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU.
  • Compounds 6 can be further functionalized at the C-3 indole position with electrophiles, such as NCS.
  • Iodo aminopyridines 2 can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 5, which can undergo a base-mediated cyclization using a reagent, such as KOtBu, to provide the 7-azaindole compounds 4.
  • Protecting groups can be removed with a strong acid, such as aqueous HCl, and the resulting amine can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU.
  • Compounds 6 can then be reduced using hydrogen and a catalyst then coupled a second time with a carboxylic acid and HATU to provide 8.
  • Treatment of 8 with an electrophilic agent, such as NCS provides the desired compounds.
  • Compounds in the D series can be synthesized by reacting dicarbonyl intermediate 2 with a 2-aminopyrimidine derivative in the presence of a Lewis acid, such as boron trifluoride etherate.
  • a Lewis acid such as boron trifluoride etherate.
  • the resulting heterocycle can be alkylated with a bromoketone analog of an amino acid, such as proline, in the presence of a tertiary amine base.
  • the nitro group can be reduced, and the resulting aniline can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU, to give the final products.
  • Scaffold E-1 can be prepared by the condensing a benzoic acid derivative, such as 1, with a phenylenediamine counterpart 2 in the presence of a dehydrating agent, such as polyphosphoric acid.
  • the resulting aniline can be acylated using an appropriately substituted carboxylic acid, such as N-Boc-L-proline, and an amide bond-forming reagent, such as HATU, and can then be subjected to acidic conditions to remove the Boc group.
  • Compounds 4 can be coupled again with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
  • the nitro group in 5 can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be further coupled with various amines to give the target compounds.
  • Scaffold E-2 can be prepared by the reacted with a benzoic acid derivative with a phenylenediamine analog and an amide bond-forming reagent, such as HATU, to give amides 3, which can be cyclodehydrated by heating with a reagent, such as HOAc.
  • the resulting aniline can be acylated using an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give intermediates 5.
  • the nitro group can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be sulfonylated with an appropriately substituted sulfonyl chloride and a tertiary amine base to give the targets.
  • Scaffold F can be prepared by the condensing a benzoic acid derivative, such as 1, with an amino phenol counterpart 2 in the presence of a dehydrating agent, such as polyphosphoric acid.
  • the resulting aniline can be acylated using an appropriately substituted carboxylic acid, such as N-Boc-L-proline, and an amide bond-forming reagent, such as HATU, and can then be subjected to acidic conditions to remove the Boc group.
  • Compounds 4 can be coupled again with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
  • the synthesis can be modified by reacting an appropriately substituted bromo salicylaldehyde with a benzyl halide, such as 4-nitrobenzyl bromide, in the presence of a tertiary amine base to give ethers 2.
  • a benzyl halide such as 4-nitrobenzyl bromide
  • the benzylic ethers can be treated with a base, such as DBU, and heated to elevated temperatures to effect cyclization to the benzofurans 3.
  • the aryl bromide can be converted to the aryl amine by reaction with LHMDS and a palladium catalyst to provide 4, which can be coupled to an appropriately substituted carboxylic acid to give 5.
  • the nitro group in 5 can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be coupled with a second carboxylic acid analog to give the target compounds G-2.
  • Appropriately substituted aminopyrimidines can be cyclodehydrated after acylation with an appropriately substituted ketone, such as 4′-nitro-2-bromobenzophenone, by heating in a solvent, such as MeOH, and an acid source, such as HBr.
  • the resulting heterocyclic nitro compound can be converted to the aromatic amine by reduction with a reagent, such as SnCl 2 .
  • the final compounds H can be obtained by reacting 4 with an appropriately substituted carboxylic acid and an amide bond-forming reagent such as HATU.
  • Compounds in scheme I can be prepared by reacting the appropriately substituted aminopyridine with 4′-nitro-2-bromobenzophenone by heating in a solvent, such as acetone, then effecting a cyclodehydration reaction using methanol and an acid source, such as HBr.
  • a solvent such as acetone
  • the resulting heterocyclic nitro compound 3 can be converted to the aromatic amine by reduction with a reagent such as SnCl 2 .
  • the final compounds can be obtained by reacting 4 with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
  • Compounds in scheme J can be prepared by coupling indole boronic acids with an appropriately substituted 2-bromoindole, such as 2, under standard Suzuki conditions.
  • the protecting groups can be removed with HCl, and the nitro group in 4 can be reduced under catalytic hydrogenation conditions.
  • the penultimate diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as BOP, reagent to give compounds with the targeted central scaffold.
  • the synthesis of compounds with the indole core scaffold K can be prepared using standard Fisher indole synthesis protocol starting for an aryl hydrazine and a ketone such as 2. Conversion of the aryl bromide to the aryl amine 4 could be effected by the Pd-catalyzed reaction with LHMDS. The nitro group could be reduced and the diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give compounds with the targeted scaffold.
  • indoles K can be prepared starting from a suitably protected and substituted aminoindole 3.
  • Lithiation and quenching with a boronate ester affords key intermediate 4, which can be coupled to an appropriately substituted aryl or heteroaryl halide to provide targets 5.
  • the Boc groups can be removed with acid, and the resulting aniline can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
  • the nitro group in 7 can be reduced and coupled in a second amide coupling reaction to give the desired compounds.
  • Tetracyclic indole scaffold L can be prepared as outline in the scheme above. Cyclization of a carboxylic acid derivative 2 with PPA can provide the ketones 3, which can participate in a Fischer indole reaction with an appropriately substituted phenylhydrazine to give 4. The acetamide groups can be deprotected under acidic conditions and the resulting aryl amines can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give compounds with the targeted scaffold.
  • an amide bond-forming reagent such as HATU
  • Scaffold M-1 compounds can be prepared by coupling proline 2 to amino ketone 1 using standard amide bond-forming procedures to provide 3, which can be cyclized upon heating with ammonium acetate at elevated temperatures.
  • Intermediate 4 can be coupled to indole boronic acids, such as using standard Suzuki-type conditions.
  • the Boc groups can be removed with acid, and the resulting aniline can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
  • the pyrrolidine protecting group can be removed under hydrogenating conditions, and the resulting amine can coupled in a second amide coupling reaction to give the desired compounds.
  • Scaffold M-2 compounds can be prepared by reacting proline 1 with an anion of 4-ethynylbenzene to give intermediate ketone 2, which can be cyclized with hydrazine.
  • Intermediate 3 can be coupled to indole boronic acids, such as using standard Suzuki-type conditions.
  • the Boc groups can be removed with acid and the resulting aniline can be coupled with an appropriately substituted carboxylic acid, and an amide bond-forming reagent such as HATU.
  • the pyrrolidine protecting group can be removed under hydrogenating conditions, and the resulting amine can coupled in a second amide coupling reaction to give the desired compounds.
  • Thiazole analogs of scaffold M can be prepared from the cyclocondensation reaction of Z-proline thioamide 2 with an alpha-bromoacetophenone. Products 3 can be processed to the final compounds using methodology similar to that described in scheme M-2.
  • Imidazole analogs of scaffold M can be prepared from the cyclocondensation reaction of Z-proline bromomethyl ketone 1 with an aromatic amidine derivative. Products 3 can be processed to the final compounds using methodology similar to that described in scheme M-2.
  • Isomeric imidazoles can be prepared starting from a protected amino acid aldehyde, such as 1, and glyoxal in the presence of ammonia. Halogenation of the resulting imidazole 2 with NBS can be followed by a Pd-catalyzed cross coupling reaction with a functionalized indole boronate ester, such as 4. Deprotection, reduction and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide intermediate compounds 8. A second deprotection/amide-coupling procedure can provide the targeted M-5 scaffold.
  • a protected amino acid aldehyde such as 1, and glyoxal in the presence of ammonia.
  • Halogenation of the resulting imidazole 2 with NBS can be followed by a Pd-catalyzed cross coupling reaction with a functionalized indole boronate ester, such as 4.
  • Oxadiazole compounds can be prepared starting from indole hydrazide 2 and coupling to an amino acid, such as Z-proline. Cyclodehydration of intermediate 3 can be effected with a reagent, such as TPP/iodine, to give the desired oxadiazole, which can be protected on the indole nitrogen with Boc anhydride. Introduction of the boronic acid functional group activates compound 6 for coupling with a substituted aryl halide 7 to give intermediate 8. Removal of the cbz and Boc groups afford the penultimate structure 10, which can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent to give the targets M-6.
  • a reagent such as TPP/iodine
  • Oxadiazole analogs of scaffold M can be prepared by cyclocondensation reactions of diacylhydrazines 2. Coupling to heterocyclic boronic acids using methodology similar to that described in scheme M-1 can provide the targeted compounds.
  • Double imidazole containing benzofuran compounds can be prepared starting from a protected amino acid aldehyde, such as 2, and glyoxal in the presence of ammonia. Halogenation of the resulting imidazole 3 with NBS can ultimately provide intermediate 5, which can be coupled to a functionalized boronate ester, such as 11, to provide 12. Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide the targeted M-8 scaffold.
  • benzofurans can be realized starting from benzofuran 1, which can be converted to boronate ester 2, which can then coupled to an appropriately substituted aryl halide to afford 5.
  • Intermediate 5 can subsequently be converted to a functionalized boronate ester and converted to the final products in a manner similar to that described in Scheme M-8.
  • Benzoxazoles 3 can be prepared starting from a suitable substituted benzoic acid and an aminophenol, such as 2, in the presence of polyphosphoric acid. Such products can be converted to the corresponding boronate esters using standard procedures. Intermediates 4 can subsequently be coupled to a heterocyclic halide in the presence of a Pd(II) catalyst to provide compounds 5. Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide the targeted M-10 scaffold.
  • an appropriately substituted carboxylic acid and an amide bond-forming reagent such as HATU
  • the compounds in scheme N-1 can be prepared by heating hydrazines 1 with ketones 2 in a microwave reactor in a polar aprotic solvent, such as NMP.
  • the indole acetamides 3 can be deprotected with strong acid, such as HCl.
  • the resulting aryl amines can be coupled with an appropriately substituted carboxylic acid, and an amide bond-forming reagent, such as HATU, to give compounds of the targeted scaffold.
  • Scaffold O can be prepared by reacting a protected proline compound (such as Cbz) with a phenylenediamine analog and an amide bond-forming reagent, such as HATU, to give amides 3, which can be cyclodehydrated by heating with a reagent, such as HOAc.
  • a protected proline compound such as Cbz
  • a phenylenediamine analog such as HATU
  • amides 3 can be cyclodehydrated by heating with a reagent, such as HOAc.
  • the resulting benzimidazole can be coupled to an indole boronic acid derivative using standard Suzuki conditions to provide 5.
  • Removal of the Boc groups with acid provides 7, which can be acylated using an appropriately substituted carboxylic acid, such as Boc-L-proline, and an amide bond-forming reagent, such as HATU, to give intermediates 7.
  • the Cbz group can be reduced under catalytic hydrogenating conditions, and the Boc group can be de
  • Heterocycles can be fluorinated at C-3 by the action of electrophilic fluorinating agents, such as S ELECTFLUOR , to provide targets P-1.
  • electrophilic fluorinating agents such as S ELECTFLUOR
  • C-3 halogenated compounds can be converted to the corresponding cyano analogs by cyanating agents, such as CuCN.
  • the compounds in scheme P-4 can be functionalized by the acylating indoles with Grignard reagents and zinc chloride.
  • the compounds in scheme P-5 can be functionalized by deprotonating the indoles with a base such as ethylmagnesium bromide and treating the resulting intermediate with chlorosulfonyl isocyanate.
  • a base such as ethylmagnesium bromide
  • the indoles 3 can be prepared using Vilsmeier-Haack conditions, which can subsequently be protected and coupled under Suzuki conditions to give intermediates 5.
  • the aldehydes can be oxidized using standard methodology for carboxylic acid formation.
  • Amide coupling of the aniline from scheme K-1 with an appropriately substituted carboxylic acid and a coupling agent can provide intermediates 2, which can then be subjected to Pd-catalyzed cross-coupling reactions to provide the final targets R.
  • Compounds in scheme S can be prepared by coupling indole boronic acids with an appropriately substituted 2-bromobenzoxazoles, such as 5, under standard Suzuki conditions.
  • the nitro group in 6 can be reduced under catalytic hydrogenation conditions and the protecting groups can be removed with HCl.
  • the penultimate diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as BOP, reagent to give compounds with the targeted central scaffold.
  • Compounds in scheme T can be prepared by starting from a suitably substituted phenol 3 and a hydrazine reagent, such as 4, using established Fisher indole conditions.
  • the indole 3 position can then be functionalized or the indole NH can be cyclized onto the C-2 aromatic ring using standard conditions to give tetracycles 8, which can subsequently be converted to the corresponding boronate esters using standard procedures.
  • Intermediates 9 can then be coupled to a heterocyclic halide in the presence of a Pd(II) catalyst to provide compounds 10.
  • Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU can provide the targeted T scaffold.
  • step 4 The product from step 4 was pivaloylated using conditions described in step 2.
  • step 7 The product from step 7 was coupled to 2 equivalents of N-phenylacetyl-L-proline using 2 equivalents of HATU and DIEA in a manner similar to that shown in Example 1.
  • Arylglyoxal hydrate (5 g, 27.8 mmol) was added in one portion over a slurry of the heterocyclic amine (2.773 g, 29.2 mmol) in methylene chloride (10 ml). The resulting suspension was treated with 1 drop of freshly distilled BF 3 .Et 2 O and stirred until most of the amine was consumed. The reaction products were isolated as hydrates by filtration of the thick, intensely colored reaction mixture. The residue obtained by concentration is allowed to cool, filtered with suction, washed twice with diethyl ether and dried under reduced pressure to give the desired product (4 g). MS (ESI) m/e (M+H + ): 256.
  • N-protected proline (10 g, 42.8 mmol) in dry ether (60 ml) and THF (60 ml) was stirred under argon at ⁇ 25° C.
  • TEA (42.8 mol, 4.08 ml)
  • ethyl chloroformate (42.8 mmol, 2.6 4.14 ml) were added to this solution.
  • the solution was stirred for further 30 minutes, the temperature then allowed to reach ⁇ 10° C., and the diazomethane solution in ether (2-3 equivalents) was added drop wise.
  • the suspension was stirred for an additional 3 hours and allowed to reach ambient temperature.
  • the triethylamine hydrochloride was then filtered off, and the filtrate was evaporated to half of its original volume.
  • step 3 The product from step 3 (0.370 g, 1.052 mmol), pyridine-3-carboxylic acid (0.157 g, 1.27 mmol), HATU (1.2 g, 3.18 mmol) and DIPEA (0.814 g, 6.36 mmol) were taken in DMF (10 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO 4 ), concentrated and purified by column (DCM:MeOH/100:1) to afford 300 mg of desired compound.
  • step 4 The product from step 4 (0.300 g, 0.657 mmol) was taken in MeOH (10 mL) and Pd/C (0.07 g) was added under N 2 . The reaction was stirred for overnight at RT under H 2 . The Pd/C was filtered through CELITE, and the filtrate was concentrated under reduced pressure to afford 234 mg of desired compound.
  • step 5 The product from step 5 (0.370 g, crude), N-Boc-proline (0.157 g, 1.27 mmol), HATU (1.2 g, 3.18 mmol) and DIPEA (0.814 g, 6.36 mmol) were taken in DMF (10 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO 4 ), concentrated and purified by column (DCM:MeOH/100:1) to afford 300 mg of targeted compound.
  • step 7 The product from step 7 (0.100 g, 0.191 mmol), cyclobutanecarboxylic acid (0.018 mg, 0.183 mmol), HATU (0.116 g, 0.305 mmol) and DIPEA (0.059 g, 0.416 mmol) were taken in DMF (5 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO 4 ) and concentrated. The residue was purified by HPLC purification to afford 12 mg of the final product.
  • step 4 The product from step 4 (0.70 g, 1.13 mmol) was stirred in MeOH/HCl (20 mL) for 1 hour. The solvent was removed at high vacuum to afford the desired proline compound, which was used directly to the next step without further purification.
  • 3-Phenylpropanoic acid (0.428 g, 2.85 mmol) were taken in DCM (30 mL) was reacted with the proline compound (0.500 g, 0.96 mmol) and DIPEA (0.9 g, 7.1 mmol). The reaction was stirred at RT for 5 minutes, and then HATU (1.0 g, 2.85 mmol) was added. The reaction was stirred overnight and poured into brine and extracted with EtOAc.
  • step 2 The product from step 2 (600 mg, 1.3 mmol) was added into HCl (30 ml, 3M in MeOH). Then the mixture stirred at RT for 2-3 hours. When reaction was complete, the mixture was concentrated to give the crude product (400 mg). MS (ESI) m/e (M+H + ): 293.
  • step 3 The product from step 3 (400 mg, 1.36 mmol) was dissolved in EtOAc and treated with Pd/C (100 mg, 20%). Then the mixture was stirred at RT overnight under H 2 atmosphere. When the reaction was complete, the Pd/C was filtered off, and the resulting solution was concentrated to give the crude product (300 mg). MS (ESI) m/e (M+H + ): 263.
  • step 6 The product of step 6 above (0.22 mmol), N-phenylacetyl-L-proline (51 mg, 0.22 mmol), DIPEA (100 mg), and DMF (3 mL) was added HATU (84 mg, 0.22 mmol), and the mixture was stirred at RT overnight. The mixture was purified by RPLC to afford the product. MS (ESI) m/e (M+H + ): 656.
  • HATU (20 g, 52.3 mmol) was added to a heterogeneous mixture of the amino ketone (12 g, 48.5 mmol) and L-Cbz-Pro (12.4 g, 50 mmol) in MeCN (156 mL). The mixture was cooled in an ice-water bath, and immediately afterward DIPEA (27 mL, 155 mmol) was added dropwise. After the addition of the base, the cooling bath was removed, and the reaction mixture was stirred for an additional 50 minutes. The volatile component was removed, and water (125 mL) was added to the resulting crude solid and stirred for about 1 hour. The off-white solid was filtered and washed with copious water, and dried in vacuo to provide the desired compound as a white solid (20.68 g). MS (ESI) m/e (M+H + ): 446.
  • step 5 The product from step 5 (100 mg, 0.15 mmol) was dissolved in MeOH and treated with 20 mg of 20% Pd(OH) 2 then hydrogenated at 45 psi for 4 hours. The catalyst was removed by filtration through CELITE, and the filtrate was evaporated to leave the desired product. MS (ESI) m/e (M+H + ): 541.
  • NBS (838.4 mg, 4.71 mmol) was added in batches over 15 minutes to a cooled (ice/water) CH 2 Cl 2 (20 mL) solution of imidazole (1.06 g, 4.50 mmol). The reaction mixture was stirred for 75 minutes and concentrated. The crude material was purified by RPLC to separate the mono bromide from its dibromo analog and the starting material. The HPLC elute was neutralized with excess NH 3 /MeOH, and the volatile component was removed in vacuo. The residue was partitioned between CH 2 Cl 2 and water, and the aqueous layer was extracted with water. The combined organic phase was dried (MgSO 4 ), filtered, and concentrated to provide compound as a white solid (374 mg).
  • step 1 To a mixture of the benzofuran from Example 19, step 1 (15 g, 0.05 mol), bis(pinacolato)diboron (25.4 g, 0.1 mol), Pd(dppf)Cl 2 (1 g), KOAc (0.1 mol) in dioxane (500 mL) was stirred at reflux under N 2 atmosphere for 2 hours. Concentration of the reaction mixture left a residue that was chromatographed to give the desired compound (12 g).
  • step 7 The product from step 7 (0.15 mmol) was dissolved in MeOH and treated with 20 mg of 20% Pd(OH) 2 then hydrogenated at 45 psi for 4 hours.
  • the catalyst was removed by filtration through CELITE, and the filtrate was evaporated then dissolved in 1 mL of DCM then treated with 1 mL of TFA. After stirring for 2 hours, the mixture was evaporated and the residue was used directly in the next reaction without further purification.
  • step 3 The product from step 3 (500 mg, 0.9 mmol) was stirred in MeOH/HCl (20 mL) for 16 hours. The solvent was removed under reduced pressure and the residue was dried at high vacuum. MS (ESI) m/e (M+H + ): 452.
  • step 5 The product from step 5 (290 mg, 0.45 mmol) was dissolved in 5 mL of acetic acid and HBr (1 mL) was added. The reaction mixture was heated to 70-80° C. and stirred for 4 hours. The mixture was cooled to RT and concentrated in vacuo. The residue was extracted with EtOAc (2 ⁇ ), washed with aq NaHCO 3 and water (30 mL) and brine (30 mL), dried over anhydrous sodium sulfate. Evaporation of the solvent afforded the desired compound as brown solid (160 mg). MS (ESI) m/e (M+H + ): 415.
  • Example 158 tert-butyl ⁇ (1R)-2-[(2S)-2-( ⁇ 4-[5-( ⁇ [(2S)-1- ⁇ (2R)-2-[(tert-butoxycarbonyl)amino]-2-phenylacetyl ⁇ pyrrolidin-2-yl]carbonyl ⁇ amino)-3-(cyclopropylcarbamoyl)-1H-indol-2-yl]phenyl ⁇ carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl ⁇ carbamate
  • Example 159 tert-butyl ⁇ (1R)-2-[(2S)-2-( ⁇ 4-[5-( ⁇ [(2S)-1- ⁇ (2R)-2-[(tert-butoxy-carbonyl)amino]-2-phenylacetyl ⁇ pyrrolidin-2-yl]carbonyl ⁇ amino)-3-(4-methoxyphenyl)-1H-indol-2-yl]phenyl ⁇ carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl ⁇ carbamate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of application Ser. No. 15/800,172, filed Nov. 17, 2017, which is a continuation of application Ser. No. 15/272,669, filed Sep. 22, 2016, now abandoned, which is a continuation of application Ser. No. 14/711,345, filed May 13, 2015, now abandoned, which is a continuation of application Ser. No. 14/473,117, filed Aug. 29, 2014, and which granted as U.S. Pat. No. 9,090,661 on Jul. 28, 2015, which is a divisional of U.S. application Ser. No. 13/260,684, filed Dec. 19, 2011, which is the national stage application under 35 U.S.C. 371 of International Patent Application No. PCT/US2010/028653, filed Mar. 25, 2010, and which granted as U.S. Pat. No. 8,871,759 on Oct. 28, 2014, which claims priority to U.S. Provisional Application No. 61/163,958, filed Mar. 27, 2009 and U.S. Provisional Application No. 61/247,318, filed Sep. 30, 2009. Each of the aforementioned PCT and priority applications is incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present disclosure relates to antiviral compounds that are useful as inhibitors of hepatitis C virus (HCV) replication. The compounds are expected to act on HCV NS5A (non-structural 5A) protein. Compositions comprising such compounds, the use of such compounds for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, methods for inhibiting the function of the NS5A non-structural protein, and methods for inhibiting HCV viral replication and/or viral production are also provided.
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals. Current treatments for HCV infection include immunotherapy with recombinant interferon-α alone or in combination with the nucleoside-analog ribavirin.
Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (NS2-3), a serine protease (NS3, amino acid residues 1-180), a helicase (NS3, full length), an NS3 protease cofactor (NS4A), a membrane protein (NS4B), a zinc metalloprotein (NS5A) and an RNA-dependent RNA polymerase (NSSB).
One identified target for therapeutic intervention is HCV NS5A non-structural protein, which is described, for example, in Seng-Lai Tan & Michael G. Katze, How Hepatitis C Virus Counteracts the Interferon Response: The Jury Is Still Out on NS5A, 284 VIROLOGY 1-12 (2001); and in Kyu-Jin Park et al., Hepatitis C Virus NS5A Protein Modulates c-Jun N-terminal Kinase through Interaction with Tumor Necrosis Factor Receptor-associated Factor 2, 278(33) J. BIO. CHEM. 30711 (2003). A non-structural protein, NS5A is an essential component for viral replication and assembly. Mutations in NS5A at or near known sites of phosphorylation can affect the ability for high-level replication in cell-culture systems, suggesting an important role for NS5A phosphorylation in viral replication efficiency. Inhibitors of the phosphorylation of NS5A can lead to reduced viral RNA replication.
NS5A is a zinc metalloprotein organized into three discreet domains. NS5A localizes to the membrane-associated site of RNA synthesis via an N-terminal amphipathic α-helix anchor. The crystal structure of domain I demonstrates that NS5A can exist as a dimer, with a large putative RNA binding groove located at the interface of the monomers. Timothy L. Tellinghuisen et al., Structure of the zinc-binding domain of an essential component of the hepatitis C viral replicase, 435 (7040) NATURE 374 (2005). Robert A. Love et al., Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein From Hepatitis C Virus, 89 (3) J. VIROLOGY 4395-403 (2009). The interaction of NS5A with RNA is thought to be critical for the function of this protein in RNA replication. No structural information has yet been obtained for domains II or III. Recent genetic mapping has shown that although some residues in domain II are essential for RNA replication, many portions of domain II and all of domain III are dispensable. Timothy L. Tellinghuisen et al., Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein, J. VIROLOGY 1073 (2008). Mutations constructed within domain III result in virus that can maintain RNA replication but that produces lower titers of infectious virus in cell culture, demonstrating a second distinct role for NS5A after RNA replication has occurred. Timothy L. Tellinghuisen et al., Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein, 4 (3) PLOS PATHOGENS e1000032 (2008); Nicole Appel et al., Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain, 79 (5) J. VIROLOGY 3187 (2005). NS5A, unlike the other non-structural proteins, can be trans-complemented, consistent with functions outside of the viral replicase. The interaction of NS5A with numerous host-signaling pathways has been described (Michael J. Gale Jr. et al., Evidence That Hepatitis C Virus Resistance to Interferon Is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein, 230 VIROLOGY 217 (1997); Andrew Macdonald & Mark Harris, Hepatitis C virus NS5A: tales of a promiscuous protein, 85 J. GEN. VIROLOGY 2485 (2004), suggesting this protein may modify the host cell environment to a state favorable for the virus, events that may require a form of NS5A dissociated from the replication complex.
There is a clear and long-felt need to develop effective therapeutics for treatment of HCV infection. Specifically, there is a need to develop compounds that are useful for treating HCV-infected patients and compounds that selectively inhibit HCV viral replication.
SUMMARY OF THE INVENTION
The present disclosure relates to novel compounds of formula (I) and/or pharmaceutically acceptable salts, hydrates, solvates, prodrugs or isomers thereof. These compounds are useful, either as compounds or their pharmaceutically acceptable salts (when appropriate), in the inhibition of HCV (hepatitis C virus) NS5A (non-structural 5A) protein, the prevention or treatment of one or more of the symptoms of HCV infection, the inhibition of HCV viral replication and/or HCV viral production, and/or as pharmaceutical composition ingredients. As pharmaceutical composition ingredients, these compounds, which includes reference to hydrates and solvates of such compounds, and their salts may be the primary active therapeutic agent, and, when appropriate, may be combined with other therapeutic agents including but not limited to other HCV antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
More particularly, the present disclosure relates to a compound of formula (I):
Figure US11053243-20210706-C00002
and/or a pharmaceutically acceptable salt thereof, wherein:
Figure US11053243-20210706-C00003
is chosen from the group consisting of 9-membered bicyclic aryl ring systems that contain from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and that are substituted on C or N atoms by u substituents
    • each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —(CH2)0-6C(O)R3, —CO2R3a, —C(O)N(R3a)2, —SR3a, —S(O)R3a, —S(O2)R3a, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)R3, —N(R3a)COR3a, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, and C3-8cycloalkyl,
    • u is from 0 to 4,
    • each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and
    • each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
Figure US11053243-20210706-C00004
is a group chosen from the group consisting of
    • (a) —C≡C— and
    • (b) aryl ring systems B′ chosen from the group consisting of:
      • (i) 5- to 7-membered monocyclic ring systems and
      • (ii) 8- to 10-membered bicyclic ring systems,
      • and the aryl ring systems B′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by v substituents R2,
      • each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)COR4, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), —N(R4a)SO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, C1-6alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4,
      • v is from 0 to 4,
      • each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl;
      • each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
R1 and R2 may be taken together with
Figure US11053243-20210706-C00005
and
Figure US11053243-20210706-C00006
to form a 5- to 9-membered carbocyclic ring containing 1 or 2 heteroatoms independently chosen from the group consisting of N, O and S;
each D is a group independently chosen from the group consisting of:
    • (a) a single bond,
    • (b) —C(O)N(R5)—,
    • (c) —N(R5)C(O)—, and
    • (d) a 5- or 6-membered aryl ring system D′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by from 0 to 2 substituents R5,
      • each R5 is independently chosen from the group consisting of hydrogen, halogen, —OR6, —CN, —CO2R6, —C(O)N(R6)2, —N(R6)2, —N(R6)COR6, —SR6, —S(O)R6, —S(O2)R6, —N(R6)SO2R6, —NCO2R6, —NC(O)N(R6)2, C1-6alkyl substituted by from 0 to 3 R6 and C3-8cycloalkyl substituted by from 0 to 3 R6, and
      • each R6 is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
each E is a group independently chosen from the group consisting of:
    • (a) a single bond,
    • (b) —(C(R7)2)0-2NR7C(O)O04—, and
    • (c) a pyrrolidinyl derivative chosen from the group consisting of:
Figure US11053243-20210706-C00007
      • I is a bivalent group chosen from —C(O)—, —CO2— and —C(O)N(R7)—,
      • J is a fused ring system chosen from the group consisting of 3- to 7-membered carbocycles and 5- or 6-membered aryl rings containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by substituents R9,
      • each R8a is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8a may be taken together to form oxo,
      • each R8b is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8b may be taken together to form oxo,
      • each R8c is independently chosen from the group consisting of hydrogen and C1-6alkyl,
      • or any two groups selected from R8a, R8b and R8c may be taken together to form a spiro-bicyclic or bridged bicyclic ring;
      • each R9 is independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, —NH—C1-6alkyl and —NHC(O)—C1-6alkyl,
    • each R7 is independently chosen from the group consisting of hydrogen, C1-6alkyl and phenyl, and the C1-6alkyl and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl; and
each G is independently chosen from the group consisting of:
    • (a) hydrogen,
    • (b) —OR10a,
    • (c) —CN,
    • (d) —CO2R10a,
    • (e))—C(O)N(R10)2,
    • (f) —SR10a,
    • (g) —S(O)R10a,
    • (h) —S(O2) R10a,
    • (i) —N(R10)2,
    • (j) —N(R10)SO2R10a,
    • (k) —NCO2R10a,
    • (l) —NC(O)N(R10)2,
    • (m) C1-6alkyl having 0 to 4 substituents R11,
      • each R11 is independently chosen from the group consisting of:
        • (i) —OH,
        • (ii) —N(R10)2,
        • (iii) ═NR10,
        • (iv) —O—C1-6alkyl,
        • (v) —C(O)R10,
        • (vi) —S—C1-6alkyl,
        • (vii) —SO2—C1-6alkyl,
        • (viii) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R12 on N or C atoms, and each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl having from 0 to 3 substituents chosen from R10, —O—C1-6alkyl, —S—C1-6alkyl, —OR10a, —CN, —C(O)R, —CO2R10a, —C(O) N(R10)2, —SR10a, —S(O)R10a, —S(O2)R10a, —N(R10)SO2R10a, —NCO2R10a, —NC(O)N(R10)2 and —N(R10)2, or two R12 are taken together to form oxo, and
        • (ix) 5- or 6-membered aryl containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R13 on N or C atoms, and each R13 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl and 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
    • (n) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R10 on N or C atoms; and
    • (o) aryl ring systems G′ chosen from the group consisting of:
      • (i) 5- to 7-membered monocyclic ring systems and
      • (ii) 8- to 10-membered bicyclic ring systems,
      • and the aryl ring systems G′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by 0 to 3 substitutents R10;
    • each R10 is independently chosen from the group consisting of
      • (i) hydrogen,
      • (ii) —CN,
      • (iii) C1-6alkyl,
      • (iv) —O—C0-6alkyl,
      • (v) —S—C0-6alkyl,
      • (vi) C1-6alkyl-O—R14,
      • (vii) —C(O)R14,
      • (viii) —CO2R14,
      • (ix) —SO2R14,
      • (x) —N(R14)2,
      • (xi) —N(R14)SO2R14,
      • (xii) —NCO2R14,
      • (xiii) —NC(O)N(R14)2, and
      • (xiv) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
    • or two R10 may be taken together to form oxo;
    • each R10a is independently chosen from the group consisting of
      • (i) hydrogen,
      • (ii) —CN,
      • (iii) C1-6alkyl,
      • (iv) C1-6alkyl-O—R14,
      • (v) —C(O)R14,
      • (vi) —CO2R14,
      • (vii) —SO2R14,
      • (x) —N(R14)2,
      • (xi) —N(R14)SO2R14,
      • (xii) —NCO2R14,
      • (xiii) —NC(O)N(R14)2, and
      • (xiv) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
    • and two R10 or R10a groups can be taken together with the N to which they are attached to form a ring, which may be substituted by from 0 to 3 substituents R14, and
    • each R14 is independently chosen from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, —(CH2)0-3C3-8cycloalkyl and phenyl.
The present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions. The present invention further includes methods of treating or reducing the likelihood or severity of HCV infection, methods for inhibiting the function of the NS5A protein, and methods for inhibiting HCV viral replication and/or viral production.
Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention includes compounds of formula (I) above, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are HCV NS5A inhibitors.
A first embodiment of the invention relates to compounds having structural formula (I):
Figure US11053243-20210706-C00008
and/or a pharmaceutically acceptable salt thereof, wherein:
Figure US11053243-20210706-C00009
is chosen from the group consisting of 9-membered bicyclic aryl ring systems that contain from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and that are substituted on C or N atoms by u substituents R′,
    • each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —C(O)R3, —CO2R3a, —C(O)N(R3a)2, —SR3a, —S(O)R3a, —S(O2)R3a, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)R3, —N(R3a)COR3a, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl,
    • u is from 0 to 4,
    • each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and
    • each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
Figure US11053243-20210706-C00010
is a group chosen from the group consisting of
    • (a) —C≡C— and
    • (b) aryl ring systems B′ chosen from the group consisting of:
      • (i) 5- to 7-membered monocyclic ring systems and
      • (ii) 8- to 10-membered bicyclic ring systems,
      • and the aryl ring systems B′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by v substituents R2,
      • each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)COR4, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), —N(R4a)SO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, C1-6 alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4,
      • v is from 0 to 4,
      • each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl;
      • each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
R1 and R2 may be taken together with
Figure US11053243-20210706-C00011
to form a 5- to 9-membered carbocyclic ring containing 1 or 2 heteroatoms independently chosen from the group consisting of N, O and S;
each D is a group independently chosen from the group consisting of:
    • (a) a single bond,
    • (b) —C(O)N(R5)—,
    • (c) —N(R5)C(O)—, and
    • (d) a 5- or 6-membered aryl ring system D′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by from 0 to 2 substituents R5,
      • each R5 is independently chosen from the group consisting of hydrogen, halogen, —OR6, —CN, —CO2R6, —C(O)N(R6)2, —N(R6)2, —N(R6)COR6, —SR6, —S(O)R6, —S(O2)R6, —N(R6)SO2R6, —NCO2R6, —NC(O)N(R6)2, C1-6alkyl substituted by from 0 to 3 R6 and C3-8cycloalkyl substituted by from 0 to 3 R6, and
      • each R6 is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
each E is a group independently chosen from the group consisting of:
    • (a) a single bond,
    • (b) —(C(R7)2)0-2NR7C(O)O0-1—, and
    • (c) a pyrrolidinyl derivative chosen from the group consisting of:
Figure US11053243-20210706-C00012
      • I is a bivalent group chosen from —C(O)—, —CO2— and —C(O)N(R7)—,
      • J is a fused ring system chosen from the group consisting of 3- to 7-membered carbocycles and 5- or 6-membered aryl rings containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by substituents R9,
      • each R8a is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8a may be taken together to form oxo,
      • each R8b is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8b may be taken together to form oxo,
      • each R8c is independently chosen from the group consisting of hydrogen and C1-6alkyl,
      • or any two groups selected from R8a, R8b and R8c may be taken together to form a spiro-bicyclic or bridged bicyclic ring;
      • each R9 is independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, —NH—C1-6alkyl and —NHC(O)—C1-6alkyl,
    • each R7 is independently chosen from the group consisting of hydrogen, C1-6alkyl and phenyl, and the C1-6alkyl and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl; and
each G is independently chosen from the group consisting of:
    • (a) hydrogen,
    • (b) —OR10a,
    • (c) —CN,
    • (d) —CO2R10a,
    • (e) —C(O)N(R10)2,
    • (f) —SR10a,
    • (g) —S(O)R10a,
    • (h) —S(O2)R10a,
    • (i) —N(R10)2,
    • (j) —N(R10)SO2R10a,
    • (k) —NCO2R10a,
    • (l) —NC(O)N(R10)2,
    • (m) C1-6alkyl having 0 to 4 substituents R11,
      • each R11 is independently chosen from the group consisting of:
        • (i) —OH,
        • (ii) —N(R10)2,
        • (iii) ═NR10,
        • (iv) —O—C1-6alkyl,
        • (v) —C(O)R10,
        • (vi) —S—C1-6alkyl,
        • (vii) —SO2—C1-6alkyl,
        • (viii) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R12 on N or C atoms, and each R12 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl having from 0 to 3 substituents chosen from R10, —O—C1-6alkyl, —S—C1-6alkyl, —OR10a, —CN, —C(O)R10, —CO2R10a, —C(O)N(R10)2, —SR10a, —S(O)R10a, —S(O2)R10a, N(R10)SO2R10a, —NCO2R10a, —NC(O)N(R10)2 and —N(R10)2, or two R12 are taken together to form oxo, and
        • (ix) 5- or 6-membered aryl containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R13 on N or C atoms, and each R13 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl and 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
      • (n) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R10 on N or C atoms; and
      • (o) aryl ring systems G′ chosen from the group consisting of:
        • (i) 5- to 7-membered monocyclic ring systems and
        • (ii) 8- to 10-membered bicyclic ring systems,
        • and the aryl ring systems G′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by 0 to 3 substitutents R10;
      • each R10 is independently chosen from the group consisting of
        • (i) hydrogen,
        • (ii) —CN,
        • (iii) C1-6alkyl,
        • (iv) —O—O0-6alkyl,
        • (v) —S—O0-6alkyl,
        • (vi)
        • (vii) —C(O)R14,
        • (viii) —CO2R14,
        • (ix) —SO2R14,
        • (x) —N(R14)2,
        • (xi) —N(R14)SO2R14,
        • (xii) —NCO2R14,
        • (xiii) —NC(O)N(R14)2, and
        • (xiv) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
      • or two R10 may be taken together to form oxo;
      • each R10a is independently chosen from the group consisting of
        • (i) hydrogen,
        • (ii) —CN,
        • (iii) C1-6alkyl,
        • (iv) C1-6alkyl-O—R14,
        • (v) —C(O)R14,
        • (vi) —CO2R14,
        • (vii) —SO2R14,
        • (x) —N(R14)2,
        • (xi) —N(R14)SO2R14,
        • (xii) —NCO2R14,
        • (xiii) —NC(O)N(R14)2, and
        • (xiv) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
      • and two R10 or R10a groups can be taken together with the N to which they are attached to form a ring, which may be substituted by from 0 to 3 substituents R14, and
      • each R14 is independently chosen from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, —(CH2)0-3C3-8cycloalkyl and phenyl. In this embodiment, all other groups are as provided in the general formula above.
In a second embodiment of the invention,
Figure US11053243-20210706-C00013
is chosen from the group consisting of
Figure US11053243-20210706-C00014
where each X is independently chosen from the group consisting of CR1 and N,
Figure US11053243-20210706-C00015
is chosen from the group consisting of
Figure US11053243-20210706-C00016
each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —C(O)R3, —CO2R3a, —C(O)N(R3a)2, —SR3a, —S(O)R3a, —S(O2)R3a, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)R3, —N(R3a)COR3a, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl, each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl. In all aspects of this embodiment, all other groups are as provided in the general formula above or in the first embodiment above.
In a first aspect of the second embodiment of the invention,
Figure US11053243-20210706-C00017
is chosen from the group consisting of
Figure US11053243-20210706-C00018
where
Figure US11053243-20210706-C00019
is substituted by from 0 to 3 additional R′, which are as provided above.
In a second aspect of the second embodiment,
Figure US11053243-20210706-C00020
is chosen from the group consisting of
Figure US11053243-20210706-C00021
where
Figure US11053243-20210706-C00022
is substituted by from 0 to 3 additional R1, which are as provided above. In preferred instances of this aspect,
Figure US11053243-20210706-C00023
is
Figure US11053243-20210706-C00024
where
Figure US11053243-20210706-C00025
is substituted by from 0 to 3 additional R1, which are as provided above.
In a third aspect of the second embodiment,
Figure US11053243-20210706-C00026
is chosen from the group consisting of
Figure US11053243-20210706-C00027
where
Figure US11053243-20210706-C00028
is substituted by from 0 to 3 additional R1, which are as provided above. In preferred instances of this aspect,
Figure US11053243-20210706-C00029
is
Figure US11053243-20210706-C00030
where
Figure US11053243-20210706-C00031
is substituted by from 0 to 3 additional R1, which are as provided above.
In further aspects of the second embodiment, each R1 is chosen from the group consisting of hydrogen, halogen, —CN and C1-6alkyl. In particular, each R1 is chosen from the group consisting of hydrogen, fluorine and —CN.
In a third embodiment of the invention,
Figure US11053243-20210706-C00032
is chosen from the group consisting of —C≡C—, phenyl, pyridinyl, pyrazinyl, pyrimidyl, 1,2,4-triazinyl, pyridazinyl, thiazyl and 9-membered bicyclic ring systems that contain from 1 to 3 heteroatoms independently chosen from the group consisting of N, O and S, v is from 0 to 4, each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)CO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, —N(R4a)SO2R4a, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), C1-6alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4, each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl, and each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl. In particular aspects of this embodiment,
Figure US11053243-20210706-C00033
is phenyl, v is from 0 to 2, and each R2 is independently chosen from the group consisting of fluorine, chlorine, —OH, —CH3, —OCH3 and —CN. In all aspects of this embodiment, all other groups are as provided in the general formula above and/or in the first or second embodiments.
In a fourth embodiment of the invention,
Figure US11053243-20210706-C00034
taken together with one substituent R1 and one substituent R2, are represented by a group chosen from the group consisting of:
Figure US11053243-20210706-C00035
where W is chosen from the group consisting of —(CH2)1-3—, —(CH2)0-2NH(CH2)0-2—, —(CH2)0-2N(C1-6alkyl)(CH2)0-2—, —(CH2)0-2O(CH2)0-2— and —(CH2)0-2C(O)(CH2)0-2—, where W is substituted by from 0 to 4 Rw, where each Rw is independently selected from C1-6alkyl and C3-8cycloalkyl; and V is chosen from the group consisting of —C(O)— and —CH2—, and where V is —CH2—, V is substituted by from 0 to 2 Rv, where each Rv is independently selected from the group consisting of C1-6alkyl and C3-8cycloalkyl. In a first aspect of this embodiment,
Figure US11053243-20210706-C00036
taken together with one substituent R1 and one substituent R2, are represented by a group chosen from the group consisting of
Figure US11053243-20210706-C00037
In particular instances of this embodiment, and of the first aspect of this embodiment, W is chosen from the group consisting of —CH2—, —NH—, —N(C1-6alkyl)-, —C(O)—, —CH2NH—, —CH2N(C1-6alkyl)-, —CH2CH2—, —C(O)CH2—, —CH2C(O)—, —CH2O—, —CH2CH2CH2—, —C(O)CH2CH2—, —CH2C(O)CH2—, —CH2OCH2—, —CH2CH2C(O)—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2N(C1-6alkyl)-, —CH2NHCH2—, —CH2N(C1-6alkyl)CH2—, —NHCH2CH2—, and —N(C1-6alkyl)CH2CH2—. In all aspects of this embodiment, all other groups are as provided in the general formula above.
In a fifth embodiment of the invention, each D is independently chosen from the group consisting of a single bond, —C(O)N(R5)—, —NR5C(O)—,
Figure US11053243-20210706-C00038
where R5 is independently chosen from the group consisting of hydrogen, halogen —OR6, —CN, —CO2R6, —C(O)N(R6)2, —N(R6)2, —N(R6)COR6, —SR6, —S(O)R6, —S(O2)R6, —N(R6)SO2R6, —NCO2R6, —NC(O)N(R6)2, C1-6alkyl substituted by from 0 to 3 substituents R6 and C3-8cycloalkyl substituted by from 0 to 3 substituents R6, and each R6 is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl. In particular aspects of this embodiment, each D is independently chosen from the group consisting of
Figure US11053243-20210706-C00039
In this embodiment, all other groups are as provided in the general formula above and/or in the first through fourth embodiments.
In a sixth embodiment of the invention, each E is independently chosen from the group consisting of a single bond, —CH2NHC(O)—, —CH2N(CH3)C(O)—, —C(CH3)HNHC(O)—, —C(CH3)HN(CH3)C(O)—, —C(CH3)2NHC(O)—, —C(CH3)2N(CH3)C(O)—, —CH2NHC(O)O—, —CH2N(CH3)C(O)O—, —C(CH3)HNHC(O)O—, —C(CH3)HN(CH3)C(O)O—, —C(CH3)2NHC(O)O—, —C(CH3)2N(CH3)C(O)O—,
Figure US11053243-20210706-C00040
where one of R8a and R8b is —OH or fluorine. In a first aspect of this embodiment, each E is independently chosen from the group consisting of a single bond,
Figure US11053243-20210706-C00041
where one of R8a and R8b is —OH or fluorine. In all aspects of this embodiment, all other groups are as provided in the general formula above and/or in the first through fifth embodiments.
In some embodiments, adjacent D and E groups each may be selected to be a single bond. In such embodiments, D and E are combined to be one single bond, and all other groups are as provided in the general formula above and/or in the first, second, third and fourth embodiments. That is, where D is a single bond and the adjacent E is a single bond,
Figure US11053243-20210706-C00042
is connected directly to G by one single bond.
In a seventh embodiment of the invention, each G is independently chosen from the group consisting of:
(a) C1-6alkyl having 0 to 4 substituents R11,
(b) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R10 on N or C atoms; and
(c) aryl ring systems G′ chosen from the group consisting of:
    • (i) 5- to 7-membered monocyclic ring systems and
    • (ii) 8- to 10-membered bicyclic ring systems,
    • and the aryl ring systems G′ containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by 0 to 3 substitutents R10. In all aspects of the seventh embodiment, G is chosen such that stable compounds result. In all aspects of this seventh embodiment, all other groups are as provided in the general formula above and/or in the first through sixth embodiments.
In an eighth embodiment, each G is independently chosen from the group consisting of:
(a) hydrogen,
(b) —CN,
(c) C1-5alkyl having 1 to 3 substituents R11,
    • each R11 is independently chosen from the group consisting of —OH, —NH2, —NCH3H, —N(CH3)2, —N(CH2CH3)2, ═NH, ═NCH3, —C(O)H, —C(O)OH, —C(O)CH3, —C(O)OCH3, —NHC(O)H, —NHC(O)OH, —NHC(O)CH3, —NHC(O)OCH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, and oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl, where
    • the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl are substituted by from 0 to 2 substitutents R12 on N or C atoms, and each R12 is independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl; and
    • the phenyl, pyridinyl, pyrimidinyl and pyrrolyl are substituted by from 0 to 3 substitutents R13 on N or C atoms, and each R13 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl and 3- to 8-membered cycloalkyl containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
(d) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl having from 0 to 3 substitutents R10 on N or C atoms, the R10 independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, phenyl and benzyl, and
(e) aryl ring systems G′ chosen from the group consisting of: phenyl, pyridinyl and 9-membered bicyclic ring systems containing from 0 to 2 heteroatoms independently chosen from the group consisting of N and O.
In a first aspect of the eighth embodiment, G is independently chosen from the group consisting of C1-4alkyl having 1 to 2 substituents R11, wherein each R11 is independently chosen from the group consisting of —OH, —NH2, —NCH3H, —N(CH3)2, —N(CH2CH3)2, —C(O)OCH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl. In all aspects of the eighth embodiment, G is chosen such that stable compounds result. In all aspects of this eighth embodiment, all other groups are as provided in the general formula above and/or in the first through sixth embodiments.
In a ninth embodiment of the invention,
Figure US11053243-20210706-C00043
is chosen from the group consisting of
Figure US11053243-20210706-C00044
where
each X is independently chosen from the group consisting of CR1 and N,
Figure US11053243-20210706-C00045
is chosen from the group consisting of
Figure US11053243-20210706-C00046
each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —C(O)R3, —CO2R3a, —C(O)N(R3a)2, —SR3a, —S(O)R3a, —S(O2)R3a, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3a, —N(Z3a)CO2R3a, —N(Z3a)C(O)R3, —N(R3a)COR3a, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl, each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and
each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
Figure US11053243-20210706-C00047
is chosen from the group consisting of —C≡C—, phenyl, pyridinyl, pyrazinyl, pyrimidyl, 1,2,4-triazinyl, pyridazinyl, thiazyl and 9-membered bicyclic ring systems that contain from 1 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
v is from 0 to 4,
each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)CO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, —N(R4a)SO2R4a, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), C1-6alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4,
each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl, and
each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
wherein each D is independently chosen from the group consisting of a single bond, —C(O)N(R5)—, —NR5C(O)—,
Figure US11053243-20210706-C00048
where
    • R5 is independently chosen from the group consisting of hydrogen, halogen —OR6, —CN, —CO2R6, —C(O)N(R6)2, —N(R6)2, —N(R6)COR6, —SR6, —S(O)R6, —S(O2)R6, —N(R6)SO2R6, —NCO2R6, —NC(O)N(R6)2, C1-6alkyl substituted by from 0 to 3 substituents R6 and C3-8cycloalkyl substituted by from 0 to 3 substituents R6, and
    • each R6 is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
wherein each E is independently chosen from the group consisting of a single bond, —CH2NHC(O)—, —CH2N(CH3)C(O)—, —C(CH3)HNHC(O)—, —C(CH3)HN(CH3)C(O)—, —C(CH3)2NHC(O)—, —C(CH3)2N(CH3)C(O)—, —CH2NHC(O)O—, —CH2N(CH3)C(O)O—, —C(CH3)HNHC(O)O—, —C(CH3)HN(CH3)C(O)O—, —C(CH3)2NHC(O)O—, —C(CH3)2N(CH3)C(O)O—,
Figure US11053243-20210706-C00049
where one of R8a and R8b is —OH or fluorine;
wherein each G is independently chosen from the group consisting of
(a) hydrogen,
(b) —CN,
(c) C1-5alkyl having 1 to 3 substituents R11,
    • each R11 is independently chosen from the group consisting of —OH, —NH2, —NCH3H, —N(CH3)2, —N(CH2CH3)2, ═NH, ═NCH3, —C(O)H, —C(O)OH, —C(O)CH3, —C(O)OCH3, —NHC(O)H, —NHC(O)OH, —NHC(O)CH3, —NHC(O)OCH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, and oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl, where
    • the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl are substituted by from 0 to 2 substitutents R12 on N or C atoms, and each R12 is independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6 alkyl, —O—C1-6alkyl and —S—C1-6alkyl; and
    • the phenyl, pyridinyl, pyrimidinyl and pyrrolyl are substituted by from 0 to 3 substitutents R13 on N or C atoms, and each R13 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl and 3- to 8-membered cycloalkyl containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
(d) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl having from 0 to 3 substitutents R10 on N or C atoms, the R10 independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, phenyl and benzyl, and
(e) aryl ring systems G′ chosen from the group consisting of: phenyl, pyridinyl and 9-membered bicyclic ring systems containing from 0 to 2 heteroatoms independently chosen from the group consisting of N and O. In all aspects of this embodiment, all other groups are as provided in the general formula above.
In a tenth embodiment of the invention,
Figure US11053243-20210706-C00050
is chosen from the group consisting of
Figure US11053243-20210706-C00051
where
Figure US11053243-20210706-C00052
is substituted by from 0 to 3 additional R1;
Figure US11053243-20210706-C00053
is phenyl; v is from 0 to 2; each R2 is independently chosen from the group consisting of fluorine, chlorine, —OH, —CH3, —OCH3 and —CN; each D is independently chosen from the group consisting of
Figure US11053243-20210706-C00054
each E is independently chosen from the group consisting of a single bond,
Figure US11053243-20210706-C00055
where one of R8a and R8b is —OH or fluorine;
and each G is independently chosen from the group consisting of C1-4alkyl having 1 to 2 substituents R11, wherein each R11 is independently chosen from the group consisting of —OH, —NH2, —NCH3H, —N(CH3)2, —N(CH2CH3)2, —C(O)OCH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl. In all aspects of this embodiment, all other groups are as provided in the general formula above or in the eighth embodiment.
In an eleventh embodiment of the invention, the compound having structural formula (I) is a compound having structural formula (Ia):
Figure US11053243-20210706-C00056
or a pharmaceutically acceptable salt thereof, wherein
Figure US11053243-20210706-C00057
is substituted by u substituents R1, and Y is selected from the group consisting of 0 and NR1. In all aspects of this embodiment, all other groups are as provided in the general formula above or in any one of the first through tenth embodiments.
In a twelfth embodiment of the invention, the compound having structural formula (Ia) is a compound having structural formula (Ib):
Figure US11053243-20210706-C00058
or a pharmaceutically acceptable salt thereof, wherein
Figure US11053243-20210706-C00059
is substituted by u substituents R1, and Y is selected from the group consisting of O and NR1. In particular aspects of this embodiment,
Figure US11053243-20210706-C00060
is substituted by u substituents R1, Y is O, and both instances of G are
Figure US11053243-20210706-C00061
In all aspects of this embodiment, all other groups are as provided in the general formula above or in the eleventh embodiment.
In a thirteenth embodiment of the invention, the compound having structural formula (Ia) is a compound having structural formula (Ib):
Figure US11053243-20210706-C00062
or a pharmaceutically acceptable salt thereof, wherein said
Figure US11053243-20210706-C00063
is substituted by u substituents R1, and said
Figure US11053243-20210706-C00064
and said
Figure US11053243-20210706-C00065
taken together with one substituent R1 and one substituent R2, are represented by a group chosen from the group consisting of
Figure US11053243-20210706-C00066
In particular aspects of this embodiment,
Figure US11053243-20210706-C00067
and said
Figure US11053243-20210706-C00068
taken together with one substituent R1 and one substituent R2, are represented by
Figure US11053243-20210706-C00069
wherein V is —CH2—, W is —(CH2)0-2O(CH2)0-2—, R1 is fluorine, and both instances of G are
Figure US11053243-20210706-C00070
In all aspects of this embodiment, all other groups are as provided in the general formula above or in the eleventh embodiment.
In a fourteenth embodiment of the invention,
Figure US11053243-20210706-C00071
taken together with one substituent R1 and one substituent R2, are represented by a group chosen from the group consisting of:
Figure US11053243-20210706-C00072
where
W is chosen from the group consisting of —(CH2)1-3—, —(CH2)0-2NH(CH2)0-2—, —(CH2)0-2N(C1-6alkyl)(CH2)0-2—, —(CH2)0-2O(CH2)0-2— and —(CH2)0-2C(O)(CH2)0-2—, where W is substituted by from 0 to 4 Rw, where each Rw is independently selected from C1-6alkyl and C3-8cycloalkyl; and
V is chosen from the group consisting of —C(O)— and —CH2—, and where V is —CH2—, V is substituted by from 0 to 2 Rv, where each Rv is independently selected from the group consisting of C1-6alkyl and C3-8cycloalkyl;
    • each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3, —CN, —C(O)R3, —CO2R3, —C(O)N(R3a)2, —SR3, —S(O)R3, —S(O2)R3, —N(R3a)2, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3, —N(R3a)CO2R3, —N(R3a)COR3, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl,
    • each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and
    • each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)CO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, —N(R4a)SO2R4a, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), C1-6alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4,
    • each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl, and
    • each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
wherein each D is independently chosen from the group consisting of a single bond, —C(O)N(R5)—, —NR5C(O)—,
Figure US11053243-20210706-C00073
where
    • R5 is independently chosen from the group consisting of hydrogen, halogen —OR6, —CN, —CO2R6, —C(O)N(R6)2, —N(R6)2, —N(R6)COR6, —SR6, —S(O)R6, —S(O2)R6, —N(R6)SO2R6, —NCO2R6, —NC(O)N(R6)2, C1-6alkyl substituted by from 0 to 3 substituents R6 and C3-8cycloalkyl substituted by from 0 to 3 substituents R6, and
    • each R6 is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
wherein each E is independently chosen from the group consisting of a single bond, —CH2NHC(O)—, —CH2N(CH3)C(O)—, —C(CH3)HNHC(O)—, —C(CH3)HN(CH3)C(O)—, —C(CH3)2NHC(O)—, —C(CH3)2N(CH3)C(O)—, —CH2NHC(O)O—, —CH2N(CH3)C(O)O—, —C(CH3)HNHC(O)O—, —C(CH3)HN(CH3)C(O)O—, —C(CH3)2NHC(O)O—, —C(CH3)2N(CH3)C(O)O—,
Figure US11053243-20210706-C00074
where one of R8a and R8b is —OH or fluorine;
wherein each G is independently chosen from the group consisting of
(a) hydrogen,
(b) —CN,
(c) C1-5alkyl having 1 to 3 substituents R11,
    • each R11 is independently chosen from the group consisting of —OH, —NH2, —NCH3H, —N(CH3)2, —N(CH2CH3)2, ═NH, ═NCH3, —C(O)H, —C(O)OH, —C(O)CH3, —C(O)OCH3, —NHC(O)H, —NHC(O)OH, —NHC(O)CH3, —NHC(O)OCH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl, and oxacyclohexyl, phenyl, pyridinyl, pyrimidinyl and pyrrolyl, where
    • the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl are substituted by from 0 to 2 substitutents R12 on N or C atoms, and each R12 is independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6alkyl, —O—C1-6alkyl and S—C1-6alkyl; and
    • the phenyl, pyridinyl, pyrimidinyl and pyrrolyl are substituted by from 0 to 3 substitutents R13 on N or C atoms, and each R13 is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl and 3- to 8-membered cycloalkyl containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
(d) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyranyl, pyrrolidinyl, piperidinyl, oxacyclopentyl and oxacyclohexyl having from 0 to 3 substitutents R10 on N or C atoms, the R10 independently selected from the group consisting of hydrogen, halogen, carboxy, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, phenyl and benzyl, and
(e) aryl ring systems G′ chosen from the group consisting of: phenyl, pyridinyl and 9-membered bicyclic ring systems containing from 0 to 2 heteroatoms independently chosen from the group consisting of N and O. In all aspects of this embodiment, all other groups are as provided in the general formula above.
In another embodiment of the invention, the compound of the invention is selected from the exemplary species depicted in Examples 1 through 215 shown below, or pharmaceutically acceptable salts thereof.
In another embodiment of the invention, for the compounds of formula (I), variables
Figure US11053243-20210706-C00075
D, E, G, R1, R2, u, v, R3, R3a, R4, R4a, R5, R6, R7, I, J, R8a, R8b, R8c, R9, R10, R10a, R11, R12, R13, R14, W, Rw, V, and Rv, are selected independently from each other.
Other embodiments of the present invention include the following:
(a) A pharmaceutical composition comprising an effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.
(b) The pharmaceutical composition of (a), further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
(c) The pharmaceutical composition of (b), wherein the HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
    • (d) A pharmaceutical combination that is (i) a compound of formula (I) and (ii) a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents; wherein the compound of formula (I) and the second therapeutic agent are each employed in an amount that renders the combination effective for inhibiting HCV NS5A activity, or for treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, or for inhibiting HCV viral replication and/or HCV viral production in a cell-based system.
(e) The combination of (d), wherein the HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
(f) A method of inhibiting HCV NS5A activity in a subject in need thereof, which comprises administering to the subject an effective amount of a compound of formula (I).
(g) A method of treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection in a subject in need thereof, which comprises administering to the subject an effective amount of a compound of formula (I).
(h) The method of (g), wherein the compound of formula (I) is administered in combination with an effective amount of at least one second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
(i) The method of (h), wherein the HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
(j) A method of inhibiting HCV viral replication and/or HCV viral production in a cell-based system, which comprises administering to the subject an effective amount of a compound of formula (I).
(k) The method of (j), wherein the compound of formula (I) is administered in combination with an effective amount of at least one second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
(l) The method of (k), wherein the HCV antiviral agent is an antiviral selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
(m) A method of inhibiting HCV NS5A activity in a subject in need thereof, which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
    • (n) A method of treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection in a subject in need thereof, which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
    • (o) A method of inhibiting HCV viral replication and/or HCV viral production in a cell-based system, which comprises administering to the subject the pharmaceutical composition of (a), (b), or (c) or the combination of (d) or (e).
In the embodiments of the compounds and salts provided above, it is to be understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound or salt and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (o) above are understood to include all embodiments of the compounds and/or salts, including such embodiments as result from combinations of embodiments.
The present invention also includes a compound of the present invention for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inhibiting HCV NS5A activity, or (b) treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, or (c) inhibiting HCV viral replication and/or HCV viral production in a cell-based system, or (d) use in medicine. In these uses, the compounds of the present invention can optionally be employed in combination with one or more second therapeutic agents selected from HCV antiviral agents, anti-infective agents, and immunomodulators.
Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(o) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, aspects, classes, sub-classes, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt, or may be present in the form of a solvate or hydrate as appropriate.
As used herein, all ranges are inclusive, and all sub-ranges are included within such ranges, although not necessarily explicitly set forth. In addition, the term “or,” as used herein, denotes alternatives that may, where appropriate, be combined; that is, the term “or” includes each listed alternative separately as well as their combination.
As used herein, the term “alkyl” refers to any linear or branched chain alkyl group having a number of carbon atoms in the specified range. Thus, for example, “C1-6 alkyl” (or “C1-C6 alkyl”) refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl and methyl. As another example, “C1-4 alkyl” refers to n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl and methyl. Where indicated, “C0” refers to hydrogen; thus, for example, “C0-6 alkyl” (or “C0-C6 alkyl”) refers to all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl, methyl and hydrogen. Alkyl groups may be substituted as indicated.
The term “halogenated” refers to a group or molecule in which a hydrogen atom has been replaced by a halogen. Similarly, the term “haloalkyl” refers to a halogenated alkyl group. The term “halogen” (or “halo”) refers to atoms of fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo), preferably fluorine.
The term “alkoxy” refers to an “alkyl-O—” group, where alkyl is as defined above. Alkoxy groups may be substituted as indicated.
The term “cycloalkyl” refers to any cyclic ring of an alkane or alkene having a number of carbon atoms in the specified range. Thus, for example, “C3-8 cycloalkyl” (or “C3-C8 cycloalkyl”) refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The term “cycloalkoxy” refers to a “cycloalkyl-O—” group, where cycloalkyl is as defined above. Cycloalkyl groups may be substituted as indicated.
The term “aryl” (or “aryl ring system”) refers to aromatic mono- and poly-carbocyclic or heterocyclic ring systems wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. As used herein, the term aryl includes aromatic mono- and poly-carbocyclic ring systems that include from 0 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S. Suitable aryl groups include phenyl, naphthyl, biphenylenyl, pyridinyl, pyrimidinyl and pyrrolyl, as well as those discussed below. Aryl groups may be substituted as indicated. Aryl ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached. Unless otherwise indicated, substituents to the aryl ring systems can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.
The term “carbocycle” (and variations thereof such as “carbocyclic”) as used herein, unless otherwise indicated, refers to (i) a C5 to C7 monocyclic, saturated or unsaturated ring, or (ii) a C8 to C10 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated. Carbocycle groups may be substituted as indicated. When the carbocycles contain one or more heteroatoms independently chosen from N, O and S, the carbocycles may also be referred to as “heterocycles,” as defined below. The carbocycle may be attached to the rest of the molecule at any carbon or nitrogen atom that results in a stable compound. The fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term “fused bicyclic carbocycle” generally refers to a C8 to C10 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. A fused bicyclic carbocycle in which both rings are saturated is a saturated bicyclic ring system. Saturated carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc. A fused bicyclic carbocycle in which one or both rings are unsaturated is an unsaturated bicyclic ring system. Carbocycle ring systems may include, where appropriate, an indication of the variable to which a particular ring atom is attached. Unless otherwise indicated, substituents to the ring systems can be attached to any ring atom, provided that such attachment results in formation of a stable ring system.
Unless indicated otherwise, the term “heterocycle” (and variations thereof such as “heterocyclic” or “heterocyclyl”) broadly refers to (i) a stable 5- to 7-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 8- to 10-membered bicyclic ring system, wherein each ring in (ii) is independent of, or fused to, the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) independently selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the bicyclic ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized. Unless otherwise specified, the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. Heterocycle groups may be substituted as indicated, and unless otherwise specified, the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results. Representative examples include pyranyl, piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl). Unless expressly stated to the contrary, the term “heteroaryl ring system” refers to aryl ring systems, as defined above, that include from 1 to 4 heteroatoms (non-carbon atoms) that are independently chosen from N, O and S. In the case of substituted heteraromatic rings containing at least one nitrogen atom (e.g., pyridine), such substitutions can be those resulting in N-oxide formation. Representative examples of heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Representative examples of bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl and benzo-1,3-dioxolyl.
Unless otherwise specifically noted as only “substituted”, alkyl, cycloalkyl, and aryl groups are not substituted. If substituted, preferred substituents are selected from the group that includes, but is not limited to, halo, C1-C20 alkyl, —CF3, —NH2, —N(C1-C6 alkyl)2, —NO2, oxo, —CN, —N3, —OH, —O(C1-C6 alkyl), C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C0-C6 alkyl) S(O)0-2—, aryl-S(O)0-2—, (C0-C6 alkyl)S(O)0-2(C0-C6 (C0-C6 alkyl)C(O)NH—, H2N—C(NH)—, —O(C1-C6 alkyl)CF3, (C0-C6 alkyl)C(O)—, (C0-C6 alkyl)OC(O)—, (C0-C6alkyl)O(C1-C6 (C0-C6 alkyl)C(O)1-2(C0-C6 (C1-C6 alkyl)OC(O)NH—, aryl, aralkyl, heteroaryl, heterocycloalkyl, halo-aryl, halo-aralkyl, halo-heterocycle and halo-heterocycloalkyl.
Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaryl ring described as containing from “0 to 3 heteroatoms” means the ring can contain 0, 1, 2, or 3 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. The oxidized forms of the heteroatoms N and S are also included within the scope of the present invention.
When any variable (for example, R1 or R3) occurs more than one time in any constituent or in formula (I) or in any other formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom provided such substitution is chemically allowed and results in a stable compound. A “stable” compound is a compound that can be prepared and isolated and that has a structure and properties that remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
As used herein, the term “compound” is intended to encompass chemical agents described by generic formula (I) in all forms, including hydrates and solvates of such chemical agents.
In the compounds of generic formula (I), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic formula (I). For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H or D). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
As a result of the selection of substituents and substituent patterns, certain of the compounds of the present invention can have asymmetric centers and can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether isolated or in mixtures, are within the scope of the present invention.
As would be recognized by one of ordinary skill in the art, certain of the compounds of the present invention can exist as tautomers. For the purposes of the present invention a reference to a compound of formula (I) is a reference to the compound per se, or to any one of its tautomers per se, or to mixtures of two or more tautomers.
The compounds of the present invention may be administered in the form of pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt” refers to a salt that possesses the effectiveness of the parent compound and that is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Many of the compounds of the invention carry an acidic moiety, in which case suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (—COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
The term “administration” and variants thereof (e.g., “administering” a compound) in reference to a compound of the invention mean providing the compound or a prodrug of the compound to the individual in need of treatment. When a compound of the invention or a prodrug thereof is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating HCV infection), “administration” and its variants are each understood to include concurrent and sequential provision of the compound or salt (or hydrate) and other agents.
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients, as well as any product that results, directly or indirectly, from combining the specified ingredients.
By “pharmaceutically acceptable” is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
The terms “subject” (alternatively referred to herein as “patient”) as used herein, refer to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term “effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. In one embodiment, the effective amount is a “therapeutically effective amount” for the alleviation of one or more symptoms of the disease or condition being treated. In another embodiment, the effective amount is a “prophylactically effective amount” for reduction of the severity or likelihood of one or more symptoms of the disease or condition. In another embodiment, the effective amount is a “therapeutically effective amount” for inhibition of HCV viral replication and/or HCV viral production. The term also includes herein the amount of active compound sufficient to inhibit HCV NS5A and thereby elicit the response being sought (i.e., an “inhibition effective amount”). When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.
It is understood that claimed compounds cause inhibition in replicon assay testing. Thus, compounds described herein are useful for inhibiting HCV replication, specifically the NS5A protein. Compounds described herein have different uses, including the prevention or treatment of one or more of the symptoms of HCV infection, the inhibition of HCV viral replication and/or HCV viral production, and/or as pharmaceutical composition ingredients.
The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for identifying resistant HCV replicon cell lines harboring mutations within NS5A, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to the HCV replicase.
For the purposes of inhibiting HCV NS5A protein, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection and inhibiting HCV viral replication and/or HCV viral production, the compounds of the present invention, optionally in the form of a salt or a hydrate, can be administered by any means that produces contact of the active agent with the agent's site of action. They can be administered by one or more conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The compounds of the invention can, for example, be administered by one or more of the following: orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation (such as in a spray form), or rectally, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups, elixirs and the like) can be prepared according to techniques known in the art and can employ any of the usual media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (e.g., powders, pills, capsules and tablets) can be prepared according to techniques known in the art and can employ such solid excipients as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions can be prepared according to techniques known in the art and typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids. Injectable solutions can be prepared according to methods known in the art wherein the carrier comprises a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further description of methods suitable for use in preparing pharmaceutical compositions of the present invention and of ingredients suitable for use in said compositions is provided in Remington's Pharmaceutical Sciences, 18th edition (ed. A. R. Gennaro, Mack Publishing Co., 1990).
The compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses. One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
As noted above, the present invention also relates to a method of inhibiting HCV replicon activity, inhibiting HCV viral replication and/or HCV viral production, treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection with a compound of the present invention in combination with one or more therapeutic agents and a pharmaceutical composition comprising a compound of the present invention and one or more therapeutic agents selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent. Such therapeutic agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha-1, R7025 (an enhanced interferon (Roche)), interferon-β, interferon-α, pegylated interferon-α (peginterferon-α), a combination of interferon-α and ribavirin, a combination of peginterferon-α and ribavirin, a combination of interferon-α and levovirin, and a combination of peginterferon-α and levovirin. The combination of peginterferon-α and ribaviron represents the current Standard of Care for HCV treatment. The combination of one or more compounds of the present invention with the Standard of Care for HCV treatment, pegylated-interferon and ribaviron is specifically contemplated as being encompassed by the present invention. Interferon-α includes, but is not limited to, recombinant interferon-α2a (such as ROFERON interferon), pegylated interferon-α2a (PEGASYS), interferon-α2b (such as INTRON-A interferon), pegylated interferon-α2b (PEGINTRON), a recombinant consensus interferon (such as interferon alphacon-1), albuferon (interferon-α bound to human serum albumin (Human Genome Sciences)), and a purified interferon-α product. Amgen's recombinant consensus interferon has the brand name INFERGEN. Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin. Viramidine represents an analog of ribavirin disclosed in International Patent Application Publication WO 01/60379. In accordance with the method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme on the biosynthetic route in de novo guanine nucleotide biosynthesis. Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH. Thus, inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication. Therefore, the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as those disclosed in International Patent Application Publications WO 97/41211, WO 01/00622 and WO 00/25780; or mycophenolate mofetil. See Anthony C. Allison and Elsie M. Eugui, Immunosuppressive and Other Anti-Rheumetic Activities of Mychophenolate Mofetil, 44 (SUPPL.) AGENTS ACTION 165 (1993).
For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with the antiviral agent polymerase inhibitor R7128 (Roche).
The compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 2′-C-branched ribonucleosides disclosed in Rogers E. Harry-O'Kuru et al., A Short, Flexible Route to 2′-C-Branched Ribonucleosides, 62 J. ORG. CHEM. 1754-59 (1997); Michael S. Wolfe and Rogers E. Harry-O'Kuru, A Consise Synthesis of 2′-C-Methylribonucleosides, 36 TET. LETT. 7611-14 (1995); U.S. Pat. No. 3,480,613; and International Patent Application Publications WO 01/90121, WO 01/92282, WO 02/32920, WO 04/002999, WO 04/003000 and WO 04/002422; the contents of each of which are incorporated by reference in their entirety. Such 2′-C-branched ribonucleosides include, but are not limited to, 2′-C-methyl-cytidine, 2′-C-methyl-uridine, 2′-C-methyl-adenosine, 2′-C-methyl-guanosine, and 9-(2-C-methyl-β-D-ribofuranosyl)-2,6-diaminopurine, and the corresponding amino acid ester of the ribose C-2′, C-3′, and C-5′ hydroxyls and the corresponding optionally substituted cyclic 1,3-propanediol esters of the 5′-phosphate derivatives.
For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease. HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication. Exemplary substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in International Patent Application Publications WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, WO 02/48116, WO 02/48172, WO 2008/057208 and WO 2008/057209, in British Patent No. GB 2 337 262, and in U.S. Pat. Nos. 6,323,180, 7,470,664, and 7,012,066 and in Ashok Arasappan et al., Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor, ACS MED. CHEM. LETT. DOI: 10.1021/m19000276 (Feb. 15, 2010).
The compounds of the present invention may also be combined for the treatment of HCV infection with nucleosides having anti-HCV properties, such as those disclosed in International Patent Application Publications WO 02/51425, WO 01/79246, WO 02/32920, WO 02/48165 and WO 2005/003147 (including R1656, (2′R)-2′-deoxy-2′-fluoro-2′-C-methylcytidine, shown as compounds 3-6 on page 77); WO 01/68663; WO 99/43691; WO 02/18404 and WO 2006/021341, and U.S. Patent Application Publication US 2005/0038240, including 4′-azido nucleosides such as R1626, 4′-azidocytidine; U.S. Patent Application Publications US 2002/0019363, US 2003/0236216, US 2004/0006007, US 2004/0063658 and US 2004/0110717; U.S. Pat. Nos. 7,105,499, 7,125,855, 7,202,224; and International Patent Application Publications WO 02/100415, WO 03/026589, WO 03/026675, WO 03/093290, WO 04/011478, WO 04/013300 and WO 04/028481; the content of each is incorporated herein by reference in its entirety.
For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NSSB polymerase. Such HCV NSSB polymerase inhibitors that may be used as combination therapy include, but are not limited to, those disclosed in International Patent Application Publications WO 02/057287, WO 02/057425, WO 03/068244, WO 2004/000858, WO 04/003138 and WO 2004/007512; U.S. Pat. Nos. 6,777,392, 7,105,499, 7,125,855, 7,202,224 and U.S. Patent Application Publications US 2004/0067901 and US 2004/0110717; the content of each is incorporated herein by reference in its entirety. Other such HCV polymerase inhibitors include, but are not limited to, valopicitabine (NM-283; Idenix) and 2′-F-2′-beta-methylcytidine (see also WO 2005/003147).
In one embodiment, nucleoside HCV NSSB polymerase inhibitors that are used in combination with the present HCV inhibitors are selected from the following compounds: 4-amino-7-(2-C-methyl-β-D-arabinofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-methylamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-dimethylamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-cyclopropylamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C-vinyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C-hydroxymethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C-fluoromethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-5-methyl-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid; 4-amino-5-bromo-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-5-chloro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-5-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 2,4-diamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 2-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 2-amino-4-cyclopropylamino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 2-amino-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one; 4-amino-7-(2-C-ethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2-C,2-0-dimethyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one; 2-amino-5-methyl-7-(2-C, 2-O-dimethyl-(3-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one; 4-amino-7-(3-deoxy-2-C-methyl-(3-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(3-deoxy-2-C-methyl-β-D-arabinofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-2-fluoro-7-(2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(3-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(3-C-methyl-β-D-xylofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(2,4-di-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; 4-amino-7-(3-deoxy-3-fluoro-2-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; and the corresponding 5′-triphosphates; or a pharmaceutically acceptable salt thereof.
The compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in U.S. Patent Application Publications US 2006/0100262 and US 2009-0048239; International Patent Application Publications WO 01/77091, WO 01/47883, WO 02/04425, WO 02/06246, WO 02/20497, WO 2005/016927 (in particular JTK003), WO 2004/041201, WO 2006/066079, WO 2006/066080, WO 2008/075103, WO 2009/010783 and WO 2009/010785; the content of each is incorporated herein by reference in its entirety.
In one embodiment, non-nucleoside HCV NSSB polymerase inhibitors that are used in combination with the present HCV NS5A inhibitors are selected from the following compounds: 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-(2-morpholin-4-ylethyl)-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-3-methoxy-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; methyl ({[(14-cyclohexyl-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocin-11-yl)carbonyl]amino}sulfonyl)acetate; ({[(14-cyclohexyl-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocin-11-yl)carbonyl]amino}sulfonyl)acetic acid; 14-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-methyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxamide; 3-chloro-14-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine 11-carboxylic acid; N-(11-carboxy-14-cyclohexyl-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocin-7-yl)-N,N-dimethylethane-1,2-diaminium bis(trifluoroacetate); 14-cyclohexyl-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid; 14-cyclohexyl-6-methyl-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-3-methoxy-6-methyl-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-3-methoxy-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[3-(dimethylamino)propyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-7-oxo-6-(2-piperidin-1-ylethyl)-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-(2-morpholin-4-ylethyl)-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[2-(diethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-(1-methylpiperidin-4-yl)-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-N-[(dimethylamino)sulfonyl]-7-oxo-6-(2-piperidin-1-ylethyl)-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxamide; 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-N-[(dimethylamino)sulfonyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxamide; 14-cyclopentyl-6-[2-(dimethylamino)ethyl]-7-oxo-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 6-allyl-14-cyclohexyl-3-methoxy-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclopentyl-6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 14-cyclohexyl-6-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydroindolo[2,1-a][2,5]benzodiazocine-11-carboxylic acid; 13-cyclohexyl-5-methyl-4,5,6,7-tetrahydrofuro[3′,2′:6,7][1,4]diazocino[1,8-a]indole-10-carboxylic acid; 15-cyclohexyl-6-[2-(dimethylamino)ethyl]-7-oxo-6,7,8,9-tetrahydro-5H-indolo[2,1-a][2,6]benzodiazonine-12-carboxylic acid; 15-cyclohexyl-8-oxo-6,7,8,9-tetrahydro-5H-indolo[2,1-a][2,5]benzodiazonine-12-carboxylic acid; 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[1,2-d][1,4]benzodiazepine-10-carboxylic acid; and pharmaceutically acceptable salts thereof.
The HCV replicons and NS5A inhibitory activity of the present compounds may be tested using assays known in the art. HCV inhibitors, such as those described in the Examples herein have activities in genotype 1b, 2a and 1a replicon assays of from about 1 pM to about 1 μM. The assay is performed by incubating a replicon harboring cell-line in the presence of inhibitor for a set period of time and measuring the effect of the inhibitor on HCV replicon replication either directly by quantifying replicon RNA level, or indirectly by measuring enzymatic activity of a co-encoded reporter enzyme such as luciferase or β-lactamase. By performing a series of such measurements at different inhibitor concentrations, the effective inhibitory concentration of the inhibitor (EC50 or EC90) is determined. See Jan M. Vrolijk et al., A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C, 110 J. VIROLOGICAL METHODS 201 (2003). Such assays may also be run in an automated format for high through-put screening. See Paul Zuck et al., A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication, 334 ANALYTICAL BIOCHEMISTRY 344 (2004).
The present invention also includes processes for making compounds of formula (I). The compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above. The following reaction schemes and examples serve only to illustrate the invention and its practice.
General Schemes
Figure US11053243-20210706-C00076
Figure US11053243-20210706-C00077
The synthesis of analogs containing the 4-azaindole core can be accomplished starting from a suitably protected 2-amino-5-nitropyridine 2, which can then be reduced by catalytic hydrogenation in order to convert the resulting free amino group to its hydrazine by the action of NaNO2 and SnCl2. The resulting pyridylhydrazine can be condensed with a ketone then subjected to Fisher indole cyclization conditions to afford the indole 6. Acidic deprotection of the acetyl groups can be accomplished by using a strong acid to liberate the diamine, which can be selectively coupled on the more reactive aniline nitrogen using standard coupling agents, such as HATU. The aminopyridine group can then be acylated with a reagent, such as acetyl chloride or a carboxylic acid, in the presence of an amide bond-forming reagent.
Figure US11053243-20210706-C00078
2-Bromo-3-aminopyridines can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 5, which can undergo TFAA-mediated cyclization to provide the 4-azaindole compounds 6. Protecting groups can be removed with a strong acid, such as aqueous HCl, and the resulting amine can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU.
Figure US11053243-20210706-C00079
The synthesis of scaffolds B containing a 6-azaindole core can be accomplished by the metallation of the 4-methylpyridine analog 2 with a strong base, such as BuLi, and quenching the resulting anion with the acylating agent, such as 3. Intermediate 4 can be globally deprotected by the action of a strong acid, such as HBr, to give the diamino azaindole structure 5. Both amino groups can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU. Compounds 6 can be further functionalized at the C-3 indole position with electrophiles, such as NCS.
Figure US11053243-20210706-C00080
Figure US11053243-20210706-C00081
Iodo aminopyridines 2 can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 5, which can undergo a base-mediated cyclization using a reagent, such as KOtBu, to provide the 7-azaindole compounds 4. Protecting groups can be removed with a strong acid, such as aqueous HCl, and the resulting amine can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU. Compounds 6 can then be reduced using hydrogen and a catalyst then coupled a second time with a carboxylic acid and HATU to provide 8. Treatment of 8 with an electrophilic agent, such as NCS, provides the desired compounds.
Figure US11053243-20210706-C00082
Figure US11053243-20210706-C00083
Compounds in the D series can be synthesized by reacting dicarbonyl intermediate 2 with a 2-aminopyrimidine derivative in the presence of a Lewis acid, such as boron trifluoride etherate. The resulting heterocycle can be alkylated with a bromoketone analog of an amino acid, such as proline, in the presence of a tertiary amine base. The nitro group can be reduced, and the resulting aniline can be acylated using an appropriately substituted carboxylic acid and an amide bond forming reagent, such as HATU, to give the final products.
Figure US11053243-20210706-C00084
Figure US11053243-20210706-C00085
Scaffold E-1 can be prepared by the condensing a benzoic acid derivative, such as 1, with a phenylenediamine counterpart 2 in the presence of a dehydrating agent, such as polyphosphoric acid. The resulting aniline can be acylated using an appropriately substituted carboxylic acid, such as N-Boc-L-proline, and an amide bond-forming reagent, such as HATU, and can then be subjected to acidic conditions to remove the Boc group. Compounds 4 can be coupled again with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU. The nitro group in 5 can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be further coupled with various amines to give the target compounds.
Figure US11053243-20210706-C00086
Scaffold E-2 can be prepared by the reacted with a benzoic acid derivative with a phenylenediamine analog and an amide bond-forming reagent, such as HATU, to give amides 3, which can be cyclodehydrated by heating with a reagent, such as HOAc. The resulting aniline can be acylated using an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give intermediates 5. The nitro group can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be sulfonylated with an appropriately substituted sulfonyl chloride and a tertiary amine base to give the targets.
Figure US11053243-20210706-C00087
Scaffold F can be prepared by the condensing a benzoic acid derivative, such as 1, with an amino phenol counterpart 2 in the presence of a dehydrating agent, such as polyphosphoric acid. The resulting aniline can be acylated using an appropriately substituted carboxylic acid, such as N-Boc-L-proline, and an amide bond-forming reagent, such as HATU, and can then be subjected to acidic conditions to remove the Boc group. Compounds 4 can be coupled again with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
Figure US11053243-20210706-C00088
Compounds having the benzofuran structure G can be prepared by reacting an appropriately substituted salicylaldehyde with a benzyl halide, such as 4-nitrobenzyl bromide, in the presence of a tertiary amine base to give ethers 2. The benzylic ethers can be treated with a base, such as DBU, and heated to elevated temperatures to effect cyclization to the benzofurans 3. The nitro groups in 3 can be reduced under catalytic hydrogenating conditions, and the resulting anilines can be coupled with various carboxylic acids to give the target compounds G-1.
Figure US11053243-20210706-C00089
For differentially substituted compounds (R, R′) having the benzofuran structure G, the synthesis can be modified by reacting an appropriately substituted bromo salicylaldehyde with a benzyl halide, such as 4-nitrobenzyl bromide, in the presence of a tertiary amine base to give ethers 2. The benzylic ethers can be treated with a base, such as DBU, and heated to elevated temperatures to effect cyclization to the benzofurans 3. The aryl bromide can be converted to the aryl amine by reaction with LHMDS and a palladium catalyst to provide 4, which can be coupled to an appropriately substituted carboxylic acid to give 5. The nitro group in 5 can be reduced under catalytic hydrogenating conditions, and the resulting aniline can be coupled with a second carboxylic acid analog to give the target compounds G-2.
Figure US11053243-20210706-C00090
Appropriately substituted aminopyrimidines can be cyclodehydrated after acylation with an appropriately substituted ketone, such as 4′-nitro-2-bromobenzophenone, by heating in a solvent, such as MeOH, and an acid source, such as HBr. The resulting heterocyclic nitro compound can be converted to the aromatic amine by reduction with a reagent, such as SnCl2. The final compounds H can be obtained by reacting 4 with an appropriately substituted carboxylic acid and an amide bond-forming reagent such as HATU.
Figure US11053243-20210706-C00091
Compounds in scheme I can be prepared by reacting the appropriately substituted aminopyridine with 4′-nitro-2-bromobenzophenone by heating in a solvent, such as acetone, then effecting a cyclodehydration reaction using methanol and an acid source, such as HBr. The resulting heterocyclic nitro compound 3 can be converted to the aromatic amine by reduction with a reagent such as SnCl2. The final compounds can be obtained by reacting 4 with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
Figure US11053243-20210706-C00092
Compounds in scheme J can be prepared by coupling indole boronic acids with an appropriately substituted 2-bromoindole, such as 2, under standard Suzuki conditions. The protecting groups can be removed with HCl, and the nitro group in 4 can be reduced under catalytic hydrogenation conditions. The penultimate diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as BOP, reagent to give compounds with the targeted central scaffold.
Figure US11053243-20210706-C00093
The synthesis of compounds with the indole core scaffold K can be prepared using standard Fisher indole synthesis protocol starting for an aryl hydrazine and a ketone such as 2. Conversion of the aryl bromide to the aryl amine 4 could be effected by the Pd-catalyzed reaction with LHMDS. The nitro group could be reduced and the diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give compounds with the targeted scaffold.
Figure US11053243-20210706-C00094
In an alternative procedure indoles K can be prepared starting from a suitably protected and substituted aminoindole 3. Lithiation and quenching with a boronate ester affords key intermediate 4, which can be coupled to an appropriately substituted aryl or heteroaryl halide to provide targets 5. The Boc groups can be removed with acid, and the resulting aniline can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU. The nitro group in 7 can be reduced and coupled in a second amide coupling reaction to give the desired compounds.
Figure US11053243-20210706-C00095
Tetracyclic indole scaffold L can be prepared as outline in the scheme above. Cyclization of a carboxylic acid derivative 2 with PPA can provide the ketones 3, which can participate in a Fischer indole reaction with an appropriately substituted phenylhydrazine to give 4. The acetamide groups can be deprotected under acidic conditions and the resulting aryl amines can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, to give compounds with the targeted scaffold.
Figure US11053243-20210706-C00096
Scaffold M-1 compounds can be prepared by coupling proline 2 to amino ketone 1 using standard amide bond-forming procedures to provide 3, which can be cyclized upon heating with ammonium acetate at elevated temperatures. Intermediate 4 can be coupled to indole boronic acids, such as using standard Suzuki-type conditions. The Boc groups can be removed with acid, and the resulting aniline can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU. The pyrrolidine protecting group can be removed under hydrogenating conditions, and the resulting amine can coupled in a second amide coupling reaction to give the desired compounds.
Figure US11053243-20210706-C00097
Scaffold M-2 compounds can be prepared by reacting proline 1 with an anion of 4-ethynylbenzene to give intermediate ketone 2, which can be cyclized with hydrazine. Intermediate 3 can be coupled to indole boronic acids, such as using standard Suzuki-type conditions. The Boc groups can be removed with acid and the resulting aniline can be coupled with an appropriately substituted carboxylic acid, and an amide bond-forming reagent such as HATU. The pyrrolidine protecting group can be removed under hydrogenating conditions, and the resulting amine can coupled in a second amide coupling reaction to give the desired compounds.
Figure US11053243-20210706-C00098
Thiazole analogs of scaffold M can be prepared from the cyclocondensation reaction of Z-proline thioamide 2 with an alpha-bromoacetophenone. Products 3 can be processed to the final compounds using methodology similar to that described in scheme M-2.
Figure US11053243-20210706-C00099
Imidazole analogs of scaffold M can be prepared from the cyclocondensation reaction of Z-proline bromomethyl ketone 1 with an aromatic amidine derivative. Products 3 can be processed to the final compounds using methodology similar to that described in scheme M-2.
Figure US11053243-20210706-C00100
Figure US11053243-20210706-C00101
Isomeric imidazoles can be prepared starting from a protected amino acid aldehyde, such as 1, and glyoxal in the presence of ammonia. Halogenation of the resulting imidazole 2 with NBS can be followed by a Pd-catalyzed cross coupling reaction with a functionalized indole boronate ester, such as 4. Deprotection, reduction and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide intermediate compounds 8. A second deprotection/amide-coupling procedure can provide the targeted M-5 scaffold.
Figure US11053243-20210706-C00102
Figure US11053243-20210706-C00103
Oxadiazole compounds can be prepared starting from indole hydrazide 2 and coupling to an amino acid, such as Z-proline. Cyclodehydration of intermediate 3 can be effected with a reagent, such as TPP/iodine, to give the desired oxadiazole, which can be protected on the indole nitrogen with Boc anhydride. Introduction of the boronic acid functional group activates compound 6 for coupling with a substituted aryl halide 7 to give intermediate 8. Removal of the cbz and Boc groups afford the penultimate structure 10, which can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent to give the targets M-6.
Figure US11053243-20210706-C00104
Oxadiazole analogs of scaffold M can be prepared by cyclocondensation reactions of diacylhydrazines 2. Coupling to heterocyclic boronic acids using methodology similar to that described in scheme M-1 can provide the targeted compounds.
Figure US11053243-20210706-C00105
Double imidazole containing benzofuran compounds can be prepared starting from a protected amino acid aldehyde, such as 2, and glyoxal in the presence of ammonia. Halogenation of the resulting imidazole 3 with NBS can ultimately provide intermediate 5, which can be coupled to a functionalized boronate ester, such as 11, to provide 12. Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide the targeted M-8 scaffold.
Figure US11053243-20210706-C00106
An alternative synthesis of benzofurans can be realized starting from benzofuran 1, which can be converted to boronate ester 2, which can then coupled to an appropriately substituted aryl halide to afford 5. Intermediate 5 can subsequently be converted to a functionalized boronate ester and converted to the final products in a manner similar to that described in Scheme M-8.
Figure US11053243-20210706-C00107
Benzoxazoles 3 can be prepared starting from a suitable substituted benzoic acid and an aminophenol, such as 2, in the presence of polyphosphoric acid. Such products can be converted to the corresponding boronate esters using standard procedures. Intermediates 4 can subsequently be coupled to a heterocyclic halide in the presence of a Pd(II) catalyst to provide compounds 5. Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide the targeted M-10 scaffold.
Figure US11053243-20210706-C00108
The compounds in scheme N-1 can be prepared by heating hydrazines 1 with ketones 2 in a microwave reactor in a polar aprotic solvent, such as NMP. The indole acetamides 3 can be deprotected with strong acid, such as HCl. The resulting aryl amines can be coupled with an appropriately substituted carboxylic acid, and an amide bond-forming reagent, such as HATU, to give compounds of the targeted scaffold.
Figure US11053243-20210706-C00109
Iodo anilines 1 can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 2, which can undergo cyclization using a reagent, such as indium bromide, to provide the indole compounds 3. Protecting groups can be removed with a strong acid, such as aqueous HCl, and the resulting amine can be acylated using an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU. Compounds 5 can then be reduced using hydrogen and a catalyst, then coupled a second time with a carboxylic acid and HATU to provide the desired compounds.
Figure US11053243-20210706-C00110
In a slight variation of scheme N-2, iodo anilines 1 can be coupled to a terminally substituted alkyne using standard Sonagashira coupling procedures to give intermediates 2, which can undergo cyclization using a reagent such as palladium chloride/ferric chloride to provide the indole compounds 3. Compounds 3 can then be reduced using H2, and the protecting group can be removed with a strong acid, such as aqueous HCl, and the resulting amines can be acylated using an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
Figure US11053243-20210706-C00111
Figure US11053243-20210706-C00112
Scaffold O can be prepared by reacting a protected proline compound (such as Cbz) with a phenylenediamine analog and an amide bond-forming reagent, such as HATU, to give amides 3, which can be cyclodehydrated by heating with a reagent, such as HOAc. The resulting benzimidazole can be coupled to an indole boronic acid derivative using standard Suzuki conditions to provide 5. Removal of the Boc groups with acid provides 7, which can be acylated using an appropriately substituted carboxylic acid, such as Boc-L-proline, and an amide bond-forming reagent, such as HATU, to give intermediates 7. The Cbz group can be reduced under catalytic hydrogenating conditions, and the Boc group can be deprotected with acid to provide penultimate compounds 9. Amide bond formation between 9 and carboxylic acids afford the targeted compounds.
Figure US11053243-20210706-C00113
Heterocycles can be halogenated at C-3 by the action of electrophilic agents, such as N-halosuccinimides, to provide targets P-1.
Figure US11053243-20210706-C00114
Heterocycles can be fluorinated at C-3 by the action of electrophilic fluorinating agents, such as SELECTFLUOR, to provide targets P-1.
Figure US11053243-20210706-C00115
C-3 halogenated compounds can be converted to the corresponding cyano analogs by cyanating agents, such as CuCN.
Figure US11053243-20210706-C00116
The compounds in scheme P-4 can be functionalized by the acylating indoles with Grignard reagents and zinc chloride.
Figure US11053243-20210706-C00117
The compounds in scheme P-5 can be functionalized by deprotonating the indoles with a base such as ethylmagnesium bromide and treating the resulting intermediate with chlorosulfonyl isocyanate. Alternatively, the indoles 3 can be prepared using Vilsmeier-Haack conditions, which can subsequently be protected and coupled under Suzuki conditions to give intermediates 5. The aldehydes can be oxidized using standard methodology for carboxylic acid formation. Indole carboxylic acids 6 can be coupled to amines using a reagent, such as HATU, to give 7, which can be further functionalized by reduction of the nitro group, deprotection of the Boc group and coupling of the anilines to an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU.
Figure US11053243-20210706-C00118
C-3 halogenated compounds can be coupled to a variety of alkyl and aryl boronic acids using standard Suzuki conditions.
Figure US11053243-20210706-C00119
Compounds of scheme Q can be prepared starting from the lactam 1. Reaction with ethyl chloroformate and treatment of the product with a mild base, such as ammonium carbonate, provides intermediate 3, which can be activated for coupling by conversion to the corresponding vinyl triflate 4. Sonagashira coupling provides compounds 5, which can be reduced with iron and ammonium chloride to provide aniline 6. Deprotection of the indole and coupling of the aniline to an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, provides the desired targets.
Figure US11053243-20210706-C00120
Amide coupling of the aniline from scheme K-1 with an appropriately substituted carboxylic acid and a coupling agent can provide intermediates 2, which can then be subjected to Pd-catalyzed cross-coupling reactions to provide the final targets R.
Figure US11053243-20210706-C00121
Compounds in scheme S can be prepared by coupling indole boronic acids with an appropriately substituted 2-bromobenzoxazoles, such as 5, under standard Suzuki conditions. The nitro group in 6 can be reduced under catalytic hydrogenation conditions and the protecting groups can be removed with HCl. The penultimate diamine can be coupled with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as BOP, reagent to give compounds with the targeted central scaffold.
Figure US11053243-20210706-C00122
Compounds in scheme T can be prepared by starting from a suitably substituted phenol 3 and a hydrazine reagent, such as 4, using established Fisher indole conditions. The indole 3 position can then be functionalized or the indole NH can be cyclized onto the C-2 aromatic ring using standard conditions to give tetracycles 8, which can subsequently be converted to the corresponding boronate esters using standard procedures. Intermediates 9 can then be coupled to a heterocyclic halide in the presence of a Pd(II) catalyst to provide compounds 10. Deprotection and coupling with an appropriately substituted carboxylic acid and an amide bond-forming reagent, such as HATU, can provide the targeted T scaffold.
The following examples serve only to illustrate the invention and its practice. The examples are not to be construed as limitations on the scope or spirit of the invention.
LIST OF ABBREVIATIONS
    • Ac2O Acetic anhydride
    • B(OiPr)3, (iPrO)3B Triisopropyl borate
    • B(OMe)3 Trimethyl borate
    • BF3 Boron trifluoride
    • BOC, Boc, boc tert-Butyloxycarbonyl
    • BOP Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
    • BrCN Cyanogen bromide
    • BuLi, n-BuLi Butyl lithium
    • CBZ, Cbz, cbz Benzyloxycarbonyl
    • CDCl3 Deuterio-trichloromethane
    • CH3CN, MeCN Acetonitrile
    • Cs2CO3 Cesium carbonate
    • CuBr2 Copper(II) bromide
    • CuCN Copper(I) cyanide
    • CuI Copper iodide
    • DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
    • DCE Dichloroethane
    • DCM, CH2Cl2 Dichloromethane
    • DIPEA, DIEA Diisopropylethylamine
    • DMAP 4-Dimethylamino pyridine
    • DMF Dimethylformamide
    • DMSO Dimethyl sulfoxide
    • DPPF, Dppf, dppf 1,1′-bis(Diphenylphosphino)ferrocene
    • EDC, EDCI N-β-Dimethylaminopropyl)-N′-ethylcarbodiimide
    • Et2O Diethyl ether
    • Et3N, TEA Triethylamine
    • EtMgBr Bromo(ethyl)magnesium or ethyl magnesium bromide
    • EtOAc Ethyl acetate
    • EtOH Ethanol
    • FeCl3 Ferric chloride or Iron(III) chloride
    • H2 Hydrogen or hydrogen atmosphere
    • H2O Water
    • H2SO4 Sulfuric acid
    • HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
    • HBr Hydrobromic acid
    • HCl Hydrochloric acid
    • HNO3 Nitric Acid
    • HOAc, HAc Acetic acid
    • HOBT, HOBt 1-Hydroxy benzotriazole
    • HPLC High performance liquid chromatography
    • InBr3 Indium tribromide
    • iPr2NH Diisopropylamine
    • K2CO3 Potassium carbonate
    • KI Potassium iodide
    • KIO3 Potassium iodate
    • KOAc, AcOK Potassium acetate
    • KOH Potassium hydroxide
    • LDA Lithium diisopropylamide
    • LHMDS, LiHMDS Lithium hexamethyldisilamide
    • MeMgBr Bromo(methyl)magnesium or methyl magnesium bromide
    • MeOD Methan(2H)ol
    • MeOH, CH3OH Methanol
    • MgSO4 Magnesium sulfate
    • MOC, Moc Methoxy carbonyl
    • MS Mass spectroscopy
    • N2 Nitrogen or nitrogen atmosphere
    • Na2CO3 Sodium carbonate
    • Na2SO4 Sodium sulfate (anhydrous)
    • NaClO2 Sodium perchlorate
    • NaH2PO4 Dihydrogen sodium phosphate
    • NaHCO3 Sodium hydrogen carbonate (sodium bicarbonate)
    • NaNO2 Sodium nitrite
    • NaOH Sodium hydroxide
    • NBS N-bromosuccinimide
    • NCS N-chlorosuccinimide
    • NH4OAc Ammonium acetate
    • NMM N-methylmorpholine
    • NMR, 1H-NMR Proton nuclear magnetic resonance spectroscopy
    • NXS N-halosuccinimide
    • P2O5, P4O10 Phosphorus pentoxide
    • Pd Palladium
    • Pd(dppf)Cl2 Dichloro(1,1′-bis(Diphenylphosphino)ferrocene) palladium(II)
    • Pd(II) Palladium(II)
    • Pd(PPh3)2Cl2, PdCl2(PPh3)2 Dichlorobis(triphenylphosphine)palladium(II)
    • Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0)
    • Pd/C, Pd—C Palladium on carbon
    • Pd2(dba)3 Tris(dibenzylidene acetone)dipalladium(0)
    • PdCl2 Palladium(II) chloride
    • PE Petroleum ether
    • Phg Phenylglycine
    • PhCH3, PhMe Toluene
    • Piv Pivaloyl
    • PivCl Pivaloyl chloride
    • POBr3 Phosphorus oxybromide
    • PPA Polyphosphoric acid
    • PPH3, TPP Triphenylphosphine
    • Pro Proline
    • Proc iso-Propylcarbamate
    • PtBu3 Tri-tert-butyl phosphine
    • Py Pyradine
    • PyBOP (Benzotriazole-1-yl-oxy)-tripyrrolidinophosphonium hexafluorophosphate
    • RPLC Reverse phase liquid chromatography
    • RT, rt, r.t. Room temperature, approximately 25° C.
    • SiO2 Silica or silica gel
    • SnCl2 Stannous chloride or Tin(II) chloride
    • SOCl2 Thionyl chloride
    • STP Standard temperature and pressure
    • t-BuLi tert-Butyl lithium
    • t-BuNO2 tert-Butyl nitrate
    • t-BuOH tert-Butanol
    • t-BuOK, KOt-Bu Potassium tert-butoxide
    • TFA Trifluoroacetic acid
    • TFAA Trifluoroacetic anhydride
    • THF Tetrahydrofuran
    • TLC Thin layer chromatography
    • ZnCl2 Zinc chloride
EXAMPLES Example 1—N-{4-[5-(acetylamino)-1H-pyrrolo[3,2-b]pyridin-2-yl]phenyl}-1-(phenylacetyl)-L-prolinamide
Figure US11053243-20210706-C00123
Step 1
Figure US11053243-20210706-C00124
To a suspension of 2-amino-5-nitropyridine (25.0 g, 0.18 mol) and 0.5 g of DMAP in 200 mL of pyridine, Ac2O (37 g, 0.36 mol) was added drop wise at 0° C. The mixture was stirred at RT for 5 hours. The volatile was removed in vacuo. The residue was washed with EtOAc to yield an off-white solid (28 g, 86%). MS (ESI) m/e (M+H+): 182.
Step 2
Figure US11053243-20210706-C00125
A heterogeneous mixture of 2-acetamido-5-nitropyridine (28 g, 0.15 mol) and 10% Pd/C (2.8 g) in 300 mL of MeOH was stirred in 50 psi of H2 for 6 hours. The mixture was filtered through CELITE, and concentrated in vacuo to yield a solid (20.5 g). MS (ESI) m/e (M+H+): 152.
Step 3
Figure US11053243-20210706-C00126
NaNO2 (5.4 g, 78.2 mmol) was added slowly to a solution of 2-acetamido-5-aminopyridine (9.0 g, 60 mmol) in 6 M aqueous HCl (300 mL) at 0° C. and was stirred for 45 minutes. A solution of SnCl2 (40.5 g, 180 mmol) in 15 mL of 6 M aqueous HCl was added, and the reaction mixture was allowed to warm to RT slowly while stirring for 16 hours. The reaction mixture was basified with 40 percent aqueous KOH, extracted with EtOAc (3×), and the organic layers are combined, dried over Na2SO4 and concentrated in vacuo to give the desired compound (3.2 g). MS (ESI) m/e (M+H+): 167.
Step 4
Figure US11053243-20210706-C00127
A suspension of the product from step 3 (3.32 g, 20 mmol) and N-(4-acetylphenyl)acetamide (3.54 g, 20 mmol) in 8 mL of EtOH was diluted with TEA to adjust the pH to about 9.5. The resulting reaction mixture was refluxed for 3 hours. The solvent was removed in vacuo, and the resulting residue was treated with 5% aqueous citric acid to form a precipitate. The precipitate was filtrated, washed with water and dried in vacuo (3.2 g). MS (ESI) m/e (M+H+): 326.
Step 5
Figure US11053243-20210706-C00128
A mixture of the product from step 4 above (0.6 g, 1.8 mmol) and PPA (5 mL) was heated to 90° C. for 75 minutes under N2. After cooling to RT, the reaction mixture was poured to an ice water, neutralized with solid NaOH, while maintaining the temperature of the mixture at or below RT. A solution of iso-propanol and DCM (1:3) was added to exact the organic. The combine organic phase was washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by preparative HPLC to yield a solid (280 mg). MS (ESI) m/e (M+H+): 309.
Step 6
Figure US11053243-20210706-C00129
A mixture of the 4-azaindole (280 mg, 0.9 mmol) in 10 mL of 3 N HCl was refluxed for 2 hours. The solvent was removed in vacuo. The residue was purified by HPLC to yield a solid (120 mg). MS (ESI) m/e (M+H+): 225.
Step 7
Figure US11053243-20210706-C00130
To a suspension of the product from step 6 (23 mg, 0.1 mmol), acid (23 mg, 0.1 mmol) and DIPEA (20 mg, 0.15 mmol) in 1 mL of CH3CN was added HATU (42 mg, 0.12 mmol). The resulting mixture was stirred at RT overnight. After reaction completed, the mixture was purified by pre-HPLC (10 mg). MS (ESI) m/e (M+H+): 440.
Step 8
Figure US11053243-20210706-C00131
A mixture of product from step 7 (10 mg, 0.023 mmol) and TEA (3 g, 0.03 mmol) in CH3CN (100 mL) was stirred at 0° C. Acetyl chloride (2 mg, 0.023 mmol) was added dropwise, and the resulting mixture was stirred at RT for 0.5 hour. The solvent was evaporated in vacuo, and the residue was purified by preparative HPLC to afford the desired product (5 mg). MS (ESI) m/e (M+H+): 482. 1H NMR (MeOD): δ 8.25 (d, J=8.4 Hz, 1H), 7.74˜7.89 (m, 4H), 7.26˜7.32 (m, 5H), 7.00˜7.02 (m, 2H), 4.63˜4.64 (m, 1H), 3.72˜3.84 (m, 4H), 2.18˜2.33 (m, 2H), 2.07˜2.10 (m, 5H).
Examples 2-3
The compounds of Examples 2 and 3 were prepared in a similar manner starting from intermediate 7 in step 6.
Example Structure MW Name
2
Figure US11053243-20210706-C00132
 		654.776 (2S)-1-(phenylacetyl)- N-{2-[4-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)phenyl]- 1H-pyrrolo[3,2-b]pyridin-5- yl}pyrrolidine-2-carboxamide
3
Figure US11053243-20210706-C00133
 		686.774 benzyl (2S)-2-[(2-{4-[({(2S)- 1-[(benzyloxy)carbonyl] pyrrolidin- 2-yl}carbonyl)amino]phenyl}- 1H-pyrrolo[3,2-b]pyridin-5- yl)carbamoyl]pyrrolidine-1- carboxylate
Example 4—tert-butyl {(1S)-2-[(2S)-2-{[4-(5-bromo-1H-pyrrolo[3,2-b]pyridin-2-yl)phenyl]carbamoyl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00134
Step 1
Figure US11053243-20210706-C00135
NBS (14.9 g, 84 mmol) was added portion wise to a solution of compound 3-aminopyridine (14.9 g, 84 mmol) in DMSO (80 mL) and water (20 mL) at 0° C., and the reaction was stirred at RT for 3 hours. The mixture was poured into ice-water (250 mL) and stirred for 30 minutes. The precipitate was collected and dried to yield a solid (7.0 g). MS (ESI) m/e (M+H+): 250. 1H NMR (DMSO): δ 7.28 (d, J=7.6 Hz, 1H), 7.03 (d, J=7.6 Hz, 1H), 5.69 (s, 2H).
Step 2
Figure US11053243-20210706-C00136
4-Ethynylacetanilide was prepared using the similar method shown in Example 1, step 1. MS (ESI) m/e (M+H+): 160.
Step 3
Figure US11053243-20210706-C00137
To a solution of 3-amino-2,6-dibromopyridine (9.41 g, 37.5 mmol), 4-ethynylacetanilide (4.77 g, 30 mmol) and Pd(PPh3)2Cl2 (1.31 g, 1.9 mmol) in a mixture of 150 mL of Et3N and 50 mL of DMF was added CuI (0.71 g, 0.4 mmol) under N2. The resulting mixture was stirred at RT overnight. The solvent was removed, and the residue was purified by chromatography (8.5 g). MS (ESI) m/e (M+H): 331. 1HNMR (DMSO): δ 7.59 (d, J=8.8 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.21 (d, J=8.8 Hz, 2H), 7.07 (d, J=8.4 Hz, 2H), 2.12 (s, 3H).
Step 4
Figure US11053243-20210706-C00138
To a 0° C. solution of the product from step 3 (8.5 g, 25.7 mmol) and pyridine (4.0 g, 51.4 mmol) in 50 mL of 1,4-dioxane was added TFAA (10.8 g, 51.4 mmol). The resulting mixture was then heated to 100° C. overnight. The mixture was cooled and poured into 200 mL of water, and the precipitate was filtered and washed by water then dried to give a solid (1.3 g). MS (ESI) m/e (M+H): 331.
Step 5
Figure US11053243-20210706-C00139
The reaction was conducted similar to that describe in Example 1, step 6. MS (ESI) m/e (M+H+): 288.
Step 6
Figure US11053243-20210706-C00140
To a suspension of the product from step 5 (0.1 mmol), N-Boc-L-Phg-L-Pro-OH (0.1 mmol) and DIPEA (20 mg, 0.15 mmol) in 1 mL of CH3CN was added HATU (42 mg, 0.12 mmol). The resulting mixture was stirred at RT overnight, concentrated and purified by RPLC to give the desired compound. MS (ESI) m/e (M+H): 619. 1H NMR (MeOD 400) δ: 7.85 7.77 (m, 5H), 7.43˜7.36 (m, 6H), 6.89 (s, 1H), 5.50 (s, 1H), 4.54 (d, J=8.0 Hz 1H), 3.93 (t, 1H), 2.10˜1.87 (m, 4H) 1.41 (s, 9H).
Example 5—(2S)—N-{3-chloro-2-[4-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)phenyl]-1H-pyrrolo[2,3-c]pyridin-5-yl}-1-(phenylacetyl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00141
Step 1
Figure US11053243-20210706-C00142
A heterogeneous mixture of 2-amino-4-methyl-5-nitropyridine (4.15 g, 27 mmol) and 10% Pd/C (0.4 g) in 50 mL of THF was stirred in 50 psi of H2 for 3 hours. The mixture was filtered through CELITE and concentrated to yield a yellow solid (3.20 g). MS (ESI) m/e (M+H+): 124. 1H NMR (DMSO): δ 7.38 (s, 1H), 6.16 (s, 1H), 4.84 (s, 2H), 4.06 (s, 2H), 1.96 (s, 3H).
Step 2
Figure US11053243-20210706-C00143
A mixture of diamine from step 1 (3.20 g, 26 mmol), TEA (5.25 g, 52 mmol) and a catalytic amount of DMAP in THF (100 mL) was stirred at 5-10° C., then treated with pivaloyl chloride (3.74 g, 31 mmol). The resulting mixture was stirred at RT for 5 hours, diluted with a 5% solution of citric acid, and extracted with EtOAc. The combined organic extracts were sequentially washed with water and brine, dried, filtered, and the filtrate was concentrated in vacuo to yield a residue. The residue was purified by column chromatography on silica gel to afford 7.4 g of the desired compound. MS (ESI) m/e (M+H+): 292. 1H NMR (CDCl3): δ 8.77 (s, 1H), 8.47 (s, 1H), 8.20 (s, 1H), 7.15 (s, 1H), 2.24 (s, 3H), 1.30˜1.32 (m, 18H).
Step 3
Figure US11053243-20210706-C00144
To a cooled solution of 4-nitrobenzoic acid (12 g, 72 mmol) in 50 mL of PhMe was added 20 mL of SOCl2 drop wise. After the addition, the suspension was heated to reflux for 4 hours. The solvent was removed, and the residue was azeotroped with 50 mL of PhMe to afford 14.5 g of crude acid chloride. To a solution of TEA (101 g, 100 mmol), a catalytic amount of DMAP and NO-dimethylhydroxylamine (5.3 g, 87 mmol) in 100 mL of DCM was added drop wise 14.5 g of the freshly prepared acid chloride in 100 mL of DCM. The resulting mixture was stirred at RT for 5 hours, then diluted with a 5% solution of citric acid, and extracted with DCM. The combined organic extracts were sequentially washed with water and brine, dried and filtered, and the filtrate was concentrated to yield a residue. The residue was purified by column chromatography on silica gel to afford 7.0 g of the Weinreb amide. MS (ESI) m/e (M+H+): 211. 1H NMR (CDCl3): δ 8.25 (d, J=8.8 Hz, 2H), 7.82 (d, J=9.6 Hz, 2H), 3.52 (s, 3H), 3.82 (s, 3H).
Step 4
Figure US11053243-20210706-C00145
A heterogeneous mixture of the nitro compound above and 10% Pd/C in THF was stirred at STP with a balloon of H2 for 3 hours. The mixture was filtered through CELITE, and concentrated to yield a yellow solid MS (ESI) m/e (M+H+): 181.
Step 5
Figure US11053243-20210706-C00146
The product from step 4 was pivaloylated using conditions described in step 2. MS (ESI) m/e (M+H+): 265. 1H NMR (CDCl3): δ 7.66 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.8 Hz, 2H), 3.51 (s, 3H), 3.32 (s, 3H).
Step 6
Figure US11053243-20210706-C00147
A solution of compound isolated from step 2 above (2.2 g, 7.5 mmol) in 15 mL of THF was cooled to below −40° C. t-BuLi in hexane (15 mL, 2.5 M, 37.5 mmol) was added dropwise, and the resulting solution was stirred at −40° C. for 1 hour. A solution of compound from step 5 (2.2 g, 8.25 mmol) in 10 mL of THF was added drop wise, and the resulting solution was continued to stir at this temperature for 30 minutes before being warmed to RT and stirred for 30 minutes again. An aqueous 5% citric acid solution was added to quench the reaction, which was extracted with DCM (×3), and the combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by preparative HPLC to yield a solid (0.4 g). MS (ESI) m/e (M+H+): 495. 1H NMR (CDCl3): δ 8.85 (s, 1H), 8.68 (s, 1H), 8.26 (s, 1H), 8.03˜8.05 (m, 3H), 7.21 (d, J=8.8 Hz, 2H), 7.53 (s, 1H), 4.20 (s, 2H), 1.33˜1.29 (m, 27H).
Step 7
Figure US11053243-20210706-C00148
A solution of the product from step 6 (400 mg, 0.8 mmol) in 33% aqueous HBr (15 mL) was refluxed overnight. After cooling, the mixture was concentrated in vacuo. The residue was purified by preparative HPLC to give a solid (120 mg). MS (ESI) m/e (M+H+): 225. 1H NMR (MeOD): δ 8.04 (s, 1H), 7.78 (d, 2H), 7.04 (d, 2H), 6.86 (s, 1H), 6.71 (s, 1H).
Step 8
Figure US11053243-20210706-C00149
The product from step 7 was coupled to 2 equivalents of N-phenylacetyl-L-proline using 2 equivalents of HATU and DIEA in a manner similar to that shown in Example 1. MS (ESI) m/e (M+H+): 687. 1H NMR (MeOD): δ 8.49˜8.57 (m, 1H), 7.38˜7.45 (m, 2H), 7.72˜7.80 (m, 2H), 5.15˜5.20 (m, 4H), 4.42˜4.50 (m, 2H), 3.57˜2.59 (m, 4H), 2.31˜2.42 (m, 4H), 1.89˜2.15 (m, 6H).
Step 9
Figure US11053243-20210706-C00150
To a solution of product from step 8 (15 mg, 0.02 mmol) in 2 mL of dry THF was added NCS (2 mg, 0.015 mmol). The resulting mixture was stirred at RT for 30 minutes. The solvent was evaporated, and the residue was purified by prep HPLC to give 5 mg of the desired product. MS (ESI) m/e (M+H+): 689. 1H NMR (MeOD): δ 8.53 (s, 1H), 7.91 (d, J=9.2 Hz, 2H), 7.77 (d, J=8.8 Hz, 2H), 7.49 (s, 1H), 7.20˜7.23 (m, 10H), 4.53˜4.59 (m, 2H), 3.64˜3.79 (m, 8H), 1.98˜2.25 (m, 8H).
Example 6—(2S)—N-{3-chloro-2-[4-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)phenyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-1-(phenylacetyl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00151
Step 1
Figure US11053243-20210706-C00152
2-Amino-5-nitropyridine (7.00 g, 50.0 mmol) was dissolved in H2SO4 (2 M, 100 mL). Potassium iodate (4.28 g, 20 mmol) was added portion at RT with stirring. The solution was heated to 100° C. under reflux. Potassium iodide (8.00 g, 48.2 mmol) was added drop wise over 1 hour as a solution in water (20 mL). A brown solution resulted, with solid iodine collecting in the reflux condenser. Heating at reflux was continued for 30 minutes, and the mixture was cooled to RT. The mixture was adjusted to pH 7 with the careful addition of solid NaHCO3. The mixture was diluted with water (200 mL) and CH2Cl2 (250 mL) was added. Solid sodium thiosulfate was added with vigorous stirring until the iodine coloration had been disappeared. A significant amount of yellowish solid remained out of solution, which was collected by filtration, washed with water and dried to give a yellow solid (10.5 g). The CH2Cl2 fraction was filtered through a silicone-treated filter paper and evaporated to give a yellow solid (2.4 g). The solids were combined to give the desired iodopyridine (12.7 g). MS (ESI) m/e (M+H+): 266. 1H NMR (DMSO): δ 8.89 (s, 1H), 8.62 (s, 1H), 7.75 (bs, 1H).
Step 2
Figure US11053243-20210706-C00153
A solution of the iodide (1.05 g, 4.8 mmol), 4-ethynylacetanilide (636 mg, 4.0 mmol) and Pd(PPh3)2Cl2 (76 mg, 0.4 mmol) in 10 mL of Et3N and 5 mL of DMF was stirred at RT over 17 hours under N2. The solvent was removed, and the residue was purified by column chromatography to give the product (0.9 g). MS (ESI) m/e (M+H+): 297. 1H NMR (DMSO): δ 10.11 (s, 1H), 8.80 (s, 1H), 8.22 (s, 1H), 7.59 (s, 1H), 2.01 (s, 3H).
Step 3
Figure US11053243-20210706-C00154
To a solution of the product from step 2 (730 mg, 2.5 mmol) in 3 mL of THF and 6 mL of DMF was added t-BuOK (580 mg, 5.25 mmol). The resulting mixture was heated to 70° C. for 6 hours. The solvent was removed and 10 mL of DCM, 5 mL of water was added, and the resulting precipitate was filtered to give the desired product as a yellow solid (680 mg). MS (ESI) m/e (M+H+): 297. 1H NMR (DMSO): δ 10.11 (s, 1H), 8.96 (s, 1H), 8.65 (s, 1H), 7.88 (d, J=8.8 Hz, 2H), 7.63 (d, J=8.8 Hz, 2H), 6.98 (s, 1H), 2.02 (s, 3H).
Step 4
Figure US11053243-20210706-C00155
The synthetic method for the removal of the acetyl group was the same as used in Example 1, step 6. MS (ESI) m/e (M+H+): 285.
Step 5
Figure US11053243-20210706-C00156
The synthetic method used for the coupling of the proline analog to the aniline prepared in step 4 was the same as used in Example 1, step 7. MS (ESI) m/e (M+H+): 470.
Step 6
Figure US11053243-20210706-C00157
A heterogeneous mixture of product from step 6 (20 mg, 0.04 mmol) and 10% Pd/C in 5 mL of MeOH was stirred in 10 psi of H2 for 3 hours. The mixture was filtered through CELITE, and concentrated in vacuo to yield a yellow solid (17 g). MS (ESI) m/e (M+H+): 440.
Step 7
Figure US11053243-20210706-C00158
The product from step 6 was coupled to 1 equivalent of N-phenylacetyl-L-proline using 1 equivalent of HATU and DIEA in a manner similar to that shown in Example 1. MS (ESI) m/e (M+H+): 655. 1H NMR (MeOD): δ 8.26 (s, 1H), 8.19 (s, 1H), 7.30˜7.51 (m, 3H), 7.18˜7.27 (m, 1H), 6.65 (s, 1H), 4.51˜4.56 (m, 2H), 3.61˜3.76 (m, 8H), 1.95˜2.15 (m, 8H).
Step 8
Figure US11053243-20210706-C00159
To a solution of product from step 7 (30 mg, 0.04 mmol) in 4 mL of dry THF was added NCS (4 mg, 0.03 mmol). The resulting mixture was stirred at RT for 30 minutes. The solvent was evaporated, and the residue was purified by prep HPLC to give the desired product. MS (ESI) m/e (M+H+): 690. 1H NMR (MeOD): δ 8.29 (s, 1H), 8.20 (s, 1H), 7.81˜7.84 (m, 2H), 7.66˜7.69 (m, 2H), 7.18˜7.29 (m, 10H), 4.52˜4.55 (m, 2H), 3.62˜3.78 (m, 8H), 1.90˜2.29 (m, 8H).
Example 7—N-[4-(3-oxo-7-{2-oxo-2-[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]ethyl}-3,7-dihydroimidazo[1,2-a]pyrazin-2-yl)phenyl]-1-(phenylacetyl)-L-prolinamide
Figure US11053243-20210706-C00160
Step 1
Figure US11053243-20210706-C00161
To a stirred solution of 4-nitroacetophenone (20 g, 121 mmol) in 100 ml of DMSO was added slowly 42 ml of 48% aqueous HBr (363 mmol). The solution was stirred in an open flask at 55° C. and the reaction was followed by TLC. When the starting material was consumed, the solution was poured into ice. The solid products were filtered, washed with water, and dried under vacuum at RT over P2O5.
Step 2
Figure US11053243-20210706-C00162
Arylglyoxal hydrate (5 g, 27.8 mmol) was added in one portion over a slurry of the heterocyclic amine (2.773 g, 29.2 mmol) in methylene chloride (10 ml). The resulting suspension was treated with 1 drop of freshly distilled BF3.Et2O and stirred until most of the amine was consumed. The reaction products were isolated as hydrates by filtration of the thick, intensely colored reaction mixture. The residue obtained by concentration is allowed to cool, filtered with suction, washed twice with diethyl ether and dried under reduced pressure to give the desired product (4 g). MS (ESI) m/e (M+H+): 256.
Step 3
Figure US11053243-20210706-C00163
The N-protected proline (10 g, 42.8 mmol) in dry ether (60 ml) and THF (60 ml) was stirred under argon at −25° C. TEA (42.8 mol, 4.08 ml) and ethyl chloroformate (42.8 mmol, 2.6 4.14 ml) were added to this solution. The solution was stirred for further 30 minutes, the temperature then allowed to reach −10° C., and the diazomethane solution in ether (2-3 equivalents) was added drop wise. The suspension was stirred for an additional 3 hours and allowed to reach ambient temperature. The triethylamine hydrochloride was then filtered off, and the filtrate was evaporated to half of its original volume. The resulting solution was washed with saturated aqueous NaHCO3 (50 ml) and brine (50 ml). The organic layer was dried and evaporated to give a crude product, which was used without further purification. MS (ESI) m/e (M+H+): 258.
Figure US11053243-20210706-C00164
Step 4
To a solution of a-diazoketone (2 g, 7.78 mmol) in glacial HOAc (25 ml) was treated with 48% HBr (2.8 ml) drop wise with stirring. After stirring for 1 hour, the reaction mixture was extracted with DCM and washed with water. Evaporation of the solvent and crystallization from ether-pet ether gave the pure product. MS (ESI) m/e (M+H+): 310.
Step 5
Figure US11053243-20210706-C00165
The product from step 4 (420 mg, 1.35 mmol) and the heterocycle from step 2 (347 mg, 1.35 mmol) in THF (2 ml) were stirred at RT overnight with Et3N (0.3 mL). When the reaction was completed, the mixture was concentrated, and the residue was purified by RPLC to give the product (300 mg). MS (ESI) m/e (M+H+): 486.
Step 6
Figure US11053243-20210706-C00166
A solution of the product from step 5 (180 mg, 0.371 mmol) in absolute EtOH (3 ml) was added to stannous chloride dihydrate (418.6 mg, 1.85 mmol), and the mixture was stirred at 70° C. for 2 hours. The reaction mixture was cooled to RT and poured into ice/water (50 ml), and the pH was made strongly alkaline by the addition of saturated NaOH (100 ml) before being extracted with EtOAc (2×). The organic phase was combined and washed with brine, dried by MgSO4, filtered, and concentrated to yield the crude product (150 mg). MS (ESI) m/z: (M+H+) 456.
Step 7
Figure US11053243-20210706-C00167
The mixture of the product from step 6 (30 mg, 0.066 mmol), N-phenylacetyl-L-proline (46.08 mg, 0.197 mmol), DIPEA (50.1 mg, 0.197 mmol) in CH3CN (2 mL) was stirred at RT for 5 minutes, then HATU (74.86 mg, 0.197 mmol) was added into the mixture. The mixture was stirred at RT overnight, concentrated, and the residue was purified by RPLC to give the desired compound (20 mg). 1H NMR (DMSO) δ: 9.26 (s, 1H), 8.84-8.86 (m, 2H), 7.79-8.03 (m, 4H), 7.11˜7.31 (m, 12H), 4.41˜4.63 (m, 2H), 3.52˜3.80 (m, 12H), 2.26˜2.12 (m, 2H), 1.87˜1.75 (m, 6H).
Example 8—(2S)-1-(cyclobutylcarbonyl)-N-{2-[4-({[(2S)-1-(pyridin-3-ylcarbonyl)pyrrolidin-2-yl]carbonyl}amino)phenyl]-1H-benzimidazol-5-yl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00168
Step 1
Figure US11053243-20210706-C00169
p-Aminobenzoic acid (0.200 g, 1.45 mmol) and nitrophenylene diamine (0.221 g, 1.45 mmol) were added into PPA (30 mL). The mixture was stirred at 210° C. for 20 minutes. Then, it was poured into ice water and extracted with DCM. The organic layer was washed with brine, dried (NaSO4), filtered and concentrated to afford 200 mg of the desired compound. MS m/z: 255 (M+1).
Step 2
Figure US11053243-20210706-C00170
Compound from step 1 above (1.2 g, 4.7 mmol), N-Boc-proline (1.52 g, 7.07 mmol), EDCI (1.8 g, 9.44 mmol), HOBT (1.27 g, 9.44 mmol) and DIPEA (2.4 g, 18.8 mmol) were taken in DMF (30 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO4), concentrated and purified by column (DCM:MeOH/100:1) to afford 1.2 g of the desired compound. 1H NMR (MeOD) δ 8.49 (s, 1H), 8.28-8.19 (m, 3H), 7.79-7.76 (d, J=4.4 Hz, 2H), 7.72-7.65 (m, 1H), 4.41-4.29 (t, J=8.8 Hz, 1H), 3.59-3.51 (m, 2H), 2.18-1.95 (m, 4H), 1.49 (s, 9H).
Step 3
Figure US11053243-20210706-C00171
Compound from step 2 (0.600 g, 1.06 mmol) was stirred in MeOH/HCl (10 mL) for 1 hour at RT, and solvent was removed under reduced pressure. The resulting compound was dried at high vacuum to afford 370 mg of desired compound.
Step 4
Figure US11053243-20210706-C00172
The product from step 3 (0.370 g, 1.052 mmol), pyridine-3-carboxylic acid (0.157 g, 1.27 mmol), HATU (1.2 g, 3.18 mmol) and DIPEA (0.814 g, 6.36 mmol) were taken in DMF (10 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO4), concentrated and purified by column (DCM:MeOH/100:1) to afford 300 mg of desired compound. 1H NMR (MeOD) δ ppm: 0.883 (s, 1H), 0.87-0.85 (d, J=4.4 Hz, 1H), 8.49 (s, 1H), 8.21-8.18 (m, 1H), 8.17-8.10 (m, 3H), 7.98-7.95 (d, J=8.8 Hz, 2H), 7.73-7.68 (m, 1H), 7.60-7.51 (m, 1H), 4.79-4.76 (t, J=6 Hz, 1H), 3.77-3.73 (m, 2H), 3.27-3.19 (m, 2H), 2.19-2.12 (m, 2H).
Step 5
Figure US11053243-20210706-C00173
The product from step 4 (0.300 g, 0.657 mmol) was taken in MeOH (10 mL) and Pd/C (0.07 g) was added under N2. The reaction was stirred for overnight at RT under H2. The Pd/C was filtered through CELITE, and the filtrate was concentrated under reduced pressure to afford 234 mg of desired compound.
Step 6
Figure US11053243-20210706-C00174
The product from step 5 (0.370 g, crude), N-Boc-proline (0.157 g, 1.27 mmol), HATU (1.2 g, 3.18 mmol) and DIPEA (0.814 g, 6.36 mmol) were taken in DMF (10 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO4), concentrated and purified by column (DCM:MeOH/100:1) to afford 300 mg of targeted compound.
Step 7
Figure US11053243-20210706-C00175
The product from step 6 (0.600 g, 1.06 mmol) was stirred in MeOH/HCl (15 mL) for 1 hour at RT, and the solvent was removed under reduced pressure. The compound was dried at high vacuum to afford 370 mg of desired compound. 1H NMR (MeOD) δ: 9.39 (s, 1H), 9.18-8.82 (m, 2H), 8.39-8.38 (m, 1H), 8.32-8.22 (m, 1H), 8.21-8.10 (m, 2H), 8.09-7.98 (m, 2H), 7.86-7.72 (m, 1H), 7.71-7.65 (m, 1H), 4.87-4.84 (t, J=8.8 Hz, 2H), 3.51-3.34 (m, 8H), 2.49-2.38 (m, 4H).
Step 8
Figure US11053243-20210706-C00176
The product from step 7 (0.100 g, 0.191 mmol), cyclobutanecarboxylic acid (0.018 mg, 0.183 mmol), HATU (0.116 g, 0.305 mmol) and DIPEA (0.059 g, 0.416 mmol) were taken in DMF (5 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO4) and concentrated. The residue was purified by HPLC purification to afford 12 mg of the final product. 1H NMR (MeOD) δ: 8.91 (s, 1H), 8.75 (s, 1H), 8.41 (s, 1H), 8.25 (s, 1H), 7.96-7.95 (d, J=5.2 Hz, 4H), 7.73-7.67 (d, J=3.2 Hz, 2H), 7.52-7.51 (d, J=3.2 Hz, 1H), 4.54-4.82 (t, J=3.6 Hz, 2H), 3.63-3.46 (m, 4H), 2.48-2.46 (t, J=2 Hz, 1H), 2.34-2.29 (m, 6H), 2.18-2.10 (m, 4H), 2.08-2.02 (m, 4H).
Examples 9-15
Compounds of Examples 9-15 were prepared in a similar manner to Example 8.
Example Structure MW Name
9
Figure US11053243-20210706-C00177
 		626.721 (2S)-1-(phenylcarbonyl)-N-{4- [5-({[(2S)-1- (phenylcarbonyl)pyrrolidin-2- yl]carbonyl}amino)-1H- benzimidazol-2- yl]phenyl}pyrrolidine-2- carboxamide
10
Figure US11053243-20210706-C00178
 		682.83 (2S)-1-[(4Z,5Z)-4- ethylidenehept-5-enoyl]-N-{2- [4-({[(2S)-1-(3- phenylpropanoyl)pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- benzimidazol-5-yl}pyrrolidine- 2-carboxamide
11
Figure US11053243-20210706-C00179
 		682.83 (2S)-1-[(4Z,5Z)-4- ethylidenehept-5-enoyl]-N-{2- [3-({[(2S)-1-(3- phenylpropanoyl)pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- benzimidazol-5-yl}pyrrolidine- 2-carboxamide
12
Figure US11053243-20210706-C00180
 		686.774 (2S)-1-[(2R)-2-hydroxy-2- phenylacetyl]-N-(4-{5-[({(2S)-1- [(2R)-2-hydroxy-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H- benzimidazol-2- yl}phenyl)pyrrolidine-2- carboxamide
13
Figure US11053243-20210706-C00181
 		654.776 (2S)-1-(phenylacetyl)-N-{4-[5- ({[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl} amino)-1H-benzimidazol-2- yl]phenyl}pyrrolidine-2- carboxamide
14
Figure US11053243-20210706-C00182
 		885.041 tert-butyl {(1S)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2S)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1H- benzimidazol-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
15
Figure US11053243-20210706-C00183
 		885.041 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1H- benzimidazol-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
Example 16—Benzyl (2S)-2-{[4-(4-{[(4-methylphenyl)sulfonyl]amino}-1H-benzimidazol-2-yl)phenyl]carbamoyl}pyrrolidine-1-carboxylate
Figure US11053243-20210706-C00184
Step 1
Figure US11053243-20210706-C00185
To a solution of N-Boc-p-aminobenzoic acid (1.86 g, 7.84 mmol) in DMF, 3-nitrophenylenediamine (1.0 g, 6.536 mmol), HOBt (0.875 g, 6.536 mmol) and EDCI (2.5 g, 9.804 mmol) were added, and reaction was stirred for overnight at RT. The excess of solvent was removed under reduced pressure, and the residue was diluted with DCM. The organic layer was washed with brine, dried (NaSO4), filtered, concentrated and purified by column to obtain 400 mg of compound. MS m/z: 273 (M+1).
Step 2
Figure US11053243-20210706-C00186
The compound from step 1 above (0.600 g, 1.611 mmol) and KOAc (0.158 g, 1.609 mmol) were taken in HOAc (9.3 mL). The reaction was stirred at 120° C. for overnight, cooled to RT and poured into ice-water. The aqueous layer was extracted with DCM. The organic layer was washed with brine, dried (NaSO4), filtered and concentrated to obtain 120 mg of the desired compound. MS m/z: 255 (M+1). 1H NMR (DMSO) δ: 11.44 (s, 1H), 8.95-9.01 (m, 2H), 8.81-8.83 (d, J=8.0 Hz, 2H), 8.22-8.27 (m, 1H), 8.22-8.27 (m, 2H), 4.97 (s, 2H).
Step 3
Figure US11053243-20210706-C00187
To a solution of the aniline (0.200 g, 0.787 mmol) in DMF, N-Boc-proline (0.186 g, 0.865 mmol), DIPEA (0.302 g, 2.361 mmol) and HATU (0.329 g, 0.865 mmol) were added. The reaction was stirred for overnight. The excess of solvent was removed under reduced pressure, and the residue was diluted with DCM. The organic layer was washed with brine, dried (NaSO4), filtered, concentrated and purified by column to obtain 150 mg of the desired. MS m/z: 452 (M+1). 1H NMR (MeOD) δ: 8.70-8.73 (m, 2H), 8.40-8.42 (d, J=8 Hz, 2H), 7.87-7.89 (d, J=8 Hz, 1H), 7.50-7.53 (m, 2H), 6.78-6.80 (d, J=8 Hz, 1H), 3.83 (s, 1H), 3.69-3.76 (m, 2H), 3.56-3.60 (m, 4H), 1.37-1.43 (m, 9H).
Step 4
Figure US11053243-20210706-C00188
To a solution of compound from step 3 above (0.200 g, 0.443 mmol), Pd/C (10 mg) was added under argon, and the reaction was stirred for 2 hours in H2. The Pd/C was filtered and washed with MeOH for several times. The solvent was evaporated to obtain 180 mg of desired compound. MS m/z: 422 (M+1). 1H NMR (MeOD) δ: 9.51 (s, 1H), 7.95-8.20 (m, 1H), 7.58-7.60 (m, 1H), 7.19-7.48 (m, 2H), 6.78-6.87 (m, 2H), 6.38 (s, 1H), 4.25-4.42 (m, 1H), 3.34-3.67 (m, 2H), 1.79-2.20 (m, 4H), 1.17-1.41 (m, 9H).
Step 5
Figure US11053243-20210706-C00189
To a solution of the compound from step 4 above (0.196 g, 0.465 mmol) in THF, TEA (0.070 g, 0.693 mmol) and 4-methylbenzene-1-sulfonyl chloride (0.088 g, 0.461 mmol) were added drop wise at 0° C. The reaction was stirred for overnight, and the solvent was removed under reduced pressure. The residue was diluted with DCM and washed with brine. The organic layer was dried (NaSO4), filtered and concentrated. The residue was purified by preparative TLC to afford 110 mg of desired compound. MS m/z: 576 (M+1). 1H NMR (MeOD) δ: 7.98-8.00 (d, J=8.0 Hz, 2H), 7.78-7.80 (d, J=8.0 Hz, 2H), 7.66-7.68 (d, J=8.0 Hz, 2H), 7.26-7.28 (m, 11H), 7.19-7.21 (d, J=8.0 Hz, 2H), 7.07-7.09 (m, 2H), 4.36-4.38 (m, 1H), 3.55-3.58 (m, 2H), 2.32-2.35 (m, 4H), 1.89-2.11 (m, 3H), 1.50 (s, 9H).
Step 6
Figure US11053243-20210706-C00190
The product from step 5 above (0.180 g, 0.312 mmol) was stirred in MeOH/HCl (5.0 mL) for 1 hour at RT. The solvent was removed under reduced pressure and dried at high vacuum. It was used directly without any further purification. The residue was taken in DMF, benzoic acid (0.042 g, 0.344 mmol), DIPEA (0.320 g, 2.504 mmol) and HATU (0.143 g, 0.375 mmol) were added. The reaction was stirred for overnight at RT. The excess of solvent was removed under reduced pressure, and the residue was diluted with DCM. The organic layer was washed with brine, dried (NaSO4), filtered, concentrated and purified by column to afford 40 mg of the final compound. MS m/z: 580 (M+1). 1H NMR (MeOD) δ: 7.92-7.94 (d, J=8.8 Hz, 2H), 7.23-7.68 (m, 14H), 6.81-6.83 (d, J=10 Hz, 1H), 5.21 (s, 2H), 4.65-4.79 (m, 1H), 3.52-3.89 (m, 2H), 2.47-2.58 (m, 1H), 2.43 (s, 3H), 1.93-2.23 (m, 3H).
Example 17—(2S)-1-(3-phenylpropanoyl)-N-{4-[5-{[(2S)-1-(3-phenylpropanoyl)pyrrolidin-2-yl]carbonyl}amino)-1,3-benzoxazol-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00191
Step 1
Figure US11053243-20210706-C00192
p-Aminobenzoic acid (1.37 g, 10 mmol) and 2,4-diaminophenol (1.24 g, 10 mmol) were combined under argon and treated with 12 mL of PPA. The resulting solution was heated at 200° C. for 30 minutes. The black solution was poured onto ice, and the resulting yellow solid was collected (1.12 g). 1H-NMR (DMSO) δ: 10.2-10.5 (s, 2H), 8.10-8.20 (m, 4H), 7.10-7.80 (m, 3H). MS m/z: 226 (M+1).
Step 2
Figure US11053243-20210706-C00193
The product from step 1 above (0.100 g, 0.236 mmol), N-Boc-proline (0.098 g, 0.355 mmol), HATU (0.135 g, 0.355 mmol), TEA (0.100 g, 0.944 mmol) were taken in DCM (10 mL) and stirred overnight at RT. The reaction was diluted with DCM, and the organic layer was washed with water, brine, dried (NaSO4), concentrated and purified by preparative TLC to afford 100 mg of desired compound. MS m/z: 620 (M+1).
Step 3
Figure US11053243-20210706-C00194
The product from step 2 above (0.100 g, 0.161 mmol) was stirred in MeOH/HCl (3.0 mL) for 1 hour at RT, and the solvent was removed under reduced pressure. The compound was dried at high vacuum to afford 80 mg of the desired compound. MS m/z: 420 (M+1).
Step 4
Figure US11053243-20210706-C00195
Compound from step 3 (0.080 g, 0.191 mmol), 3-phenylpropanoic acid (0.086 g, 0.574 mmol), HATU (0.218 g, 0.574 mmol), DIPEA (0.146 g, 1.146 mmol) were taken in DMF (3 mL) and stirred for overnight at RT. DMF was removed under reduced pressure, and the residue was extracted with DCM/water. The organic layer was washed with brine, dried (NaSO4) and concentrated. The residue was purified by HPLC purification to afford 108 mg of target. 1H NMR (DMSO) δ: 10.2-10.5 (s, 2H), 8.10-8.20 (m, 3H), 7.10-7.80 (m, 14H), 4.37-4.55 (m, 2H), 3.32-3.58 (m, 4H), 2.67-2.85 (m, 7H), 1.80-2.4 (m, 9H).
Example 18—(2S)-1-(3-phenylpropanoyl)-N-{4-[5-({[(2S)-1-(3-phenylpropanoyl)pyrrolidin-2-yl]carbonyl}amino)-1-benzofuran-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00196
Step 1
Figure US11053243-20210706-C00197
To a solution of 5-nitrosalicylaldehyde (1.0 g, 5.90 mmol) in 1,4-dioxane (10 mL), p-nitrobenzyl bromide (1.33 g, 6.15 mmol) and DIPEA (1.25 g, 9.70 mmol) were added, and the reaction was refluxed at 100° C. for 2 hours. The reaction was cooled, and the solids were filtered, washed with EtOH and dried with high vacuum to afford the desired compound. MS m/z: 303 (M+1).
Step 2
Figure US11053243-20210706-C00198
To a solution of the target compound from step 1 (1.5 g, 4.96 mmol) in 1, 4-dioxane (5 mL), DBU (0.9 g, 6.45 mmol) was added. The reaction was heated to 100° C. for 3 hours, then cooled to RT, and the resulting solid was filtered off and sufficiently washed with EtOH to afford 927 mg of the desired compound. 1H NMR (MeOD) δ: 8.66 (s, 1H), 8.37-8.39 (d, J=8.0 Hz, 2H), 8.30-8.32 (d, J=8.0 Hz, 1H), 8.18-8.21 (d, J=12 Hz, 2H), 7.78-7.80 (d, J=8.0 Hz, 1H), 7.70 (s, 1H).
Step 3
Figure US11053243-20210706-C00199
To a solution of the product from step 2 above (0.050 g, 0.176 mmol) in 1,4-dioxane (1.8 mL), water (1.8 mL), Fe (0.054 g) and HCl (1.14) were added. The reaction was heated to 110° C. for 3 hours. Then, the solid was filtered, and the organic layer was concentrated to afford 40 mg of the desired compound. 1H NMR (MeOD) δ: 8.01-8.05 (m, 2H), 7.90-7.96 (m, 1H), 7.79 (s, 1H), 7.46-7.51 (m, 1H), 7.34 (s, 1H), 7.17-7.21 (m, 2H). MS m/z: 225 (M+1).
Step 4
Figure US11053243-20210706-C00200
To a solution of the product from step 3 above (0.020 g, 0.089 mmol) in DCM (10 mL) N-Boc-proline (0.042 g, 0.196 mmol) and DIPEA (0.035 g, 0.267 mmol) were added. The reaction was stirred at RT for 5 minutes and then HATU (0.101 g, 0.267 mmol) was added. The reaction was stirred overnight and poured into brine and extracted with EtOAc. The organic layer was dried (Na2SO4), filtered and concentrated to afford 30 mg of the desired compound. MS m/z: 619 (M+1).
Step 5
Figure US11053243-20210706-C00201
The product from step 4 (0.70 g, 1.13 mmol) was stirred in MeOH/HCl (20 mL) for 1 hour. The solvent was removed at high vacuum to afford the desired proline compound, which was used directly to the next step without further purification. 3-Phenylpropanoic acid (0.428 g, 2.85 mmol) were taken in DCM (30 mL) was reacted with the proline compound (0.500 g, 0.96 mmol) and DIPEA (0.9 g, 7.1 mmol). The reaction was stirred at RT for 5 minutes, and then HATU (1.0 g, 2.85 mmol) was added. The reaction was stirred overnight and poured into brine and extracted with EtOAc. The organic layer was dried (Na2SO4), concentrated and purified by HPLC to afford 30 mg of the desired compound. 1H NMR (CDCl3) δ: 9.85-9.87 (d, J=8.0 Hz, 2H), 7.86 (s, 1H), 7.42-7.44 (d, J=8.8 Hz, 2H), 7.46-7.48 (d, J=8.8 Hz, 2H), 7.03-7.31 (m, 9H), 6.90-6.99 (d, J=3.6 Hz, 1H), 6.58 (s, 1H), 4.71-4.82 (m, 2H), 3.62-3.71 (m, 2H), 3.43-3.50 (m, 2H), 2.95-3.05 (m, 4H), 2.63-2.88 (m, 4H), 2.21-2.43 (m, 4H), 1.87-2.14 (m, 4H). MS m/z: 683 (M+1).
Example 19—N-{2-[4-(acetylamino)phenyl]-1-benzofuran-5-yl}-1-{(2R)-2-[(tert-butoxycarbonyl)amino]-2-phenylacetyl}-L-prolinamide
Figure US11053243-20210706-C00202
Step 1
Figure US11053243-20210706-C00203
K2CO3 (68 g, 0.497 mol) was added to a solution of bromosalicylaldehyde (50 g, 0.248 mol) in DMF (300 ml). The resulting solution was stirred at RT for 1 hour, then to it was added compound 4-nitrobenzyl bromide (54 g, 0.25 mol). The reaction mixture was stirred for 30 minutes, filtered, and the filtrate was poured into water and extracted with EtOAc (3×). The combined organic layers were dried and concentrated. The product was recrystallized from dioxane to afford a white solid (50 g). 1H NMR (CDCl3) δ: 10.43 (s, 1H), 8.24 (d, J=4H), 7.51-7.58 (m, 2H), 7.37-7.42 (m, 4H), 7.31-7.36 (m, 6H), 5.52 (s, 1H), 4.57 (s, 2H), 3.90 (s, 2H), 3.34 (s, 2H), 2.06-2.15 (m, 6H), 1.86-1.88 (m, 1H), 1.41 (d, 18H).
Step 2
Figure US11053243-20210706-C00204
DBU (9 ml, 61.58 mmol) was added to a solution of the product from step 1 (10 g, 29.85 mmol) in dioxane (70 ml). The resulting solution was heated to reflux for 1 hour, cooled and filtered. The filter cake was washed with EtOAc and dried in air to afford a yellow solid (6.5 g).
Figure US11053243-20210706-C00205
Step 3
PtBu3 (1.93 ml, 0.32 mmol) was added to a solution of the product from step 2 (2 g, 6.3 mmol) and Pd2(dba)3 (0.29 g, 0.32 mmol) in THF (100 ml) under N2. Then a solution of LiHMDS (18.9 ml, 18.9 mmol) was added dropwise. The resulting solution was heated to reflux for 3 hours and then cooled to RT. The reaction mixture was adjusted to pH=1 using 1M HCl, then stirred for 0.5 hour. The reaction mixture was basified to pH=8-9 using aq. saturated NaHCO3, and extracted with EtOAc (3×). The combined organic layers were dried and concentrated. The residue was recrystallized from MeOH to afford the product as brown solid.
Step 4
Figure US11053243-20210706-C00206
The mixture of the product from step 3 (500 mg, 2 mmol), R-Boc-Phg-L-Pro-OH (660 mg, 2.16 mmol), NMM (400 mg, 4 mmol) and DMF (30 ml) was stirred at RT for 30 minutes, then to it was added HATU (1.13 g, 3 mmol). The resulting mixture was stirred at RT overnight. The reaction mixture was diluted with water and filtered. The cake was washed with water and dried; the solid was used next step without purification.
Step 5
Figure US11053243-20210706-C00207
The product from step 4 (0.4 g, 1.3 mmol) in THF (10 ml) was hydrogenated using Raney Ni (0.2 mg) as the catalyst. After being stirred under H2 atmosphere at RT overnight, the reaction slurry was filtered through CELITE, and the filtrate was concentrated under reduced pressure to afford 0.33 g of the desired compound.
Step 6
Figure US11053243-20210706-C00208
Ac2O (18 mg, 0.18 mmol) was added to a solution of the aniline from step 5 (50 mg, 0.09 mmol) in THF (2 ml) at RT. The resulting solution was stirred at RT overnight, concentrated, and the residue was purified by RPLC to afford the desired product. 1H NMR (acetone-d6) δ: 7.95 (s, 1H, NH), 7.65-7.74 (m, 7H, ArH), 7.40-7.43 (m, 3H, ArH), 7.30-7.34 (m, 2H, ArH), 7.01 (s, 1H, ArH), 5.64 (s, 1H, CH), 4.56-4.59 (m, 1H, CH), 3.93-3.99 (m, 1H, CH2), 3.27-3.42 (m, 2H, CH2), 3.02-3.17 (m, 3H, CH2), 1.98 (s, 3H, CH3), 1.98-1.95 (m, 4H, CH2), 1.22 (t, J=7.2 Hz, 6H, CH3).
Examples 20-36
Compounds of Examples 20-36 were prepared in a similar manner as described in either Example 18 or Example 19.
Example Structure MW Name
20
Figure US11053243-20210706-C00209
 		654.773 (2S)-1-(phenylacetyl)-N- {4-[5- ({[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl} amino)- 1-benzofuran-2-yl]phenyl} pyrrolidine-2-carboxamide
21
Figure US11053243-20210706-C00210
 		885.039 tert-butyl {(1S)-2-[(2S)-2- ({4-[5- ({[(2S)-1-{(2S)-2-[tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl} carbamate
22
Figure US11053243-20210706-C00211
 		885.039 tert-butyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2-yl] carbonyl}amino)-1- benzofuran- 2-yl]phenyl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
23
Figure US11053243-20210706-C00212
 		856.984 propan-2-yl [(1R)-2-oxo-1- phenyl-2-{(2S)-2-[(4-{5-[({(2S)- 1-[(2R)-2-phenyl-2-{[(propan-2- yloxy)carbonyl]amino}acetyl] pyrrolidin-2-yl}carbonyl)amino]- 1-benzofuran-2-yl}phenyl) carbamoyl]pyrrolidin-1- yl}ethyl]carbamate
24
Figure US11053243-20210706-C00213
 		800.876 methyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2- [(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
25
Figure US11053243-20210706-C00214
 		740.91 (2S)-1-[(2R)-2-(dimethylamino)- 2-phenylacetyl]-N-(4-{5-[({(2S)- 1-[(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl} carbonyl)amino]-1-benzofuran-2- yl}phenyl)pyrrolidine-2- carboxamide
26
Figure US11053243-20210706-C00215
 		797.019 (2S)-1-[(2R)-2-(diethylamino)-2- phenylacetyl]-N-(4-{5-[({(2S)-1- [(2R)-2-(diethylamino)-2- phenylacetyl]pyrrolidin-2-yl} carbonyl)amino]-1-benzofuran-2- yl}phenyl)pyrrolidine-2- carboxamide
27
Figure US11053243-20210706-C00216
 		798.947 propan-2-yl [(1R)-2-{(2S)-2-[(4- {5-[({(2S)-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl} carbonyl)amino]-1-benzofuran-2- yl}phenyl)carbamoyl]pyrrolidin- l-yl}-2-oxo-1- phenylethyl]carbamate
28
Figure US11053243-20210706-C00217
 		482.587 N-[2-(4-aminophenyl)-1- benzofuran-5-yl]-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]-L-prolinamide
29
Figure US11053243-20210706-C00218
 		853.127 (2S)-1-{(2R)-2-[methyl(3- methylbutyl)amino]-2- phenylacetyl}-N-{4-[5-({[(2S)- 1-{(2R)-2-[methyl(3- methylbutyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} pyrrolidine-2-carboxamide
30
Figure US11053243-20210706-C00219
 		552.679 N-{2-[4-(acetylamino)pheny]]- 1-benzofuran-5-yl}-1-[(2R)-2- (diethylamino)-2-phenylacetyl]- L-prolinamide
31
Figure US11053243-20210706-C00220
 		649.797 (2S)-1-acetyl-N-(2-{4-[({(2S)-1- [(2R)-2-(diethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1- benzofuran-5-yl)pyrrolidine-2- carboxamide
32
Figure US11053243-20210706-C00221
 		693.807 tert-butyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-acetylpyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
33
Figure US11053243-20210706-C00222
 		621.743 (2S)-1-acetyl-N-(2-{4-[({(2S)-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1- benzofuran-5-yl)pyrrolidine-2- carboxamide
34
Figure US11053243-20210706-C00223
 		596.689 N-{4-[5-(acetylamino)-1- benzofuran-2-yl]phenyl}-1- {{2R)-2-[{tert- butoxycarbonyl)amino]-2- phenylacelyl}-L-prolinamide
35
Figure US11053243-20210706-C00224
 		814.903 methyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2- [(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-7-methyl-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-pheylethyl}carbamate
36
Figure US11053243-20210706-C00225
 		825.073 (2S)-1-{(2R)-2-[ethyl(propyl) amino]-2-phenylacetyl}-N-{4-[5- ({[(2S)-1-{(2R)-2-[ethyl(propyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 1-benzofuran-2-yl]phenyl} pyrrolidine-2-carboxamide
Example 37—(2S)-1-(phenylacetyl)-N-{4-[6-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)imidazo[1,2-a]pyrimidin-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00226
Step 1
Figure US11053243-20210706-C00227
A suspension of pyrimidine (280 mg, 2 mmol), Pd/C (15 mg, 0.1 mmol) in 40 mL EtOH was hydrogenated under 30 psi for 1 hour. The mixture was then filtered, and the filtrate was then concentrated to give the product (200 mg). The residue was dissolved in 20 ml THF and CbzCl (375 mg, 2.19 mmol) and pyridine (1 ml) were added. The mixture was stirred at RT for 1 hour, then the mixture was concentrated in vacuo, and the residue was extracted with EtOAc (2×), washed with H2O (30 mL) and brine (30 mL), dried over anhydrous NaSO4, concentrated in vacuo to give the desired compound as white powder (330 mg). MS (ESI) m/e (M+H+): 245.
Step 2
Figure US11053243-20210706-C00228
A solution of the product from step 1 above (244 mg, 1.00 mmol) and 2-bromo-1-(4-nitrophenyl)ethanone (244 mg, 1 mmol) in 40 mL of acetone was heated to reflux and stirred for 6 hours. Then, the mixture was cooled to RT and filtered, and the filtrate was then dissolved in 30 ml MeOH, and 0.5 ml HBr was added, the mixture was heated to reflux for another 3 hours; after that, the mixture was concentrated in vacuo to give the product as a pale yellow powder (120 mg). MS (ESI) m/e (M+H+): 390.
Step 3
Figure US11053243-20210706-C00229
To the product from step 2 above (50 mg, 0.128 mmol) was dissolved in 10 mL CH3OH was added SnCl2 (144 mg, 0.64 mmol). The reaction mixture was stirred at RT for 30 minutes and then heated to reflux for 3 hours. MeOH was removed in vacuo, and the residue was purified (DCM/MeOH=50:1) to afford the desired compound (35 mg). MS (ESI) m/e (M+H+): 360.
Step 4
Figure US11053243-20210706-C00230
The compound from step 3 (35 mg, 0.1 mmol) was dissolved in 5 ml of HOAc, then HBr (1.5 ml) was added. The reaction mixture was heated to reflux and stirred for 6 hours, cooled and concentrated. The residue was extracted with EtOAc (2×), washed with aq. NaHCO3 and water (30 mL) and brine (30 mL), dried over anhydrous NaSo4. Concentration afforded the desired compound as a brown solid (16 mg). MS (ESI) m/e (M+H+): 226.
Step 5
Figure US11053243-20210706-C00231
A mixture of the diamine product from step 4 above (16 mg, 0.071 mmol), N-phenylacetyl-L-proline (40 mg, 0.170 mmol), DIPEA (36.9 mg, 0.02 mmol) in CH3CN (5 mL) was stirred at RT for 10 minutes, then HATU (54 mg, 0.142 mmol) was added. The mixture was stirred at RT overnight then the mixture was concentrated, and the residue was purified to give compound (15 mg). MS (ESI) m/e (M+H+): 657. 1H NMR (MeOD) δ: 9.45 (s, 1H), 8.31 (s, 1H), 8.05 (s, 1H), 7.61-7.48 (m, 4H), 7.34˜7.21 (m, 10H), 4.60˜4.52 (m, 2H), 3.83˜3.69 (m, 8H), 2.24˜1.97 (m, 8H).
Example 38—(2S)-1-(phenylacetyl)-N-{4-[6-{[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)imidazo[1,2-a]pyridin-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00232
Step 1
Figure US11053243-20210706-C00233
The mixture containing 2-amino-5-nitropyridine (1.39 g, 10 mmol) and p-nitro-alpha-bromoacetophenone (2.42 g, 10 mmol) in 100 mL of acetone was heated at reflux for 12 hours. The solid was collected by filtration and then dissolved in 20 mL of MeOH and treated with a trace amount of HBr. The mixture was stirred at reflux for 1 hour, cooled and the solid was collected by filtration to give the desired (1.4 g). MS (m/z): 285 (M+H)+.
Step 2
Figure US11053243-20210706-C00234
To a suspension of the product from step 1 above (0.7 g, 2.5 mmol) in MeOH (50 mL) was added 0.1 g of Pd/C (20%), and the suspension was stirred under 25 psi of H2 at RT. After filtration, the filtrate was concentrated in vacuo to give the desired compound. MS (m/z): 225 (M+H)+.
Step 3
Figure US11053243-20210706-C00235
The mixture of the diamine from step 2 above (225 mg, 1 mmol), N-phenylacetylproline (1 mmol), DIPEA (5 mmol) and HATU (380 mg, 1 mmol) in 10 mL of MeCN was stirred at RT for 1 hour. The reaction mixture was concentrated, and the residue was purified by column chromatography to give the desired compound. 1H NMR (MeOD) δ: 9.3 (s, 1H), 8.2 (s, 1H), 7.5-7.1 (m, 16H), 4.6 (m, 1H), 4.5 (m, 1H), 3.8 (m, 8H), 2.3-1.8 (m, 8H).
Example 39—(2S,2′S)—N,N′,1H,1′H-2,2′-biindole-5,5′-diylbis[1-(phenylacetyl)pyrrolidine-2-carboxamide]
Figure US11053243-20210706-C00236
Step 1
Figure US11053243-20210706-C00237
To a suspension of the lactam (10.0 g, 56 mmol) in 200 ml of 1,2-dichloroethane, was added POBr3 (15.3 g, 53.2 mmol) at RT. The resulting mixture was heated at reflux temperature in a 90° C. oil bath for 0.5 hour (the reaction formed a copious amount of precipitate, and an oil bath was preferred over a heating mantle, as it provided gentle heating and avoided a darkening of the precipitate). The reaction was cooled just below reflux temperature, and imidazole (4.57 g, 62 mmol) was added in one portion. The resulting gummy suspension was heated at reflux temperature in an oil bath for another 2 hours. The reaction was cooled to RT, and 100 mL of ice-water was added. Solid NaHCO3 (ca. 50 g) was added to the mixture until no further gas was evolved. The suspension was extracted with DCM (4×), and the combined DCM extracts were washed with 300 mL of brine. The DCM extracts were filtered through silica gel and concentrated to dryness to afford a crude product. The crude product was recrystallized from chloroform to give 5.41 g of the desired compound as a white solid. The filtrate was concentrated to dryness, and the residue was purified by flash column chromatography (30% EtOAc/Hex) to give an additional 2.6 g of desired product. MS (ESI) m/e (M+H+): 242.
Step 2
Figure US11053243-20210706-C00238
The mixture of compound from step 1 above (602.6 mg, 2.5 mmol), the indole boronic acid (1.034 g, 2.75 mmol), Pd(dppf)Cl2 (183 mg, 0.25 mmol), Na2CO3 (530 mg, 5.0 mmol) in 5 mL dioxane-H2O (5:1) was heated to reflux under N2 atmosphere overnight. When reaction was complete the mixture was poured into water and extracted with DCM. The organic phase was dried over Na2SO4, concentrated, and the residue was purified to give compound the desired product. MS (ESI) m/e (M+H+): 493.
Step 3
Figure US11053243-20210706-C00239
The product from step 2 (600 mg, 1.3 mmol) was added into HCl (30 ml, 3M in MeOH). Then the mixture stirred at RT for 2-3 hours. When reaction was complete, the mixture was concentrated to give the crude product (400 mg). MS (ESI) m/e (M+H+): 293.
Step 4
Figure US11053243-20210706-C00240
The product from step 3 (400 mg, 1.36 mmol) was dissolved in EtOAc and treated with Pd/C (100 mg, 20%). Then the mixture was stirred at RT overnight under H2 atmosphere. When the reaction was complete, the Pd/C was filtered off, and the resulting solution was concentrated to give the crude product (300 mg). MS (ESI) m/e (M+H+): 263.
Step 5
Figure US11053243-20210706-C00241
A solution containing (131 mg, 0.5 mmol) of the product from step 4, RCOOH (256.608 mg, 1.1 mmol), DIPEA (390 mg, 1.5 mmol) in CH3CN (2 mL) was stirred at RT for 5 minutes, then HATU (418 mg, 1.1 mmol) was added into the mixture. The mixture was stirred at RT overnight. When reaction was complete, the mixture was concentrated, and the residue was purified to give the desired product. 1H NMR (MeOD) δ: 7.15-7.75 (m, 18H), 4.51-4.59 (m, 2H), 3.56-3.80 (m, 10H), 2.37 (s, 3H), 1.97-2.30 (m, 8H). MS (ESI) m/e (M+H+): 693.
Example 40—di-tert-butyl (1H,1′H-2,2′-biindole-5,5′-diylbis{carbamoyl(2S)pyrrolidine-2,1-diyl[(1R)-2-oxo-1-phenylethane-2,1-diyl]}biscarbamate
Figure US11053243-20210706-C00242
This compound was prepared using the similar method as Example 39, step 5 using N-Boc-R-Phg-L-Pro-OH. 1H NMR (MeOD) δ: 6.78-7.78 (m, 18H), 5.49 (m, 2H), 4.55-4.58 (m, 2H), 3.94-3.97 (m, 3H), 2.37 (s, 3H), 1.87-2.14 (m, 8H), 1.40 (s, 18H). MS (ESI) m/e (M+H+): 924.
Example 41—tert-butyl {(1R)-2-oxo-1-phenyl-2-[(2S)-2-({2-[4-{[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl}amino)phenyl]-1H-indol-5-yl}carbamoyl)pyrrolidin-1-yl]ethyl}carbamate
Figure US11053243-20210706-C00243
Step 1
Figure US11053243-20210706-C00244
To a solution of 4-bromophenylhydrazine (2.5 g, 13.4 mmol) in acetic acid (19.5 mL) and EtOH (14.5 mL), 4-nitroacetophenone (1.66 g, 10.0 mmol) was added. The reaction was refluxed for 5 hours, and water (35 mL) was added. The resulting mixture was stirred for another 1 hour, and the resulting solid was filtered, washed with water to afford 3.1 g of the desired compound. 1H NMR (MeOD) δ: 8.21-8.23 (d, J=8.0 Hz, 2H), 8.01-8.03 (d, J=8.0 Hz, 2H), 7.34-7.36 (d, J=8.0 Hz, 2H), 7.20-7.22 (d, J=8.0 Hz, 2H), 2.03 (s, 3H).
Step 2
Figure US11053243-20210706-C00245
The product from step 1 above (2.0 g, 6.0 mmol) was added into PPA (20 mL), and the mixture was stirred at 80° C. for 1 hour before it was cooled in ice-bath, diluted with water/EtOAc (60/20 mL) and stirred for another 1 hour. The mixture was extracted with EtOAc and washed to yield the target. 1H NMR (MeOD) δ: 8.28-8.30 (d, J=8.0 Hz, 2H), 7.97-7.99 (d, J=8.0 Hz, 2H), 7.72 (s, 1H), 7.33-7.35 (d, J=8.0 Hz, 1H), 7.24-7.26 (d, J=8.0 Hz, 1H), 7.02 (s, 1H).
Step 3
Figure US11053243-20210706-C00246
An oven-dried argon-cooled round-bottom flask was charged with the indole from step 2 (2.0 g, 6.31 mmol) and 0.05 equivalents of Pd2(dba)3 in THF (100 mL). A solution of tri-tert-butyl phosphine (10 wt %) in hexane (1.93 mL, 0.63 mmol) was added followed by lithium hexamethyldisilazane (1.0 M in THF) (18.9 mL, 18.9 mmol). The dark solution was heated to reflux overnight then cooled to RT. This mixture was poured into ice-cold aq 1.0 M HCl (70 mL) and stirred vigorously. Hexane was added, and stirring was continued for 30 minutes. The precipitate was filtered, washed with 20 mL of cold water and then 20 mL of THF:Hexanes (5:95) solution. The precipitate was washed with 200 mL of MeOH, and the filtrate was concentrated to give 1.5 g of the desired compound. MS m/z: 254 (M+1).
Step 4
Figure US11053243-20210706-C00247
To a solution of the product from step 3 above (1 g, 3.9 mmol) in acetonitrile (20 mL) was added R—N-Boc-Phg-S-Pro-OH (1.4 g, 3.9 mmol), HATU (3 g, 7.8 mmol) and DIPEA (1 g, 7.8 mmol). The mixture was stirred at RT overnight. The solvent was distilled, and the residue was dissolved in EtOAc and washed with water. The organic layer was dried and concentrated in vacuo, and the residue was purified by column chromatography to give the desired compound (1.8 g). MS (ESI) m/e (M+H+): 584.
Figure US11053243-20210706-C00248
Step 5
To a solution of compound from step 4 (300 mg, 0.51 mmol) in MeOH (10 mL) was added Pd/C (50 mg, 0.28 mmol). The mixture was stirred under H2 atmosphere at RT for 1 hour. The catalyst was filtered off, and the filtrate was concentrated in vacuo to give the desired compound (230 mg) as a yellow oil, which was used directly in next step. MS (ESI) m/e (M+H)+: 554.
Step 6
Figure US11053243-20210706-C00249
To a solution of the compound from step 5 (100 mg, 0.18 mmol) in acetonitrile (3 mL) was added compound N-phenylacetyl-L-proline (42 mg, 0.18 mmol), HATU (140 mg, 0.36 mmol) and DIPEA (46 mg, 0.36 mmol). The mixture was stirred at RT overnight then concentrated, and the residue was purified by RPLC to give (60 mg). 1H NMR (CDCl3) δ: 9.62 (s, 1H), 9.08 (s, 1H), 7.84 (s, 1H), 7.45-7.09 (m, 15H), 6.52 (s, 1H), 5.67 (s, 1H), 5.49 (m, 1H), 4.72-4.51 (m, 2H), 3.82-3.48 (m, 5H), 3.20 (m, 1H), 2.15-1.72 (m, 8H), 1.43 (s, 9H). MS (ESI) m/e (M+H+): 769.
Example 42—(2S)-1-(phenylacetyl)-N-{2-[5-{[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]pyrimidin-5-yl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00250
Step 1
Figure US11053243-20210706-C00251
A mixture of 5-nitroindole (5 g, 30.9 mmol), Fe (8.6 g, 154 mmol), NH4Cl (16.5 g, 309 mmol), EtOH (80 mL) and water (20 mL) was refluxed under N2 protection for 2 hours. The mixture was cooled to RT and filtered. The filtrate was concentrated and dissolved in water. The mixture was basified with Na2CO3 and extracted with CH2Cl2 two times. The combined organic phases were combined, dried over Na2SO4 and filtered. The filtrate was concentrated to yield the product (3.6 g). MS (ESI) m/e (M+H+): 133. 1H NMR (DMSO) δ: 10.55 (s, 1H), 7.12-7.06 (m, 2H), 6.68 (d, J=2.0 Hz, 1H), 6.48 (dd, J=8.4 Hz, 2.0 Hz, 1H), 6.12 (t, J=2.0 Hz, 1H), 4.39 (s, 2H).
Step 2
Figure US11053243-20210706-C00252
A mixture of 5-aminoindole (20 g, 76 mmol), DMAP (9.2 g, 38 mmol) THF (250 mL) and CH3CN (100 mL) was cooled to 0° C. Boc2O (132 g, 304 mmol) was slowly added to the mixture. The reaction mixture was allowed to warm to RT and stirred over the weekend. The mixture was poured into water and exacted with CH2Cl2 three times. The organic phase was combined, dried over Na2SO4 and filtered. The filtrate was concentrated, dissolved in CH2Cl2 and poured into PE and filtered. The solid was purified by column chromatography (PE/EA=20/1) to yield the product (23 g). 1H NMR (CDCl3): δ 8.05 (d, J=8.0 Hz, 1H), 7.56 (d, J=3.2 Hz, 1H), 7.28 (d, J=2.4 Hz, 1H), 7.03 (dd, J=8.8 Hz, 1.6 Hz, 1H), 1.63 (s, 9H), 1.36 (s, 18H).
Step 3
Figure US11053243-20210706-C00253
A mixture of the product from step 2 above (5.0 g, 11.6 mmol), (iPrO)3B (17.5 mL, 92.8 mmol) and dry THF (100 mL) was cooled to 0° C. LDA (prepared from nBuLi and iPr2NH in THF, about 116 mmol) was slowly added to the mixture at 0° C. The mixture was allowed to warm to RT and stirred for 2 hours. The mixture was quenched by the addition of 1N HCl to pH=3 and extracted with CH2Cl2 three times. The combined organic phases were combined, dried over Na2SO4 and filtered. The filtrate was concentrated and purified by column chromatography (PE/CH2Cl2=1/1 to pure CH2Cl2 to CH2Cl2/acetone=10/1 to pure acetone) to afford the product (2.8 g). 1H NMR (DMSO) δ: 9.22 (s, 1H), 8.10 (s, 2H), 7.84 (d, J=9.2 Hz, 1H), 7.65 (s, 1H), 7.20 (dd, J=9.2 Hz, 2.0 Hz, 1H), 6.48 (d, 1H), 1.51 (s, 9H), 1.41 (s, 9H).
Step 4
Figure US11053243-20210706-C00254
A mixture of the pyrimidine compound (0.3 g, 2 mmol), Fe powder (560 mg, 10 mmol), NH4Cl (1.07 g, 20 mmol), EtOH (8 mL) and water (2 mL) was refluxed under N2 overnight. The mixture was cooled to RT and filtered. The filtrate was concentrated and dissolved in water. The mixture was basified with Na2CO3 and extracted with CH2Cl2 two times. The combined organic phases were dried over Na2SO4 and filtered. The filtrate was concentrated to yield the product (120 mg). MS (ESI) m/e (M+H+): 130. 1H NMR (DMSO) δ: 7.99 (s, 2H), 5.73 (s, 2H).
Step 5
Figure US11053243-20210706-C00255
A mixture of the pyrimidine from step 4 (100 mg, 0.77 mmol), indole boronic acid from step 3 (290 mg, 0.77 mmol), Pd(dppf)Cl2 (56 mg, 0.077 mmol), Na2CO3 (244 mg, 2.3 mmol), THF (20 mL) and H2O (2 mL) was refluxed under N2 overnight. The mixture was poured into water and extracted with CH2Cl2. The organic phase was combined, dried over Na2SO4 and filtered. The filtrate was purified by prep TLC (CH2Cl2/MeOH=20/1) to afford the product. MS (ESI) m/e (M+H+): 426.
Step 6
Figure US11053243-20210706-C00256
A mixture of compound from step 5 above was added to a solution HCl in MeOH (4M) cooled with ice bath. The mixture was allowed to warm to RT and stirred overnight. The mixture was concentrated, dissolved in water, washed by CH2Cl2 and concentrated. The residue was directly used in the next step without further purification. MS (ESI) m/e (M+H+): 226
Step 7
Figure US11053243-20210706-C00257
The product of step 6 above (0.22 mmol), N-phenylacetyl-L-proline (51 mg, 0.22 mmol), DIPEA (100 mg), and DMF (3 mL) was added HATU (84 mg, 0.22 mmol), and the mixture was stirred at RT overnight. The mixture was purified by RPLC to afford the product. MS (ESI) m/e (M+H+): 656. 1H NMR (CDCl3) δ: 10.42 (s, 1H), 10.01 (s, 1H), 9.77 (s, 1H), 8.32 (s, 1H), 7.34-7.27 (m, 11H), 7.05-7.00 (m, 2H), 6.58 (d, J=8.0 Hz, 1H), 4.63-4.53 (m, 2H), 3.84-3.58 (m, 8H), 2.30-1.94 (m, 8H).
Examples 43-87
Compounds of Examples 43-87 were prepared in a similar manner as described in either Example 41 or Example 42.
Example Structure MW Name
43
Figure US11053243-20210706-C00258
 		884.054 tert-butyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1H- indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
44
Figure US11053243-20210706-C00259
 		799.891 methyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2- [(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
45
Figure US11053243-20210706-C00260
 		792.002 (2S)-1-[(2R)-2-phenyl-2- (pyrrolidin-1-yl)acetyl]-N-(4-{5- [({(2S)-1-[(2R)-2-phenyl-2- (pyrrolidin-1-yl)acetyl] pyrrolidin-2-yl}carbonyl)amino]- 1H-indol-2-yl}phenyl) pyrrolidine-2-carboxamide
46
Figure US11053243-20210706-C00261
 		848.023 (2S)-1-{(2R)-2- [(cyclopropylacetyl)amino]-2- phenylacetyl}-N-{4-[5-({[(2S)-1- {(2R)-2-[(cyclopropylacetyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 1H-indol-2-yl]phenyl} pyrrolidine-2-carboxamide
47
Figure US11053243-20210706-C00262
 		852.055 (2S)-1-{(2R)-2-[(3- methylbutanoyl)amino]-2- phenylacetyl}-N-{4-[5-({[(2S)-1- {{2R)-2-[(3-methylbutanoyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 1H-indol-2-yl]phenyl} pyrrolidine-2-carboxamide
48
Figure US11053243-20210706-C00263
 		824.001 (2S)-1-[(2R)-2-(morpholin-4-yl)- 2-phenylacetyl]-N-(4-{5-[({(2S)- 1-[(2R)-2-(morpholin-4-yl)-2- phenylacetyl]|pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
49
Figure US11053243-20210706-C00264
 		834.04 (2S)-1-(2,3-diphenylpropanoyl)- N-{4-[5-({[(2S)-1-(2,3- diphenylpropanoyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}pyrrolidine-2- carboxamide
50
Figure US11053243-20210706-C00265
 		992.195 (2S)-1-[(2R)-2-{[(4- methylphenyl)sulfonyl]amino}-2- phenylacetyl]-N-(4-{5-[({(2S)-1- [(2R)-2-{[(4-methylphenyl) sulfonyl]amino}-2-phenylacetyl] pyrrolidin-2-yl}carbonyl)amino]- 1H-indol-2-yl}phenyl) pyrrolidine-2-carboxamide
51
Figure US11053243-20210706-C00266
 		904.132 (2S)-1-{(2R)-2- [(cyclohexylcarbonyl)amino]-2- phenylacetyl}-N-{4-(5-({[(2S)-1- {(2R)-2-[(cyclohexylcarbonyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 1H-indol-2-yl]phenyl} pyrrolidinc-2-carboxamide
52
Figure US11053243-20210706-C00267
 		553.623 methyl {(1R)-2-[(2S)-2-({2-[4- (acetylamino)phenyl]-indol- 5-yl}carbamoyl)pyrrolidin-1-yl]- 2-oxo-1-phenylethyl}carbamate
53
Figure US11053243-20210706-C00268
 		595.704 tert-butyl {(1R)-2-[(2S)-2-({4-[5- (acetylamino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
54
Figure US11053243-20210706-C00269
 		565.678 N-{2-[4-(acetylamino)phenyl]- 1H-indol-5-yl}-1-[(2R)-2- (morpholin-4-yl)-2- phenylacetyl]-L-prolinamide
55
Figure US11053243-20210706-C00270
 		581.677 propan-2-yl{(1R)-2-[(2S)-2-({2- [4-(acetylamino)phenyl]-1H- indol-5-yl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
56
Figure US11053243-20210706-C00271
 		817.953 (2S)-1{(2R)-2- [(cyclopentylcarbamoyl)amino]- 2-phenylacetyl}-N-(4-{5-[({(2S)- 1-[(2R)-2-(dimethylamino)-2- phenylacetyl)pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
57
Figure US11053243-20210706-C00272
 		816.019 tert-butyl {(2R)-1-[(2S)-2-({4-[5- ({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-3-methyl-1-oxobutan-2- yl}carbamate
58
Figure US11053243-20210706-C00273
 		549.679 N-{2-[4-(acetylamino)phenyl]- 1H-indol-5-yl}-1[(2R)-2-phenyl- 2-(pyrrolidin-1-yl)acetyl]-L- prolinamide
59
Figure US11053243-20210706-C00274
 		699.945 (2S)-1-[(2R)-2-(dimethylamino)- 4-methylpentanoyl]-N-(4-{5- [({(2S)-1-[(2R)-2- (dimethylamino)-4- methylpentanoyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide (non-preferred name)
60
Figure US11053243-20210706-C00275
 		820.056 (2S)-1-[(2R)-2phenyl-2- (piperidin-1-yl)acetyl]-N-(4-{5- [({(2S)-1-[(2R)-2-phenyl-2- (piperidin-1-yl)acetyl]pyrrolidin- 2-yl}carbonyl)amino]-1H-indol- 2-yl}phenyl)pyrrolidine-2- carboxamide
61
Figure US11053243-20210706-C00276
 		785.914 (2S)-1-[(2R)-2-(1H-imidazol-1- yl)-2-phenylacetyl]-N-(4-{5- [({(2S)-1-[(2R)-2-(1H-imidazol- 1-yl)-2-phenylacetyl]pyrrolidin- 2-yl}carbonyl)amino]-1H-indol- 2-yl}phenyl)pyrrolidine-2- carboxamide
62
Figure US11053243-20210706-C00277
 		796.034 (2S)-1-[(2R)-2-(diethylamino)-2- phenylacetyl]-N-(4-{5-[({(2S)-1- [(2R)-2-(diethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
63
Figure US11053243-20210706-C00278
 		692.822 tert-butyl {(1S)-2-((2S)-2-({4-[5- ({[(2S)-1-acetylpyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenyylethyl}carbamate
64
Figure US11053243-20210706-C00279
 		692.822 tert-butyl {(1R)-2-[(2S)-2-({4-[5- ({[(2S)-1-acetylpyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
65
Figure US11053243-20210706-C00280
 		692.866 tert-butyl {(1R)-2-oxo-1-phenyl- 2-[(2S)-2-({2-[4-({[(2S)-1- (propan-2-yl)pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- indol-5-yl}carbamoyl)pyrrolidin- 1-yl]ethyl}carbamate
66
Figure US11053243-20210706-C00281
 		523.64 N-{2-[4-(acetylamino)phenyl]- 1H-indol-5-yl}-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]-L-prolinamide
67
Figure US11053243-20210706-C00282
 		563.706 N-{2-[4-(acetylamino)phenyl]- 1H-indol-5-yl}-1-[(2R)-2-phenyl- 2-(piperidin-1-yl)acetyl]-L- prolinamide
68
Figure US11053243-20210706-C00283
 		811.99 tert-butyl [(1R)-2-{(2S)2-[(2-{4- [({(2S)-1-[(2R)-2- (dimethylainino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1H- indol-5-yl)carbamoyl]pyrrolidin- 1-yl}-2-oxo-1- phenylethyl]carbamate
69
Figure US11053243-20210706-C00284
 		811.99 tert-butyl [(1R)-2-{(2S)-2-[(4-{5- [({(2S)-1-[(2R)-2- (dimethylamino)-2-phenylacetyl] pyrrolidin-2-yl}carbonyl)amino]- 1H-indol-2-yl}phenyl) carbamoyl]pyrrolidin-1-yl}-2- oxo-1-phenylethyl]carbamate
70
Figure US11053243-20210706-C00285
 		810.017 (2S)-1-[(2R)-2-(dimethylamino)- 2-phenylacetyl]-N-{4-[5-({[(2S)- 1-{(2R)-2-[(3,3- dimethylbutanoyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}pyrrolidine-2- carboxamide
71
Figure US11053243-20210706-C00286
 		660.823 (2S)-1-(cyclopropylacetyl)-N-(4- {5-[({(2S)-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
72
Figure US11053243-20210706-C00287
 		676.823 (2S)-1-[(2R)-2-(dimethylamino)- 2-phenylacetyl]-N-(2-{4-[({(2S)- 1-[(2R)-tetrahydrofuran-2- ylcarbonyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1H- indol-5-y])pyrrolidine-2- carboxamide
73
Figure US11053243-20210706-C00288
 		920.035 tert-butyl [(1R)-2-{(2S)-2-[(4-{5- [({(2S)-1-[(2R)-2-[(tert- butoxycarbonyl)amino]-2-(4- fluorophenyl)acetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)carbamoyl]pyrrolidin- 1-yl}-1-(4-fluorophenyl)-2- oxoethyl]carbamate
74
Figure US11053243-20210706-C00289
 		852.142 (2S)-1-{(2R)-2-[methyl(3- methylbutyl)amino]-2- phenylacetyl}-N-{4-[5-({[(2S)-1- {(2R)-2-[methyl(3-methylbutyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 1H-indol-2-yl]phenyl} pyrrolidine-2-carboxamide
75
Figure US11053243-20210706-C00290
 		613.72 (2S)-1-[(2S)-tetrahydrofuran-2- ylcarbonyl]-N-(4-{5-[({(2S)-1- [(2S)-tetrahydrofuran-2- ylcarbonyl]pyrrolidin-2- yl}carbonyl)amino)-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
76
Figure US11053243-20210706-C00291
 		777.972 N-(tert-butoxycarbonyl)-D-valyl- N-{4-[5-({1-[(R)-2- (dimethylamino)-2- phenylacetyl]-L-prolyl}amino)- 1H-indol-2-yl]phenyl}-L- prolinamide
77
Figure US11053243-20210706-C00292
 		673.778 (2S)-1-[(2R)-2-(dimethylamino)- 2-phenylacetyl]-N-{2-[4-({[(2S)- 1-(1,3-oxazol-2- ylcarbonyl)pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- indol-5-yl}pyrrolidinc-2- carboxamide
78
Figure US11053243-20210706-C00293
 		860.032 tert-butyl [(1R)-2-{[(2S)-1-({4- [5-({(2S)-2-[{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}(methyl)amino] propanoyl}amino)-1H-indol-2- yl]phenyl}amino)-1-oxopropan- 2-yl)(methyl)amino}-2-oxo-1- phenylethyl]carbamate
79
Figure US11053243-20210706-C00294
 		567.694 tert-butyl {(1R)-2-[(2S)-2-({2-[4- (methylamino)phenyl]-1H-indol- 5-yl}carbamoyl)pyrrolidin-1-yl]- 2-oxo-1-phenylethy}carbamate
80
Figure US11053243-20210706-C00295
 		696.857 (2S)-1-[(2R)-2-(dimethylamino)- 2-phenylacetyl]-N-{2-[4-({[(2S)- 1-(phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- indol-5-yl}pyrrolidine-2- carboxamide
81
Figure US11053243-20210706-C00296
 		765.964 (2S)-1-{[(3R)-1-benzylpyrrolidin- 3-yl]carbonyl}-N-(4-{5-[({(2S)- 1-[(2R)-2-(dimethylainino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxamide
82
Figure US11053243-20210706-C00297
 		765.964 (2S)-1-{[(3S)-1-benzylpyrrolidin- 3-yl]carbonyl}-N-(4-{5-[({(2S)- 1-[(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)pyrrolidine-2- carboxainide
83
Figure US11053243-20210706-C00298
 		719.935 N,N-dimethyl-D-leucyl-N-{4-[5- ({1-[(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolyl}amino)- 1H-indol-2-yl]phenyl}-L- prolinamide
84
Figure US11053243-20210706-C00299
 		577.733 N-(2-{4-[(cyclopentylcarbonyl) amino]phenyl}-1H-indol-5-yl)-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolinamide
85
Figure US11053243-20210706-C00300
 		652.8 tert-butyl [(2S)-1-({4-[5-({1- [(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolyl}amino)- 1H-indol-2-yl]phenyl}amino)-1- oxopropan-2-yl]carbamate
86
Figure US11053243-20210706-C00301
 		714.872 tert-butyl [(1S)-2-({4-[5-({1- [(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolyl}amino)- 1H-indol-2-yl]phenyl}amino)-2- oxo-1-phenylethyl]carbamate
87
Figure US11053243-20210706-C00302
 		680.855 tert-butyl [(2R)-1-({4-[5-({1- [(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolyl}amino)- 1H-indol-2-yl]phenyl}amino)-3- methyl-1-oxobutan-2- yl]carbamate
Example 88—(2S,2′S)—N,N′-5,6,7,12-tetrahydrobenzo[6,7]cyclohepta[1,2-b]indole-3,9-diylbis[1-(phenylacetyl)pyrrolidine-2-carboxamide]
Figure US11053243-20210706-C00303
Step 1
Figure US11053243-20210706-C00304
To a mixture of HNO3 (4 mL) and H2SO4 (2 mL) at 0° C. was slowly added the above carboxylic acid (2 g, 10.4 mmol). The mixture was stirred under 0° C. for 30 minutes. The resulting solution was poured into 20 mL of H2O at 0° C., and the precipitate was filtered to give compound (2 g) as a yellow solid. MS (ESI) m/e (M+H+): 238.
Step 2
Figure US11053243-20210706-C00305
To a mixture of HOAc (10 mL) and Ac2O (3 mL) was added the nitro compound from step 1 (1 g, 4.3 mmol) and Pd/C (100 mg, 0.6 mmol). The mixture was stirred under H2 for 6 hours. The catalyst was filtered, and the filtrate was concentrated in vacuo to give the desired compound (1 g) as a brown solid. MS (ESI) m/e (M+H+): 236.
Step 3
Figure US11053243-20210706-C00306
The compound from step 2 above (150 mg, 0.64 mmol) was slowly added to PPA (6 mL) at 100° C. The mixture was stirred for 3 hours. After cooling, the resulting solution was poured into 40 mL mixture of water and ice and extracted with DCM. The organic layer was concentrated to give the cyclic product (70 mg) as a brown solid. MS (ESI) m/e (M+H+): 218.
Step 4
Figure US11053243-20210706-C00307
To a solution of the ketone from step 3 (140 mg, 0.65 mmol) in 10% HOAc/EtOH (10 mL) was added 4-acetamidophenylhydrazine (144 mg, 0.72 mmol). The mixture was stirred at reflux for 4 hours. After cooling, the resulting solution was concentrated in vacuo, washed with water and extracted by EtOAc. The organic layer was concentrated in vacuo to give the desired compound (200 mg) as a brown solid. MS (ESI) m/e (M+H+): 348.
Step 5
Figure US11053243-20210706-C00308
To a solution of the product from step 4 above (200 mg, 0.57 mmol) in EtOH (10 mL) was added 6N HCl (2 mL, 12 mmol). The mixture was stirred at reflux overnight and cooled, and the resulting solution was concentrated then purified by silica gel flash chromatography (petroleum ether/ethyl acetate=5:1) to give the desired compound (150 mg) as a brown solid. MS (ESI) m/e (M+H+): 264.
Step 6
Figure US11053243-20210706-C00309
To a solution of the aniline from step 5 (40 mg, 0.15 mmol) in MeCN (5 mL) was added the proline analog (70 mg, 0.3 mol), HATU (250 mg, 0.6 mmol) and DIPEA (80 mg, 0.6 mmol). The mixture was stirred overnight. The resulting solution was purified by pre-HPLC to give the desired compound (10 mg) as a brown solid. 1H NMR δ: 7.62-7.20 (m, 16H), 4.58-4.54 (m, 2H), 3.79-3.60 (m, 6H), 2.95 (m, 2H), 2.80 (m, 2H), 2.26-1.94 (m, 8H). MS (ESI) m/e (M+H+): 694.
Examples 89-98
Compounds of Examples 89-98 were prepared in a similar manner as described in Example 88.
Example Structure MW Name
89
Figure US11053243-20210706-C00310
 		679.826 (2S,2′S)-N,N′-6,11-dihydro-5H- benzo[a]carbazole-3,8-diylbis[1- (phenylacetyl)pyrrolidine-2- carboxamide]
90
Figure US11053243-20210706-C00311
 		711.825 dibenzyl (2S,2′S)-2,2′-(6,11- dihydro-5H-benzo[a]carbazole- 3,8-diyldicarbamoyl) dipyrrolidine-1-carboxylate
91
Figure US11053243-20210706-C00312
 		528.453 N-(8-bromo-6,11-dihydro-5H- benzo[a]carbazol-3-yl)-1- (phenylacetyl)-L-prolinamide
92
Figure US11053243-20210706-C00313
 		910.092 di-tert-butyl (6,11-dihydro-5H- benzo[a]carbazole-3,8-diylbis {carbamoyl(2S)pyrrolidine-2,1- diyl[(1S)-2-oxo-1-phenylethane- 2,1-diyl]})biscarbamate
93
Figure US11053243-20210706-C00314
 		643.586 tert-butyl [(1S)-2-{(2S)-2-[(8- bromo-6,11-dihydro-5H- benzo[a]carbazol-3-yl) carbamoyl]pyrrolidin-1-yl}-2- oxo-1-phenylethyl]carbamate
94
Figure US11053243-20210706-C00315
 		765.942 (2S,2′S)-N,N′-6,11-dihydro-5H- benzo[a]carbazole-3,8-diylbis{1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidine-2- carboxamide}
95
Figure US11053243-20210706-C00316
 		779.968 (2S,2′S)-N,N′-5,6,7,12- tetrahydrobenzo[6,7]cyclohepta[1,2- b]indole-3,9-diylbis{1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidine-2- carboxamide}
96
Figure US11053243-20210706-C00317
 		562.718 N-(6,11-dihydro-5H- benzo[a]carbazol-3-yl)-1-{(2S)- 2-[(3,3-dimethylbutanoyl)amino]- 2-phenylacetyl}-L-prolinamide
97
Figure US11053243-20210706-C00318
 		564.69 tert-butyl {(1R)-2-[(2S)-2-(6,11- dihydro-5H-benzo[a]carbazol-3- ylcarbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
98
Figure US11053243-20210706-C00319
 		924.119 di-tert-butyl (5,6,7,12- tetrahydrobenzo[6,7]cyclohepta[1,2- b]indole-3,9-diylbis {carbamoyl(2S)pyrrolidine-2,1- diyl[(1R)-2-oxo-1-phenylethane- 2,1-diyl]})biscarbamate
Example 99—tert-butyl {(1R)-2-[(2S)-2-(5-{4-[5-({[(2S)-1-{(2R)-2-[(tert-butoxy carbonyl)amino]-2-phenylacetyl}pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}-1H-imidazol-2-yl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00320
Step 1
Figure US11053243-20210706-C00321
HATU (20 g, 52.3 mmol) was added to a heterogeneous mixture of the amino ketone (12 g, 48.5 mmol) and L-Cbz-Pro (12.4 g, 50 mmol) in MeCN (156 mL). The mixture was cooled in an ice-water bath, and immediately afterward DIPEA (27 mL, 155 mmol) was added dropwise. After the addition of the base, the cooling bath was removed, and the reaction mixture was stirred for an additional 50 minutes. The volatile component was removed, and water (125 mL) was added to the resulting crude solid and stirred for about 1 hour. The off-white solid was filtered and washed with copious water, and dried in vacuo to provide the desired compound as a white solid (20.68 g). MS (ESI) m/e (M+H+): 446.
Step 2
Figure US11053243-20210706-C00322
A mixture of the product from step 1 above (12.8 g, 31.12 mmol) and NH4OAc (12.0 g, 155.7 mmol) in xylenes (155 mL) was heated in a sealed tube at 160° C. for 2 hours. The volatile component was removed in vacuo, and the residue was partitioned carefully between EtOAc and water, where by enough saturated NaHCO3 solution was added so as to make the pH of the aqueous phase slightly basic after the shaking of the biphasic system. The layers were separated, and the aqueous layer was extracted with an additional EtOAc. The combined organic phase was washed with brine, dried, filtered, and concentrated in vacuo to yield a yellow solid. MS (ESI) m/e (M+H+): 426. 1H NMR (CDCl3) δ: 7.31-7.52 (m, 9H), 7.17 (s, 1H), 5.12˜5.20 (m, 2H), 5.00˜5.01 (m, 1H), 3.50˜3.52 (m, 2H), 2.96˜2.97 (m, 1H), 1.97˜2.17 (m, 3H).
Figure US11053243-20210706-C00323
Step 3
A mixture of the product from step 2 above (327 mg, 0.77 mmol), indole boronic acid from Example 42 (290 mg, 0.77 mmol), Pd(dppf)Cl2 (56 mg, 0.077 mmol), Na2CO3 (244 mg, 2.3 mmol), THF (20 mL) and H2O (2 mL) was refluxed under N2 overnight. The mixture was poured into water and extracted with CH2Cl2. The organic phase was combined, dried over Na2SO4 and filtered to give the desired compound, which was used directly in the next step. MS (ESI) m/e (M+H+): 678.
Step 4
Figure US11053243-20210706-C00324
A solution of the product of step 3 in HCl/CH3OH (5 N) was stirred for 3 hours. Concentration in vacuo afforded the crude product. MS (ESI) m/e (M+H+): 478.
Step 5
Figure US11053243-20210706-C00325
This reaction was carried out using the standard HATU-mediated coupling procedure described in step 1 between Boc-L-Pro-OH and the product from step 4 above. MS (ESI) m/e (M+H+): 808. 1H NMR (MeOD) δ: 8.95 (bs, 1H), 6.82˜7.56 (m, 17H), 6.50˜6.62 (m, 1H), 5.74 (bs, 1H), 5.38˜5.39 (m, 1H), 4.91˜5.08 (m, 2H), 4.66 (bs, 1H), 3.79 (bs, 1H), 3.40˜3.54 (m, 2H), 3.19 (bs, 1H), 1.93˜2.25 (m, 4H), 1.75˜1.88 (m, 4H), 1.35˜1.32 (m, 9H).
Step 6
Figure US11053243-20210706-C00326
To a solution of the product from step 5 (220 mg, 0.3 mmol) in 20 mL of AcOH was added 3 mL of 48% HBr. The solution was heated to 80° C. for 6 hours. The volatiles were removed in vacuo, and the residue was dissolved in DCM/i-PrOH (3:1), washed with saturated Na2CO3 and brine, dried and concentrated in vacuo to give a solid, which was used in the next step directly. MS (ESI) m/e (M+H+): 441.
Step 7
Figure US11053243-20210706-C00327
A cooled solution containing HATU (0.6 mmol), the diamine from step 6 above (132 mg, 0.3 mmol) and R-Boc-Pro (129 mg, 0.6 mmol) in MeCN (3 mL), was treated with DIPEA (2.4 mmol), added dropwise over 13 minutes. After the addition of the base was completed, the cooling bath was removed, and the reaction mixture was stirred for an additional 30 minutes. The volatile component was removed in vacuo; water was added to the resulting crude solid and stirred for about 1 hour. The off-white solid was filtered, washed with water, and dried in vacuo to provide the desired compound as a white solid. MS (ESI) m/e (M+H+): 908. 1H NMR (MeOD) δ: 7.66˜7.84 (m, 6H), 7.28˜7.40 (m, 12H), 6.80 (s, 1H), 5.40˜5.45 (m, 2H), 5.18˜5.20 (m, 1H), 3.70˜4.02 (m, 4H), 1.80˜2.12 (m, 8H), 1.35˜1.37 (m, 18H).
Examples 100-116
Compounds of Examples 100-116 were prepared in a similar manner as described in Example 99.
Example Structure MW Name
100
Figure US11053243-20210706-C00328
 		807.958 benzyl (2S)-2-[5-(4-{5-[(1- {(2R)-2-[(tert-butoxycarbonyl) amino]-2-phenylacetyl}-L- prolyl)amino]-1H-indol-2- yl}phenyl)-1H-imidazol-2- yl]pyrrolidine-1-carboxylate
101
Figure US11053243-20210706-C00329
 		762.963 1-[(2R)-2-(dimethylamino)-2- phenylacetyl]-N-{2-[4-(2-{(2S)- 1-[(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl}- 1H-imidazol-5-yl)phenyl]-1H- indol-5-yl}-L-prolinamide
102
Figure US11053243-20210706-C00330
 		604.715 tert-butyl {(1R)-2-[(2S)-2-({2- [4-(1H-imidazol-4-yl)phenyl]- 1H-indol-5-yl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
103
Figure US11053243-20210706-C00331
 		762.963 1-[(2S)-2-(dimethylamino)-2- phenylacetyl]-N-{2-[4-(2-{(2S)- 1-[(2S)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl}- 1H-imidazol-5-yl)phenyl]-1H- indol-5-yl}-L-prolinamide
104
Figure US11053243-20210706-C00332
 		791.958 tert-butyl {(1R)-2-oxo-1-phenyl- 2-[(2S)-2-{[2-(4-{2-[(2S)-1- (phenylacetyl)pyrrolidin-2-yl]- 1H-imidazol-5-yl}phenyl)-1H- indol-5-yl]carbamoyl}pyrrolidin- 1-yl]ethyl}carbamate
105
Figure US11053243-20210706-C00333
 		715.86 tert-butyl{(1R)-2-[(2S)-2-{[2-(4- {2-[(2S)-1-acetylpyrrolidin-2- yl]-1H-imidazol-5-yl}phenyl)- 1H-indol-5-yl]carbamoyl} pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
106
Figure US11053243-20210706-C00334
 		793.931 benzyl (2S)-2-(5-{4-[5-({1- [(2R)-2-phenyl-2-{[(propan-2- yloxy)carbonyl]amino}acetyl]-L- prolyl}amino)-1H-indol-2- yl]phenyl}-1H-imidazol-2- yl)pyrrolidine-1-carboxylate
107
Figure US11053243-20210706-C00335
 		835.027 tert-butyl {(1R)-2-[(2S)-2-({2- [4-(2-{(2S)-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl}- 1H-imidazol-5-yl)phenyl]-1H- indol-5-yl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
108
Figure US11053243-20210706-C00336
 		893.064 propan-2-yl [(1R)-2-{(2S)-2-[1- methyl-4-(4-{5-[({(2S)-1-[(2R)- 2-phenyl-2-{[(propan-2- yloxy)carbonyl]amino}acetyl] pyrrolidin-2-yl}carbonyl)amino]- 1H-indol-2-yl}phenyl)-1H- imidazol-2-yl]pyrrolidin-1-yl}-2- oxo-1-phenylethyl]carbamate
109
Figure US11053243-20210706-C00337
 		701.833 propan-2-yl {(1R)-2-[(2S)-2-{[2- (4-{2-[(2S)-1-acetylpyrrolidin-2- yl]-1H-imidazol-5-yl}phenyl)- 1H-indol-5-yl]carbamoyl} pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
110
Figure US11053243-20210706-C00338
 		659.795 propan-2-yl {(1R)-2-oxo-1- phenyl-2-[(2S)-2-{[2-(4-{2- [(2S)-pyrrolidin-2-yl]-1H- imidazol-5-yl}phenyl)-1H-indol- 5-yl]carbamoyl}pyrrolidin-1- yl]ethyl}carbamate
111
Figure US11053243-20210706-C00339
 		547.663 propan-2-yl {(1R)-2-[(2S)-2-{5- [4-(1H-indol-2-yl)phenyl]-1H- imidazol-2-yl}pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
112
Figure US11053243-20210706-C00340
 		489.626 (2R)-2-(dimethylamino)-1-[(2S)- 2-{5-[4-(1H-indol-2-yl)phenyl]- 1H-imidazol-2-yl}pyrrolidin-1- yl]-2-phenylethanone
113
Figure US11053243-20210706-C00341
 		879.037 propan-2-yl [(1R)-2-oxo-1- phenyl-2-{(2S)-2-[5-(4-{5- [({(2S)-1-[(2R)-2-phenyl-2- {[(propan-2-yloxy)carbonyl] amino}acetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)-1H-imidazol-2-yl] pyrrolidin-1-yl}ethyl]carbamate
114
Figure US11053243-20210706-C00342
 		821 propan-2-yl {(1R)-2-[(2S)-2-({2- [4-(2-{(2S)-1-[(2R)-2- (dimethylamino)-2-phenylacetyl] pyrrolidin-2-yl}-1H-imidazol-5- yl)phenyl]-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
115
Figure US11053243-20210706-C00343
 		582.108 propan-2-yl {(1R)-2-[(2S)-2-{4- [4-(3-chloro-1H-indol-2- yl)phenyl]-1H-imidazol-2- yl}pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
116
Figure US11053243-20210706-C00344
 		754.894 N-(methoxycarbonyl)-L-valyl-N- {2-[4-(2-{(2S)-1-[N- (methoxycarbonyl)-L- valyl]pyrrolidin-2-yl}-1H- imidazol-5-yl)phenyl]-1H-indol- 5-yl}-L-prolinamide
Example 117—Propan-2-yl [(1R)-2-oxo-1-phenyl-2-{(2S)-2-[3-(4-{5-[({(2S)-1-[(2R)-2-phenyl-2-{[(propan-2-yloxy)carbonyl]amino}acetyl]pyrrolidin-2-yl}carbonyl)amino]-1H-indol-2-yl}phenyl)-1H-pyrazol-5-yl]pyrrolidin-1-yl}ethyl]carbamate
Figure US11053243-20210706-C00345
Step 1
Figure US11053243-20210706-C00346
A solution of 4-bromophenylacetylene (5.0 g, 27.6 mmol) in THF (100 mL) at 0° C. was treated a solution of EtMgBr (3M in THF, 9.84 mL, 29.5 mmol). After 10 minutes, the cooling bath was removed, and the mixture was allowed to stir at RT for 3 hours. The reaction mixture was then cooled to 0° C. and added to the Weinreb amide of Z-proline (6.10 g, 20.9 mmol) in THF (50 mL). The reaction mixture was warmed to RT for 48 hours. The reaction mixture was quenched with saturated NH4Cl and diluted with EtOAc/H2O. The aqueous phase was back-extracted with EtOAc (2×), and the combined organic layers were washed (H2O, brine), dried (Na2SO4), and filtered. The solvent was removed, and the residue was purified by silica gel (PE:EA=10:1-4:1) to give the product (7.0 g) as a cream-colored solid. 1H NMR (CDCl3) δ: 7.37˜7.47 (m, 2H), 7.10˜7.30 (m, 7H), 4.98˜5.32 (m, 2H), 4.32˜4.47 (m, 1H), 3.45˜3.61 (m, 2H), 2.15˜2.27 (m, 1H), 2.03˜2.12 (m, 1H), 1.76˜193 (m, 2H). MS (ESI) m/e (M+H+): 413.
Step 2
Figure US11053243-20210706-C00347
A mixture of the product from step 1 (7.0 g, 17 mmol) and hydrazine hydrate (85%, 1.6 mL) in EtOH (50 mL) was heated at 80° C. for 16 hours. The reaction mixture was cooled and concentrated to afford the desired product (6.7 g). MS (ESI) m/e (M+H+): 426.
Step 3
Figure US11053243-20210706-C00348
A mixture of the product from step 2 above (0.77 mmol), indole boronic acid from Example 42 (290 mg, 0.77 mmol), Pd(dppf)Cl2 (56 mg, 0.077 mmol), Na2CO3 (244 mg, 2.3 mmol), THF (20 mL) and H2O (2 mL) was refluxed under N2 overnight. The mixture was poured into water and extracted with CH2Cl2, dried over Na2SO4 and filtered to give the desired compound, which was used directly in the next step. MS (ESI) m/e (M+H+): 678.
Step 4
Figure US11053243-20210706-C00349
A solution of the product from step 3 above (339 mg, 0.5 mmol) was dissolved in 3 mL of DCM and cooled to 0° C. After the addition of 3 mL of TFA, the reaction mixture was warmed to RT and stirred for 3 hours. Removal of the solvent left the desired product as an oil, which was used directly in the next reaction. MS (ESI) m/e (M+H+): 378.
Step 5
Figure US11053243-20210706-C00350
A solution containing PyBOP (0.3 mmol), the amine from step 4 above (132 mg, 0.3 mmol) and N-Boc-L-Pro-OH (62 mg, 0.3 mmol) in DMF (2 mL) was treated with N-methylmorpholine (1.2 mmol). The reaction mixture was stirred for 3 hours, diluted with EtOAc and washed with water (5×). The organic phase was dried and concentrated then chromatographed by RPLC to afford the desired compound. MS (ESI) m/e (M+H+): 675.
Step 6
Figure US11053243-20210706-C00351
The product from step 5 (100 mg, 0.15 mmol) was dissolved in MeOH and treated with 20 mg of 20% Pd(OH)2 then hydrogenated at 45 psi for 4 hours. The catalyst was removed by filtration through CELITE, and the filtrate was evaporated to leave the desired product. MS (ESI) m/e (M+H+): 541.
Step 7
Figure US11053243-20210706-C00352
A solution of the product from step 6 above was dissolved in 2 mL of DCM and 2 mL of TFA. The reaction mixture was stirred for 3 hours before the solvent was evaporated to give the desired product as an oil, which was used directly in the next reaction. MS (ESI) m/e (M+H+): 441.
Step 8
Figure US11053243-20210706-C00353
A solution containing PyBOP (0.6 mmol), the diamine from step 7 above (132 mg, 0.3 mmol) and R-i-Proc-Phg-OH (125 mg, 0.6 mmol) in DMF (5 mL) was treated with N-methylmorpholine (2.4 mmol). The reaction mixture was stirred for 3 hours, diluted with 20 mL of EtOAc and washed with water (5×). The organic phase was dried and concentrated then chromatographed by RPLC to afford the desired compound. 1H NMR (MeOD) δ: 7.70˜7.80 (m, 4H), 7.05˜7.55 (m, 14H), 6.80˜7.00 (m, 1H), 5.10˜5.50 (m, 3H), 4.40˜4.65 (m, 2H), 3.25˜4.00 (m, 4H), 1.70˜2.40 (m, 9H), 1.05˜1.20 (m, 12H). MS (ESI) m/e (M+H+): 880.
Example 118—Propan-2-yl [(1R)-2-oxo-1-phenyl-2-{(2S)-2-[5-(4-{5-[({(2S)-1-[(2R)-2-phenyl-2-{[(propan-2-yloxy)carbonyl]amino}acetyl]pyrrolidin-2-yl}carbonyl)amino]-1H-indol-2-yl}phenyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl}ethyl]carbamate
Figure US11053243-20210706-C00354
Step 1
Figure US11053243-20210706-C00355
Ethyl chloroformate (12 mL, 125 mmol) in 180 mL of THF was added drop-wise to a cooled solution (−5° C.) of compound Z-Pro-OH (13.8 g, 55.5 mmol), TEA (7.71 mL, 55.5 mmol). The resulting slurry was stirred for 20 minutes at −5° C. before saturated NH4OH (15 mL) was added. The solution was stirred at RT for 18 hours, volatiles were removed, and the residue was taken up in EtOAc (180 mL). The undissolved white precipitate was filtered off and rinsed with EtOAc (100 mL). The organic layers were dried over Na2SO4 and concentrated in vacuo to give the desired product (13.5 g) as off-white amorphous solid. MS (ESI) m/e (M+H+): 249.
Step 2
Figure US11053243-20210706-C00356
Lawesson's reagent (16.1 g, 39.9 mmol) was added to a stirred slurry of the amide (18 g, 72.6 mmol) in PhMe (200 mL) at RT. The reaction mixture was heated to 100° C. for 3 hours before the solvent was removed. The residue was purified by flash SiO2 chromatography (DCM/MeOH=1:0-20:1) to afford the product (18 g). MS (ESI) m/e (M+H+): 265.
Step 3
Figure US11053243-20210706-C00357
A mixture of the thioamide from step 2 (10.0 g, 37.8 mmol) and the bromoacetophenone (10.0 g, 35.9 mmol) in EtOH (100 mL) was heated at 90° C. for 150 minutes. The reaction mixture was cooled and concentrated, and the residue was purified by SiO2 chromatography to afford the product (11 g). MS (ESI) m/e (M+H+): 444.
Step 4
Figure US11053243-20210706-C00358
The product from step 3 above can be converted to the final compounds using the same procedure as described in Example 117, steps 4-8. 1H NMR (MeOD) δ: 7.00˜8.10 (m, 19H), 5.40˜5.60 (m, 3H), 4.50˜4.70 (m, 1H), 3.45˜4.10 (m, 4H), 3.35˜3.40 (m, 1H), 1.80˜2.6 (m, 9H), 1.05˜1.30 (m, 12H). MS (ESI) m/e (M+H+): 897.
Example 119—propan-2-yl [(1R)-2-oxo-1-phenyl-2-{(2S)-2-[2-(4-{5-[({(2S)-1-[(2R)-2-phenyl-2-{[(propan-2-yloxy)carbonyl]amino}acetyl]pyrrolidin-2-yl}carbonyl)amino]-1H-indol-2-yl}phenyl)-1H-imidazol-5-yl]pyrrolidin-1-yl}ethyl]carbamate
Figure US11053243-20210706-C00359
Step 1
Figure US11053243-20210706-C00360
To a solution of 4-bromobenzonitrile (1.82 g, 10 mmol) in anhydrous THF (50 mL) was added LiHMDS (2N, 15 mmol) under N2 atmosphere at RT, and the mixture was stirred for 1 hour. After quenching with 1N HCl, the reaction mixture was heated at reflux for 5 minutes. The precipitate was collected by filtration and then dried in vacuo to give the desired compound (1.9 g). 1H NMR (DMSO) δ: 7.74 (d, 2H, J=8.2 Hz), 7.62 (d, 2H, J=8.2 Hz) 6.43 (br, 3H).
Step 2
Figure US11053243-20210706-C00361
To a solution of Cbz-Pro-OH (2.9986 g, 12.0 mmol) in THF (100 mL) was added TEA (1.7 mL, 12.2 mmol). The solution was cooled to −25° C. and ethyl chloroformate (1.6 mL, 12.3 mmol) was added. The resulting solution was stirred at RT for 1 hour. The precipitate was removed by filtration, and the filtrate was used in next step without purification. A solution of 0.5 M diazomethane was added to the above reaction mixture. The sample was stirred at −10° C. for 1 hour. The reaction mixture was concentrated to one half of its original volume and washed once with saturated NaHCO3 (50 mL). The organic layer was dried over MgSO4 and filtered. The crude material was adsorbed onto silica gel and purified by flash chromatography (40 g SiO2, 0-50% ethyl acetate in hexanes) to give the diazoketone (2.29 g). 1H NMR (CDCl3) δ: 7.32 (m, 5H) 5.13 (m, 2H), 4.61 (m, 1H), 3.81, 4.03, 4.17 (s, AB quartet, 2H, J=4.0 Hz), 3.58 (m, 2H), 1.88-2.09, 2.17-2.38 (2, br m, 4H).
To a solution of the N-carbobenzyloxy-L-proline diazoketone (1.0 g, 3.6 mmol) in anhydrous diethyl ether (10 mL) was added a saturated solution of HBr in diethyl ether until N2 evolution ceased. The solution was stirred for about 1 hour at about 25° C., then washed with saturated NaHCO3, water and brine. The crude material was purified by silica gel column chromatography and eluted with 40% ethyl acetate in pentane to obtain the bromoketone (0.49 g) as clear oil. 1H NMR (CDCl3; mixture of cis-trans amide rotamers) δ: 7.35 (m, 5H), 5.28 (t, 1H), 5.17 (m, 2H), 4.32 (m, 1H), 3.58 (m, 2H), 1.84-2.30 (br m, 4H).
Step 3
Figure US11053243-20210706-C00362
To a mixture of bromoketone (3.25 g, 10 mmol) and the amidine (1.97 g, 10 mol) in THF (100 mL) was added NaHCO3 (1.7 g, 20 mmol), and the suspension was stirred at reflux for 12 hours. The reaction was cooled, concentrated and chromatographed to give compound 7 (0.425 g). MS (ESI) m/e (M+H+): 426, 428.
Step 4
Figure US11053243-20210706-C00363
The product from step 3 above can be converted to the final compounds using the same procedure as described in Example 117, steps 4-8. 1H NMR (MeOD) δ: 7.7-8.0 (m, 5H), 7.3-7.5 (m, 10H), 6.9-7.1 (m, 3H), 6.8 (d, J=4.8 Hz, 10H), 5.4-5.6 (m, 2H), 5.2-5.3 (m, 1H), 4.8 (s, 2H), 4.5-4.7 (m, 10H), 4.0 (d, J=2.4 Hz, 1H), 3.7 (d, J=4.84 Hz, 1H), 3.1-3.3 (m, 1H), 2.3-2.5 (m, 1H), 1.8-2.2 (m, 1H), 1.1-1.4 (m, 12H). MS (ESI) m/e (M+H+): 880.
Example 120—1-[(2R)-2-phenyl-2-{[(propan-2-yloxy)carbonyl]amino}acetyl]-N-{4-[5-(2-{(2S)-1-[(2R)-2-phenyl-2-{[(propan-2-yloxy)carbonyl]amino}acetyl]pyrrolidin-2-yl}-1H-imidazol-5-yl)-1-benzofuran-2-yl]phenyl}-L-prolinamide
Figure US11053243-20210706-C00364
Step 1
Figure US11053243-20210706-C00365
Glyoxal (2.0 mL of 40% in water) was added dropwise to a MeOH solution of NH4OH (32 mL) and (S)-Boc-prolinal (8.564 g, 42.98 mmol), then the whole was stirred at ambient temperature for 19 hours. The volatile component was removed in vacuo, and the residue was purified by a flash chromatography (silica gel, ethyl acetate) followed by a recrystallization (ethyl acetate) to provide compound as a white fluffy solid (4.43 g). 1H NMR (DMSO) δ: 11.68/11.59 (br s, 1H), 6.94 (s, 1H), 6.76 (s, 1H), 4.76 (m, 1H), 3.48 (m, 1H), 3.35-3.29 (m, 1H), 2.23-1.73 (m, 4H), 1.39/1.15 (s, 9H).
Step 2
Figure US11053243-20210706-C00366
NBS (838.4 mg, 4.71 mmol) was added in batches over 15 minutes to a cooled (ice/water) CH2Cl2 (20 mL) solution of imidazole (1.06 g, 4.50 mmol). The reaction mixture was stirred for 75 minutes and concentrated. The crude material was purified by RPLC to separate the mono bromide from its dibromo analog and the starting material. The HPLC elute was neutralized with excess NH3/MeOH, and the volatile component was removed in vacuo. The residue was partitioned between CH2Cl2 and water, and the aqueous layer was extracted with water. The combined organic phase was dried (MgSO4), filtered, and concentrated to provide compound as a white solid (374 mg). 1H NMR (DMSO) δ: 12.12 (br s, 1H), 7.10 (m, 1H), 4.70 (m, 1H), 3.31 (m, 1H; overlapped with water signal), 2.25-1.73 (m, 4H), 1.39/1.17 (s, 3.8H+5.2H).
Step 3
Figure US11053243-20210706-C00367
To a mixture of the benzofuran from Example 19, step 1 (15 g, 0.05 mol), bis(pinacolato)diboron (25.4 g, 0.1 mol), Pd(dppf)Cl2 (1 g), KOAc (0.1 mol) in dioxane (500 mL) was stirred at reflux under N2 atmosphere for 2 hours. Concentration of the reaction mixture left a residue that was chromatographed to give the desired compound (12 g). 1H NMR (DMSO) δ: 8.28 (d, J=8.8 Hz, 2H), 8.10 (s, 1H), 7.95 (d, J=8.8 Hz, 2H), 7.72 (d, J=8.8 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H), 7.05 (s, 1H).
Step 4
Figure US11053243-20210706-C00368
This reaction was conducted in a similar manner to that described in Example 117. MS (ESI) m/e (M+H+): 475.
Step 5
Figure US11053243-20210706-C00369
The product from step 4 (475 mg, 1.0 mmol) was dissolved in EtOH and treated with 20 mg of 10% Pd/C then hydrogenated over 5 hours. The catalyst was removed by filtration through CELITE, and the filtrate was evaporated to leave the desired product. MS (ESI) m/e (M+H+): 445.
Step 6
Figure US11053243-20210706-C00370
A solution containing HATU (1.0 mmol), the amine from step 5 above (445 mg, 1.0 mmol) and N-Boc-L-Pro-OH (215 mg, 1.0 mmol) in MeCN (10 mL) was treated with DIPEA (1.2 mmol). The reaction mixture was stirred for 3 hours, diluted with EtOAc and washed with water (5×). The organic phase was dried and concentrated then chromatographed by silica gel chromatography (EtOAc) to afford the desired compound. MS (ESI) m/e (M+H+): 642.
Figure US11053243-20210706-C00371
Step 7
A solution of the product from step 6 above was dissolved in 2 mL of DCM and 2 mL of TFA. The reaction mixture was stirred for 3 hours before the solvent was evaporated to give the desired product as an oil, which was used directly in the next reaction. MS (ESI) m/e (M+H+): 442.
Step 8
Figure US11053243-20210706-C00372
A solution containing BOP reagent (222 mg, 0.5 mmol), the diamine from step 7 above (112 mg, 0.25 mmol) and R-i-Proc-Phg-OH (125 mg, 0.6 mmol) in DMF (5 mL) was treated with N-methylmorpholine (2.4 mmol). The reaction mixture was stirred for 3 hours, diluted with 20 mL of EtOAc and washed with water (5×). The organic phase was dried and concentrated, then chromatographed by RPLC to afford the desired compound. 1H NMR (MeOD) δ: 6.8-7.9 (m, 19H), 5.1-5.5 (m, 3H), 4.5 (m, 1H), 3.5-4.04 (m, 2H), 1.6-2.5 (m, 9H), 0.9-1.3 (m, 12H). MS (ESI) m/e (M+H+): 880.
Example 121—propan-2-yl {(1R)-2-[(2S)-2-(5-{2-[4-(acetylamino)phenyl]-1H-indol-5-yl}-1,3,4-oxadiazol-2-yl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00373
Step 1
Figure US11053243-20210706-C00374
A mixture of 5-carboxyindole (32.2 g, 0.2 mol), NaHCO3 (53.36 g, 0.64 mol), methyl iodide (122.22 g, 0.86 mol) in 60 mL of DMF were stirred at RT for 2 days. Water and EtOAc are added, and the organic layer was washed with bicarbonate solution, dried and concentrated to obtain 5-(methoxycarbonyl)indole. 1H NMR (DMSO) δ: 11.44 (s, 1H), 8.22 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.37˜7.47 (m, 2H), 6.56 (d, J=2.0 Hz, 1H), 3.80 (s, 3H). MS (ESI) m/e (M+H+): 176.
Step 2
Figure US11053243-20210706-C00375
A mixture of the ester (28 g, 0.16 mmol) and NH2NH2 (85%, 50 mL) in ethanol (200 mL) was heated at reflux for 48 hours. The reaction mixture was concentrated, and the residue was purified by column chromatography (5% MeOH/DCM) to give compound (25 g). 1H NMR (DMSO) δ: 11.27 (s, 1H), 9.54 (s, 1H), 8.06 (s, 1H), 7.57 (d, J=8.8 Hz, 1H), 7.37 (d, J=8.8 Hz, 2H), 4.42 (s, 1H), 6.48 (s, 2H), 3.32 (s, 1H). MS (ESI) m/e (M+H+): 176.
Step 3
Figure US11053243-20210706-C00376
The product from step 3 above was coupled using a standard HATU amide bond forming procedure. MS (ESI) m/e (M+H+): 407.
Step 4
Figure US11053243-20210706-C00377
To a suspension of the product from step 3 above (100 g, 0.25 mol), PPh3 (98.4 g, 0.375 mol) and DIPEA (96.7 g, 0.75 mol) in CH3CN (500 mL) at RT was added C2Cl6 (82.8 g, 0.35 mol). The reaction was stirred at RT for 1.5 hours, and the solvent was removed, and the residue was portioned with EtOAc/H2O. The layers were separated, the aqueous phase was re-extracted with EtOAc (2×), and the combined organic layers were removed in vacuo, and the residue purified by column chromatography (5% MeOH/DCM) to give compound 4 (55 g). MS (ESI) m/e (M+H+): 389
Step 5
Figure US11053243-20210706-C00378
Di-tert-butyl dicarbonate (30.7 g, 142 mmol) was added drop wise to a solution of indole (55.0 g, 142 mmol), DMAP (2.0 g) and DIPEA (18.3 g, 142 mmol) in 50 mL of DCM at 0° C. The reaction was allowed to stir to RT overnight before it was concentrated, and the residue purified by prep TLC (PE/EA=2:1). MS (ESI) m/e (M+H+): 489.
Step 6
Figure US11053243-20210706-C00379
A mixture of compound indole from step 5 (977 mg, 2 mmol), (iPrO)3B (3.0 g, 16 mmol) and dry THF (100 mL) was cooled to 0° C. LDA (prepared from n-BuLi and iPr2NH in THF, about 8 mmol) was slowly added and the mixture was allowed to warm to RT over 2 hours. The mixture was quenched by 1N HCl to pH=3 and extracted with CH2Cl2 three times. The combined organic phases were combined, dried over Na2SO4 and filtered. The filtrate was concentrated and purified by column chromatography (PE/DCM=1/1 to pure CH2Cl2 to CH2Cl2/acetone=10/1 to pure acetone) to afford the product 8 (0.5 g).
Step 7
Figure US11053243-20210706-C00380
A mixture of the product from step 6 (0.38 mmol), indole boronic acid from Example 42 (145 mg, 0.38 mmol), Pd(dppf)Cl2 (28 mg, 0.038 mmol), Na2CO3 (122 mg, 1.15 mmol), THF (10 mL) and H2O (1 mL) was refluxed under N2 overnight. The mixture was poured into water and extracted with CH2Cl2. The organic phase was combined, dried over Na2SO4 and filtered to give the desired compound, which was used directly in the next step. MS (ESI) m/e (M+H+): 622.
Step 8
Figure US11053243-20210706-C00381
The product from step 7 (0.15 mmol) was dissolved in MeOH and treated with 20 mg of 20% Pd(OH)2 then hydrogenated at 45 psi for 4 hours. The catalyst was removed by filtration through CELITE, and the filtrate was evaporated then dissolved in 1 mL of DCM then treated with 1 mL of TFA. After stirring for 2 hours, the mixture was evaporated and the residue was used directly in the next reaction without further purification. MS (ESI) m/e (M+H+): 488.
Step 9
Figure US11053243-20210706-C00382
A solution containing PyBOP (44 mg, 0.1 mmol), the amine from step 8 above (49 mg, 0.1 mmol) and R-i-Proc-Phg-OH (21 mg, 0.1 mmol) in DMF (1 mL) was treated with N-methylmorpholine (0.6 mmol). The reaction mixture was stirred for 3 hours, diluted with EtOAc and washed with water (five times). The organic phase was dried and concentrated, then chromatographed by RPLC to afford the desired compound. 1H NMR (MeOD): δ 7.90˜8.35 (m, 1H), 7.70˜7.85 (m, 2H), 7.60˜7.70 (m, 2H), 7.20˜7.52 (m, 7H), 6.55˜7.20 (m, 1H), 5.50˜5.60 (m, 1H), 5.30˜5.50 (m, 1H), 4.75˜4.85 (m, 1H), 3.70˜4.10 (m, 1H), 3.35˜3.50 (m, 1H), 1.95˜2.50 (m, 7H), 1.10˜1.30 (m, 6H). MS (ESI) m/e (M+H+): 607.
Example 122—(2S)-1-(phenylacetyl)-N-{3-[5-{[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00383
Step 1
Figure US11053243-20210706-C00384
A solution of the hydrazine (1 g, 5 mmol) and 3-acetylacetanilide (0.88 g, 5 mmol) in NMP (5 ml) was heated at 150° C. under microwave for 10 minutes. The solution was poured into water and extracted with EtOAc three times. The organic layer was washed with water, dried over sodium sulfate and then concentrated in vacuo. The residue was purified by RPLC to give the desired compound. MS (m/z): 308 (M+H)+.
Step 2
Figure US11053243-20210706-C00385
To aqueous HCl (4N, 5 mL) was added the product from step 1 above (300 mg, 1 mmol), and the mixture was heated at reflux for 1 hour. The reaction mixture was cooled and concentrated, and the residue was purified by RPLC to give compound (200 mg). MS (m/z): 224 (M+H)+.
Figure US11053243-20210706-C00386
Step 3
To a solution of the compound from step 2 above (35 mg, 0.148 mmol) in MeCN (5 mL) were added N-phenylacetyl-L-proline (15 mg, 0.0673 mmol), DIPEA (26 mg, 0.202 mmol) and HATU (56 mg, 0.148 mmol). The reaction was stirred overnight and concentrated, and the residue was purified by RPLC to give the desired product (15 mg). MS (ESI) m/e (M+H+): 654. 1H NMR (MeOD) δ: 8.0 (m, 1H), 7.7 (m, 1H), 7.6-7.1 (m, 14H), 6.7 (m, 1H), 4.6 (m, 2H), 3.9-3.5 (m, 9H), 2.4-1.7 (m, 8H).
Example 123—(2S)-1-(phenylacetyl)-N-{4-[6-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00387
Step 1
Figure US11053243-20210706-C00388
To a stirred solution of 4-ethynylaniline (1 g, 8.5 mmol) in DCM (60 ml) was added acetyl chloride (0.8 g, 10 mmol) and TEA (1.7 g, 17 mmol). The mixture was stirred for 3 hours. The resulting solution was washed with water, 1 N HCl and brine. The organic layer was concentrated in vacuo to give the desired product (900 mg), which was used in next step without purification. MS (ESI) m/e (M+H+): 160.
Step 2
Figure US11053243-20210706-C00389
To a stirred solution of 4-ethynylacetanilide (800 mg, 3.1 mmol) in anhydrous THF (6 ml) was added compound 2 (0.5 g, 3.1 mmol), PdCl2(PPh)3 (33 mg, 0.05 mmol), CuI (10 mg, 0.05 mmol) and TEA (2 mL). The mixture was protected from light and stirred at RT overnight. The resulting solution was concentrated in vacuo, and the residue was washed with DCM to give the desired compound (300 mg) as a yellow solid. MS (ESI) m/e (M+H+): 296.
Step 3
Figure US11053243-20210706-C00390
To a stirred solution of compound from step 2 above (200 mg, 0.68 mmol) in toluene (2 ml) was added InBr3 (2 mg, 0.004 mmol). The mixture was stirred at reflux for 3 hours. The resulting solution was washed with water and extracted with EtOAc. The combined organic layers were dried over sodium sulfate, concentrated in vacuo to give the desired indole (170 mg) as a brown solid. MS (ESI) m/e (M+H+): 296.
Step 4
Figure US11053243-20210706-C00391
To a stirred solution of the product from step 3 above (100 mg, 0.34 mmol) in EtOH (5 ml) was added 3N HCl (1 mg). The mixture was stirred at reflux overnight. The resulting solution was concentrated in vacuo to give the desired aniline (80 mg) as a brown solid. MS (ESI) m/e (M+H+): 254.
Step 5
Figure US11053243-20210706-C00392
To a solution of the aniline from step 4 (50 mg, 0.2 mmol) in acetonitrile (5 mL) was added N-phenylacetyl-L-proline (56 mg, 0.2 mol), HATU (167 mg, 0.4 mmol) and DIPEA (100 mg, 0.8 mmol). The mixture was stirred overnight. The resulting solution was purified by RPLC to give the desired compound (40 mg) as a brown solid. MS (ESI) m/e (M+H+): 469.
Step 6
Figure US11053243-20210706-C00393
To a solution of the nitro compound (40 mg, 0.08 mmol) in THF (2 mL) was added Pd/C (20 mg, 0.1 mmol). The mixture was stirred under H2 atmosphere for 1 hour. After replacement of H2 with N2, the Pd/C was filtered off, and the filtrate was evaporated in vacuo to give the desired aminoindole (40 mg) as a brown solid. MS (ESI) m/e (M+H+): 439.
Step 7
Figure US11053243-20210706-C00394
To a solution of the product from step 6 above (40 mg, 0.1 mmol) in acetonitrile (5 mL) was added N-phenylacetyl-L-proline (23 mg, 0.1 mmol), HATU (70 mg, 0.2 mmol) and DIPEA (25 mg, 0.2 mmol). The mixture was stirred overnight. The resulting solution was purified by RPLC to give the desired compound (15 mg) as a brown solid. 1H NMR (MeOD) δ: 7.81 (m, 1H), 7.70 (d, J=8.6 Hz, 2H), 7.60 (d, J=8.4 Hz, 2H), 7.39 (m, 1H), 7.30-7.28 (m, 10H), 6.96 (m, 1H), 6.69 (s, 1H), 4.63-4.50 (m, 2H), 3.78-3.60 (m, 8H), 2.23-1.92 (m, 8H). MS (ESI) m/e (M+H+): 654.
Example 124—(2S)-1-(phenylacetyl)-N-{3-[6-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00395
Step 1
Figure US11053243-20210706-C00396
To a solution of 3-ethynylaniline (1.17 g, 10 mmol) and 1.5 ml Et3N in 40 mL DCM was added dropwise acetyl chloride (1 g, 13 mmol). The reaction mixture was stirred at RT for 1 hour. After that, the solvents were evaporated, and the residue was extracted with EtOAc (100 mL), washed with water (50 mL) and brine (50 mL), dried over anhydrous NaSO4, and concentrated in vacuo to afford 3-ethynylacetanilide (1.5 g). MS (ESI) m/e (M+H+): 160.
Step 2
Figure US11053243-20210706-C00397
3-nitroaniline (6.9 g, 0.05 mmol) was dissolved in 150 ml ethanol, iodine chloride (8.1 g, 0.05 mmol) added with dropwise. The reaction mixture was stirred at RT for 4 hours. After that, the solvents were evaporated, and the residue was extracted with EtOAc (100 mL), washed with water (50 mL) and brine (50 mL), dried over anhydrous NaSO4. After concentrated in vacuo, the residue was purified by column chromatography (PE/EtOAc=40:1>20:1) to afford the desired product (8.9 g). MS (ESI) m/e (M+H+): 265.
Step 3
Figure US11053243-20210706-C00398
3-Ethynylacetanilide (480 mg, 3 mmol) and 2-iodo-5-introaniline (800 mg, 3 mmol) were dissolved in anhydrous THF (30 mL), PdCl2(PPh3)2 (105 mg, 0.15 mmol) and CuI (28.5 mg, 0.15 mmol) Et3N (1 ml) was added sequentially. The reaction mixture was protected by N2 and stirred at RT for overnight. After that, the solvents were evaporated, and the residue was extracted with EtOAc (50×2 mL), washed with water (40 mL) and brine (30 mL), dried over anhydrous NaSO4. After concentrated in vacuo, the residue was purified by column chromatography (DCM/MeOH=50:1>20:1) to afford the desired product (620 mg). MS (ESI) m/e (M+H+): 296.
Step 4
Figure US11053243-20210706-C00399
To a solution of the product from step 3 (295 mg, 1.0 mol) in DCE (15 mL) was added PdCl2 (9 mg, 0.05 mmol) and FeCl3 (8 mg, 0.05 mmol). The reaction mixture was heated at 80° C. for 2 hours. The reaction was cooled, and the solvents were evaporated, and the residue was extracted with EtOAc (2×), washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4. After concentrated in vacuo, the residue was purified by Prep-TLC (DCM/MeOH=50:1) to afford the desired product (240 mg). MS (ESI) m/e (M+H+): 296. 1H NMR (DMSO) δ: 0.12 (s, 1H), 8.25 (d, J=8.0 Hz, 2H), 7.45˜7.94 (m, 6H), 7.03 (s, 1H), 2.10 (s, 3H).
Figure US11053243-20210706-C00400
Step 5
A suspension of the product from step 4 (200 mg, 0.67 mmol), Pd/C (10 mg, 0.034 mmol) in 40 mL EtOH was under H2 protection and stirred for 1 hour. The mixture was then filtered, and the filtrate was then concentrated to give the product (160 mg). The residue was dissolved in 20 ml 3N HCl, the mixture was stirred at 80° C. for 1 hour. It was cooled to RT, concentrated in vacuo and the residue was purified to give desired compound (120 mg) as a brown solid. MS (m/z) (M+H+): 224
Step 6
Figure US11053243-20210706-C00401
The mixture of compound 10 (50 mg, 0.224 mmol), N-phenylacetyl-L-proline (110 mg, 0.45 mmol), DIPEA (88 mg, 0.7 mmol) in CH3CN (5 mL) was stirred at RT for 5 minutes, then HATU (82 mg, 0.54 mmol) was added to it. The mixture was stirred at RT overnight. When reaction completed, the mixture was concentrated in vacuo, the residue was purified by chromatography on silica gel to give the desired target (70 mg). MS (ESI) m/e (M+H+): 654 1H NMR (MeOD): δ 7.95 (d, J=8.0 Hz, 2H), 7.86˜7.21 (m, 13H), 6.98 (d, J=8.0 Hz, 1H), 6.72 (s, 1H), 4.57 (m, 2H), 3.53 (m, 3H), 2.02˜2.31 (m, 8H).
Example 125—tert-butyl [(1R)-2-{(2S)-2-[(2-{2-[(2S)-1-{(2R)-2-[(tert-butoxycarbonyl) amino]-2-phenylacetyl}pyrrolidin-2-yl]-1H-benzimidazol-5-yl}-1H-indol-5-yl)carbamoyl]pyrrolidin-1-yl}-2-oxo-1-phenylethyl]carbamate
Figure US11053243-20210706-C00402
Step 1
Figure US11053243-20210706-C00403
The mixture of 4-bromo-1,2-phenylenediamine (3.1 g, 16 mmol), L-proline (4.3 g, 16 mmol), DIPEA (3 ml) in MeCN (100 mL) was stirred at RT for 5 minutes, then HATU (6 g, 17 mmol) was added. The mixture was stirred at RT overnight. When reaction completed, the mixture was concentrated, the residue was washed with water (100 mL) and extracted with EtOAc (three times), washed with brine (50 mL), dried over anhydrous Na2SO4. The residue purified by was purified by column chromatography (DCM/MeOH=100:1>50:1) to afford the desired compound (5.0 g). MS (ESI) m/e (M+H+): (418, 420).
Step 2
Figure US11053243-20210706-C00404
The product from step 1 (5 g, 7.2 mmol) was dissolved in 50 mL acetic acid. The reaction mixture was stirred at 100° C. for 4 hours. The mixture was cooled, and the acetic acid was removed in vacuo. The residue was purified by column chromatography (DCM/MeOH=150:1→400:1) to afford the desired compound (3.8 g). MS (ESI) m/e (M+H+): (400, 402).
Step 3
Figure US11053243-20210706-C00405
A suspension of the product from step 3 (1.2 g, 3 mmol), 1,5-bis-Boc-5-aminoindole-2-boronic acid (1.2 g, 3 mmol), Pd(PPh3)4 (240 mg), Na2CO3 (1 g, 9 mmol) and H2O (3 mL) in 30 mL of THF under N2 protection was reacted with refluxed at 75° C. overnight. The mixture was filtered, and the filtrate was washed with 50 mL of water and extracted with 100 ml EtOAc and dried over anhydrous Na2SO4. Removal of the solvent and column chromatography (CH2Cl2/MeOH=250:1>200:1) afforded the desired compound (500 mg). MS (ESI) m/e (M+H+): 652
Step 4
Figure US11053243-20210706-C00406
The product from step 3 (500 mg, 0.9 mmol) was stirred in MeOH/HCl (20 mL) for 16 hours. The solvent was removed under reduced pressure and the residue was dried at high vacuum. MS (ESI) m/e (M+H+): 452.
Step 5
Figure US11053243-20210706-C00407
The mixture of aniline from step 4 (450 mg, 1 mmol), (S)—N-Boc proline (215 mg 1 mmol), DIPEA (0.4 mL) in CH3CN (10 mL) was stirred at RT for 10 minutes, then HATU (400 mg, 1.1 mmol) was added. The mixture was stirred at RT overnight, concentrated, and the residue was purified by column chromatography (CH2Cl2/MeOH=250:1→200:1). MS (ESI) m/e (M+H+): 649.
Step 6
Figure US11053243-20210706-C00408
The product from step 5 (290 mg, 0.45 mmol) was dissolved in 5 mL of acetic acid and HBr (1 mL) was added. The reaction mixture was heated to 70-80° C. and stirred for 4 hours. The mixture was cooled to RT and concentrated in vacuo. The residue was extracted with EtOAc (2×), washed with aq NaHCO3 and water (30 mL) and brine (30 mL), dried over anhydrous sodium sulfate. Evaporation of the solvent afforded the desired compound as brown solid (160 mg). MS (ESI) m/e (M+H+): 415.
Step 7
Figure US11053243-20210706-C00409
A mixture of the product from step 6 (100 mg, 0.24 mmol), (R)—N-Boc-Phg (120 mg, 0.48 mmol), DIPEA (0.4 mL) in CH3CN (10 mL) was stirred at RT for 10 minutes, then HATU (200 mg, 0.5 mmol) was added. The mixture was stirred at RT overnight then concentrated, and the residue was purified by RPLC to afford the desired compound (54 mg). MS (ESI) m/e (M+H+): 882. 1H NMR (MeOD) δ: 7.96˜7.69 (m, 4H), 7.49˜6.84 (m, 13H), 5.50˜5.40 (m, 2H), 4.06˜3.94 (m, 2H), 2.27˜1.88 (m, 8H), 1.37 (s, 18H).
Example 126—(2S)—N-{4-[3-bromo-5-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}-1-(phenylacetyl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00410
To a solution of the indole (1 equiv) in 5 mL of THF was added NBS (278 mg, 1 mmol) at RT, and the mixture was stirred for 1 hour. Concentration of the solvent and purification of the residue by RPLC afforded the targeted halogenated compounds. 1H NMR (MeOD) δ: 7.9-7.5 (m, 5H), 7.4-7.0 (m, 12H), 5.2-4.9 (m, 2H), 4.4 (m, 2H), 3.8-3.5 (m, 6H), 2.5-1.8 (m, 8H).
Example 127—tert-butyl {(1S)-2-[(2S)-2-({2-[4-(acetylamino)phenyl]-3-fluoro-1H-indol-5-yl}carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00411
To a solution of the indole (1 equiv.) in acetonitrile/DMSO (5 ml, 1:1) was added SELECTFLUORO (1 equiv.) at 0° C. The mixture was stirred at RT for 3 3 hours before it was concentrated, and the residue purified with RPLC. 1H NMR (MeOD) δ: 7.9-7. c8 (m, 3H), 7.8-7.7 (m, 2H), 7.5-7.3 (m, 6H), 7.3 (m, 1H), 5.5 (s, 1H), 4.6-4.5 (m, 2H), 4.0-3.9 (m, 1H), 3.8 (m, 1H), 3.7 (m, 1H), 2.4-2.3 (m, 1H), 2.2-2.1 (m, 7H), 2.1-2.0 (m, 3H), 2.0-1.9 (m, 1H), 1.4 (m, 9H). MS (m/z): 711 (M+H)+.
Examples 128-154
Compounds of Examples 128-154 can be prepared by direct halogenation of the indole or benzofuran compounds in a similar manner as described in either Example 126 or Example 127.
Example Structure MW Name
128
Figure US11053243-20210706-C00412
 		688.233 (2S)-N-{4-[3-chloro-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
129
Figure US11053243-20210706-C00413
 		671.778 (2S)-N-{4-[3-fluoro-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
130
Figure US11053243-20210706-C00414
 		902.044 tert-butyl {(1S)-2-[(2S)-2-({4-[5- ({[(2S)-1-{(2S)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3-fluoro-1H- indol-2-yl]phenyl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
131
Figure US11053243-20210706-C00415
 		630.15 tert-butyl {(1S)-2-[(2S)-2-({2-[4- (acetylamino)phenyl]-3-chloro- 1H-indol-5-yl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
132
Figure US11053243-20210706-C00416
 		779.684 (2S)-N-{4-[3-iodo-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2-yl] carbonyl}amino)-1H-indol-2-yl] phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
133
Figure US11053243-20210706-C00417
 		710.813 tert-butyl {(1S)-2-[(2S)-2-({2-[4- ({[(2S)-1-acetylpyrrolidin-2- yl]carbonyl}amino)phenyl]-3- fluoro-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
134
Figure US11053243-20210706-C00418
 		898.1 (2S)-1-{(2S)-2-[(3,3- dimethylbutanoyl)amino]-2- phenylacetyl}-N-{4-[5-({[(2S)-1- {(2S)-2-[(3,3-dimethylbutanoyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino)- 3-fluoro-1H-indol-2-yl]phenyl} pyrrolidine-2-carboxamide
135
Figure US11053243-20210706-C00419
 		902.044 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3-fluoro-1H- indol-2-yl]phenyl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
136
Figure US11053243-20210706-C00420
 		613.695 tert-butyl {(1R)-2-[(2S)-2-({2- [4-(acetylamino)phenyl]-3- fluoro-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
137
Figure US11053243-20210706-C00421
 		710.813 tert-butyl {(1R)-2-[(2S)-2-({2- [4-({[(2S)-1-acetylpyrrolidin-2- yl]carbonyl}amino)phenyl]-3- fluoro-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
138
Figure US11053243-20210706-C00422
 		639.733 tert-butyl {(1R)-2-[(2S)-2-({3- fluoro-2-[4-(2-oxopyrrolidin-1- yl)phenyl]-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
139
Figure US11053243-20210706-C00423
 		567.669 N-{2-[4-(acetylamino)phenyl]-3- fluoro-1H-indol-5-yl}-1-[(2R)-2- phenyl-2-(pyrrolidin-1- yl)acetyl]-L-prolinamide
140
Figure US11053243-20210706-C00424
 		551.623 N-(tert-butoxycarbonyl)-D- alanyl-N-{2-[4- (acetylamino)phenyl]-3-fluoro- 1H-indol-5-yl}-L-prolinamide
141
Figure US11053243-20210706-C00425
 		541.631 N-{2-[4-(acetylamino)phenyl]-3- fluoro-1H-indol-5-yl}-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]-L-prolinamide
142
Figure US11053243-20210706-C00426
 		593.705 N-(tert-butoxycarbonyl)-D- leucyl-N-{2-[4- (acetylamino)phenyl]-3-fluoro- 1H-indol-5-yl}-L-prolinamide
143
Figure US11053243-20210706-C00427
 		815.953 propan-2-yl [(1R)-2-{(2S)-2-[(4- {5-[({(2S)-1-[(2R)-2- (dimethylamino)-2- phenylacetyl]pyrrolidin-2-yl} carbonyl)amino]-3-fluoro-1H- indol-2-yl}phenyl)carbamoyl] pyrrolidin-1-yl}-2-oxo-1- phenylethyl]carbamate)
144
Figure US11053243-20210706-C00428
 		754.866 tert-butyl (2S)-2-[(3-fluoro-2-{4- [({(2S)-1-[(2R)-2-phenyl-2- {[(propan-2-yloxy)carbonyl] amino}acetyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1H- indol-5-yl)carbamoyl] pyrrolidine-1-carboxylate
145
Figure US11053243-20210706-C00429
 		935.88 propan-2-yl [(1R)-2-{(2S)-2-[(4- {3-bromo-5-[({(2S)-1-[(2R)-2- phenyl-2-{[(propan-2- yloxy)carbonyl]amino}acetyl] pyrrolidin-2-yl}carbonyl)amino]- 1-benzofuran-2-yl}phenyl) carbamoyl] pyrrolidin-1-yl}-2- oxo-1-phenylethyl]carbamate
146
Figure US11053243-20210706-C00430
 		819.806 (2S)-N-(4-{3-bromo-5-[({(2S)-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1- benzofuran-2-yl}phenyl)-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidine-2- carboxamide
147
Figure US11053243-20210706-C00431
 		879.772 methyl {(1R)-2-[(2S)-2-({4-[3- bromo-5-({[(2S)-1-{(2R)-2- [(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
148
Figure US11053243-20210706-C00432
 		749.847 methyl {(2S)-1-[(2S)-2-({4-[3- fluoro-5-({[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-3-methyl-1-oxobutan-2- yl}carbamate
149
Figure US11053243-20210706-C00433
 		603.521 N-{2-[4-(acetylamino)phenyl]-3- bromo-1-benzofuran-5-yl}-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]-L-prolinamide
150
Figure US11053243-20210706-C00434
 		875.915 (2S)-N-(4-{3-bromo-5-[({(2S)-1- [(2R)-2-(diethylamino)-2- phenylacetyl]pyrrolidin-2-yl} carbonyl)amino]-1-benzofuran- 2-yl}phenyl)-1-[(2R)-2- (diethylamino)-2-phenylacetyl] pyrrolidine-2-carboxamide
151
Figure US11053243-20210706-C00435
 		700.639 (2S)-1-acetyl-N-(4-{3-bromo-5- [({(2S)-1-[(2R)-2- (dimethylamino)-2-phenylacetyl] pyrrolidin-2-yl}carbonyl)amino]- 1-benzofuran-2-yl}phenyl) pyrrolidine-2-carboxamide
152
Figure US11053243-20210706-C00436
 		963.935 tert-butyl {(1S)-2-[(2S)-2-({4-[3- bromo-5-({[(2S)-1-{(2S)-2- [(tert-butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate)
153
Figure US11053243-20210706-C00437
 		733.669 (2S)-N-{4-[3-bromo-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2-yl] carbonyl}amino)-1-benzofuran- 2-yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
154
Figure US11053243-20210706-C00438
 		963.935 tert-butyl {(1R)-2-[(2S)-2-({4- [3-bromo-5-({[(2S)-1-{(2R)-2- [(tert-butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-1- benzofuran-2-yl]phenyl} carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
Example 155—(2S)—N-{4-[3-cyano-5-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}-1-(phenylacetyl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00439
A mixture of the bromo compound from Example 126 (150 mg, 0.2 mmol), CuCN (50 mg, 0.6 mmol) and DMF (3 mL) was refluxed under N2 protection overnight. The mixture was purified by RPLC to afford the product. MS (ESI) m/e (M+H+): 679. 1H NMR (CDCl3) δ: 7.73-7.70 (m, 4H), 7.38-7.29 (m, 4H), 7.21-7.04 (m, 6H), 4.63-4.60 (m, 1H), 4.49-4.47 (m, 1H), 3.81-3.59 (m, 4H), 2.48-1.97 (m, 8H).
Example 156—(2S)—N-{4-[3-(2,2-dimethylpropanoyl)-5-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-1H-indol-2-yl]phenyl}-1-(phenylacetyl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00440
To a stirred solution of the indole (50 mg, 0.076 mmol) in CH2Cl2 (5 mL) was added anhydrous ZnCl2 (54 mg, 0.4 mmol) then MeMgBr (3.0 M in Et2O, 0.4 mL, 0.4 mmol). The resulting suspension was stirred for 10 minutes at RT and then cooled to 0° C. at an ice bath. A solution of pivaloyl chloride (14 mg) in CH2Cl2 (0.2 mL) was added to the mixture. The reaction mixture was allowed to warm to RT and stirred overnight. The reaction mixture was quenched by saturated aqueous NH4Cl and exacted with CH2Cl2 3 times. The organic layers were combined, dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated and purified by RPLC to yield the product. MS (ESI) m/e (M+H+): 738. 1H NMR (MeOD) δ: 7.69-7.63 (m, 3H), 7.44-7.41 (m, 2H), 7.31-7.21 (m, 12H), 4.55-4.52 (m, 2H), 3.76-3.59 (m, 8H), 2.26-1.94 (m, 8H).
Example 157—5-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)-2-[4-({[(2S)-1-(phenylacetyl)pyrrolidin-2-yl]carbonyl}amino)phenyl]-1H-indole-3-carboxamide
Figure US11053243-20210706-C00441
To a solution of the indole (653 mg, 1 mmol) in THF 10 (mL) was added EtMgBr (2 mL, 6 mmol), and the mixture was stirred at RT for 30 minutes. Thereto was added chlorosulfonyl isocyanate (140 mg, 1 mmol), and the mixture was stirred at RT for 20 minutes. Then, DMF (146 mg, 2 mmol) was added to the above mixture, and the stirring continued for 20 minutes. After adding aqueous NaOH (2N, 1 mL), the resulting solution was heated at reflux for 5 minutes. Concentration in vacuo, the residue was purified with RPLC to give (67 mg). 1H NMR (MeOD) δ: 8.0 (s, 1H), 7.6 (m, 4H), 7.1-7.4 (m, 12H), 4.5 (m, 4H), 3.5-3.7 (m, 8H), 2.5-2.0 (m, 6H).
Example 158—tert-butyl {(1R)-2-[(2S)-2-({4-[5-({[(2S)-1-{(2R)-2-[(tert-butoxycarbonyl)amino]-2-phenylacetyl}pyrrolidin-2-yl]carbonyl}amino)-3-(cyclopropylcarbamoyl)-1H-indol-2-yl]phenyl}carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00442
Step 1
Figure US11053243-20210706-C00443
To a solution of POBr3 (113.2 g, 0.4 mol) in DCE (1 L) was added DMF (14.6 g, 0.2 mol) dropwise under ice bath, and the mixture was stirred at RT for 30 minutes. Thereto was added nitro compound (17.8 g, 0.1 mol), and the mixture was stirred at reflux for 4 hours. The precipitate was collected by filtration and then washed with water and MeOH. The solid was dried in vacuo to give the desired compound (13.5 g). 1H NMR (DMSO) δ: 13.6 (s, 1H), 9.8 (s, 1H), 8.8 (s, 1H), 8.1 (d, J=9.2 Hz, 1H), 7.6 (d, J=9.2 Hz, 1H).
Step 2
Figure US11053243-20210706-C00444
To a solution of the aldehyde from step 1 (13.5 g, 0.05 mol) in DCM (100 mL) was added DMAP (0.6 g, 0.005 mol), TEA (10.1 g, 0.1 mol) and (Boc)2O (21.8 g, 0.1 mol), and the mixture was stirred at RT overnight. The mixture was concentrated, and the residue was purified by column chromatography to give the desired compound (14.7 g). 1H NMR (CDCl3) δ: 9.8 (s, 1H), 8.8 (s, 1H), 8.1 (d, J=9.2 Hz, 1H), 7.6 (d, J=9.2 Hz, 1H), 1.4 (s, 9H).
Step 3
Figure US11053243-20210706-C00445
The Suzuki coupling procedure was the same as described in Example 117, step 3. MS (m/z): 482 (M+H)+.
Figure US11053243-20210706-C00446
Step 4
To a solution of compound from step 3 (2.4 g, 5 mmol) in pH 3.5 phosphate buffer (24 mL) and t-BuOH (30 mL) was added 2-methyl-2-butene (10 mL) and sodium chlorate (0.89 g, 10 mmol). The reaction was stirred at RT for 16 hours and then extracted with DCM (3×). The combined organic extracts were washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo to give the desired carboxylic acid (2.3 g). MS (m/z): 498 (M+H)+.
Step 5
Figure US11053243-20210706-C00447
The mixture of compound from step 4 (1 mmol), cyclopropyl amine (1 mmol), HATU (1 mmol) and DIPEA (5 mmol) in DCM was stirred at RT overnight. Concentration and purification of the residue by RPLC gave the desired compound (0.8 mmol). MS (m/z): 538 (M+H)+.
Step 6
Figure US11053243-20210706-C00448
To a solution of the amide from step 5 (0.8 mmol) in MeOH (10 mL) was added Pd/C (100 mg) and the mixture was stirred under H2 at RT for 1 hour. The Pd/C was removed by filtration, and the filtrate was concentrated to give the desired compound (0.7 mmol). MS (m/z): 507 (M+H)+.
Step 7
Figure US11053243-20210706-C00449
To a solution of compound from step 6 (0.7 mmol) in DCM (5 mL) was added TFA (2 mL), and the mixture was stirred at RT overnight. The solution was concentrated, and the residue was used in next step without purification. MS (m/z): 307 (M+H)+.
Step 8
Figure US11053243-20210706-C00450
The coupling procedure was the same as used in Example 72, step 7. 1H NMR (MeOD) δ: 6.9-7.9 (m, 17H), 5.2-5.5 (m, 2H), 4.4-4.5 (m, 2H), 3.5-3.9 (m, 3H), 2.7-2.8 (m, 1H), 1.7-2.2 (m, 8H), 1.4 (s, 18H), 1.2 (m, 1H), 0.4-0.8 (m, 4H). MS (m/z): 967 (M+H)+.
Example 159—tert-butyl {(1R)-2-[(2S)-2-({4-[5-({[(2S)-1-{(2R)-2-[(tert-butoxy-carbonyl)amino]-2-phenylacetyl}pyrrolidin-2-yl]carbonyl}amino)-3-(4-methoxyphenyl)-1H-indol-2-yl]phenyl}carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00451
Step 1
Figure US11053243-20210706-C00452
NBS (103 mg, 0.5769 mmol) was added in portions to the solution of the indole (510 mg, 0.5769 mmol) in 20 mL of THF, the mixture was stirred at RT for 1 hour, then concentrated. The residue was purified by Prep-HPLC to afford the desired compound (500 mg). MS (ESI) m/e (M+H+): 962.
Step 2
Figure US11053243-20210706-C00453
The mixture of the product from step 1 above (100 mg, 0.104 mmol), 4-methoxy-phenylboronic acid (24 mg, 0.1558 mmol), Pd(dppf)Cl2 (7.6 mg, 0.0104 mmol), Na2CO3 (3.3 mg, 0.0312 mmol) in 10 mL of dioxane and 2 mL of water was heated to reflux under N2 atmosphere overnight. The mixture was cooled and concentrated, then the residue was purified by RPLC to give the desired product (30 mg). 1H NMR (MeOD) δ: 7.71˜7.54 (m, 3H), 7.42˜7.26 (m, 16H), 6.96˜6.92 (m, 3H), 5.45 (s, 2H), 4.53˜4.50 (m, 2H), 3.92˜3.81 (m, 5H), 2.08˜1.84 (m, 8H), 1.42˜1.32 (m, 18H). MS (ESI) m/e (M+H+): 991.
Examples 160-177
Compounds of Examples 160-177 were prepared in a similar manner as described in Examples 155-159.
Example Structure MW Name
160
Figure US11053243-20210706-C00454
 		729.887 (2S)-1-(phenylacetyl)-N-{4-[3- phenyl-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}pyrrolidine-2- carboxamide
161
Figure US11053243-20210706-C00455
 		681.842 (2S)-N-{4-[3-ethyl-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
162
Figure US11053243-20210706-C00456
 		695.826 (2S)-N-{4-[3-acetyl-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
163
Figure US11053243-20210706-C00457
 		757.897 (2S)-1-(phenylacetyl)-N-{4-[5- ({[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl}amino)- 3-(phenylcarbonyl)-1H-indol-2- yl]phenyl}pyrrolidine-2- carboxamide
164
Figure US11053243-20210706-C00458
 		730.874 (2S)-1-(phenylacetyl)-N-{2-[4- ({[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl} amino)phenyl]-3-(pyridin-4-yl)- 1H-indol-5-yl}pyrrolidine-2- carboxamide
165
Figure US11053243-20210706-C00459
 		761.886 benzyl (2S)-2-[(4-{5-[({(2S)-1- [(benzyloxy)carbonyl]pyrrolidin- 2-yl}carbonyl)amino]-3-phenyl- 1H-indol-2-yl}phenyl) carbamoyl]pyrrolidine-1- carboxylate
166
Figure US11053243-20210706-C00460
 		678.798 (2S)-N-{4-[3-cyano-5-({[(2S)-1- (phenylacetyl)pyrrolidin-2- yl]carbonyl}amino)-1H-indol-2- yl]phenyl}-1-(phenylacetyl) pyrrolidine-2-carboxamide
167
Figure US11053243-20210706-C00461
 		693.853 (2S)-N-{4-[3-cyclopropyl-5- ({[(2S)-1-(phenylacetyl) pyrrolidin-2-yl]carbonyl}amino)- 1H-indol-2-yl]phenyl}-1- (phenylacetyl)pyrrolidine-2- carboxamide
168
Figure US11053243-20210706-C00462
 		791.912 benzyl (2S)-2-[(4-{5-[({(2S)-1- [(benzyloxy)carbonyl]pyrrolidin- 2-yl}carbonyl)amino]-3-(3- methoxyphenyl)-1H-indol-2- yl}phenyl)carbamoyl]pyrrolidine- 1-carboxylate
169
Figure US11053243-20210706-C00463
 		974.18 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3-(3- methylphenyl)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
170
Figure US11053243-20210706-C00464
 		974.18 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3-(2- methylphenyl)-1H-indol-2- yl]phenyl}carbamoyl)pyrrolidin- 1-yl]-2-oxo-1- phenylethyl}carbamate
171
Figure US11053243-20210706-C00465
 		961.14 tert-butyl {(1R)-2-[(2S)-2-({2- [4-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)phenyl]-3- (pyridin-4-yl)-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
172
Figure US11053243-20210706-C00466
 		909.064 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3-cyano-1H- indol-2-yl]phenyl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
173
Figure US11053243-20210706-C00467
 		764.936 (2S)-N-(4-{3-cyano-5-[({(2S)-1- [(2R)-2-(dimethylamino)-2- phenylacetyl]pyrrolidin-2- yl}carbonyl)amino]-1H-indol-2- yl}phenyl)-1-[(2R)-2- (dimethylamino)-2-phenylacetyl] pyrrolidine-2-carboxamide
174
Figure US11053243-20210706-C00468
 		620.714 tert-butyl {(1R)-2-[(2S)-2-({2- [4-(acetylamino)phenyl]-3- cyano-1H-indol-5- yl}carbamoyl)pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
175
Figure US11053243-20210706-C00469
 		955.133 tert-butyl {(1R)-2-[(2S)-2-({4- [5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-3- (dimethylcarbamoyl)-1H-indol- 2-yl]phenyl}carbamoyl) pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
176
Figure US11053243-20210706-C00470
 		942.091 methyl 5-({[(2S)-1-{(2R)-2- [(tert-butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-2-[4-({[(2S)- 1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)phenyl]-1H- indole-3-carboxylate
177
Figure US11053243-20210706-C00471
 		928.064 5-({[(2S)-1-{(2R)-2-[(tert- butoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2- yl]carbonyl}amino)-2-[4-({[(2S)- 1-{(2R)-2-[(tert-butoxycarbonyl) amino]-2-phenylacetyl} pyrrolidin-2-yl]carbonyl}amino) phenyl]-1H-indole-3-carboxylic acid
Example 178—tert-butyl {(1R)-2-[(2S)-2-({2-[3-(acetylamino)prop-1-yn-1-yl]-1H-indol-5-yl}carbamoyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00472
Step 1
Figure US11053243-20210706-C00473
Ethyl carbonochloridate (3 mL) was added to the nitro lactam (2.0 g, 11.2 mmol), and the mixture was stirred for 3 hours before being concentrated to give the crude product. MS (ESI) m/e (M+H+): 325. The crude product was dissolved in DMF (25 mL), then (NH4)2CO3 (1.5 g) was added, and the mixture was stirred overnight. The mixture was evaporated and the residue was poured into ice-water and extracted with DCM, and the organics were dried. The solvent was removed, and the residue was purified by chromatography on silica gel to give the desired compound as a white solid. MS (ESI) m/e (M+H+): 251.
Figure US11053243-20210706-C00474
Step 2
The mixture of the triflate (382 mg, 1.0 mmol), N-(prop-2-ynyl)acetamide (97 mg, 1.0 mmol), Et3N (3 mL) in CH3CN (3 mL) was stirred at RT for 3 hours. The mixture was concentrated, and the residue was purified by chromatography on silica gel to give compound target compound (254 mg). MS (ESI) m/e (M+H+): 330.
Step 3
Figure US11053243-20210706-C00475
A solution of the nitro compound from step 2 above (165 mg, 0.50 mmol) in absolute EtOH (3 mL) was added Fe power (280 mg, 2.5 mmol) and NH4Cl (535 mg, 5.0 mmol). The mixture was stirred at 70° C. for 2 hours, cooled and poured into ice/water (50 ml). The mixture was extracted with EtOAc (200 ml), and the organic phase was combined and washed with brine, dried and concentrated to yield the crude product (150 mg). MS (ESI) m/z: (M+H) 300.
Step 4
Figure US11053243-20210706-C00476
To a solution of the aniline from step 3 (150 mg, 0.50 mmo) in absolute EtOH (3 mL) was added K2CO3 (138 mg, 1.0 mmol), and the mixture was stirred at RT for 12 hours. The reaction mixture was poured into water (10 mL), extracted with EtOAc (20 mL), and the organic phases were combined and washed with brine, dried over MgSO4 and concentrated to yield the crude product (113 mg). MS (ESI) m/z: (M+H+) 228.
Step 5
Figure US11053243-20210706-C00477
The mixture of the indole (113 mg, 0.5 mmol), R-Boc-Phg-L-Pro-OH (175 mg, 0.5 mmol), DIPEA (115 mg, 1.0 mmol) in MeCN (2 mL) was stirred at RT for 5 minutes, then HATU (190 mg, 0.5 mmol) was added into the mixture. The mixture was stirred at RT overnight then concentrated. The residue was purified by RPLC to give the desired compound (110 mg). 1H NMR (MeOD) δ: 1.37 (s, 9H), 1.96˜2.14 (m, 7H), 3.92˜3.94 (m, 2H), 4.51˜4.54 (m, 1H), 5.41 (s, 1H), 6.56 (s, 1H), 7.20˜7.43 (m, 7H), 7.72 (s, 1H). MS (ESI) m/z: (M+H+) 576.
Example 179—N-{4-[5-(furan-3-yl)-1H-indol-2-yl]phenyl}-1-(phenylacetyl)-L-prolinamide
Figure US11053243-20210706-C00478
Step 1
Figure US11053243-20210706-C00479
The mixture of the indole from Example 41 (1.6 mg, 5.575 mmol), 1-phenylacetyl pyrrolidine-2-carboxylic acid (1.3 g, 5.575 mmol), DIPEA (1.45 g, 11.15 mmol) in DMF (50 mL) was stirred at RT for 30 minutes, then HATU (2.54 g, 6.689 mmol) was added. The mixture was stirred at RT overnight, concentrated in vacuo, and the residue was purified by chromatography on silica gel to give the desired product (2.3 g). MS (ESI) m/e (M+H+): 504.
Step 2
Figure US11053243-20210706-C00480
A suspension of the product from step 1 above (18 mg, 0.03583 mmol), furan-2-boronic acid (6 mg, 0.05374 mmol), Pd(PPh3)2Cl2 (1.4 mg), Na2CO3 (7.6 mg, 0.07166 mmol) and H2O (0.15 mL) in 0.5 mL of acetonitrile under N2 protection was heated at 150° C. for 10 minutes in a microwave reactor. The mixture was cooled, filtered and washed with 10 mL of DCM. The solvents were removed, and the residue was purified by HPLC to give the desired product. 1H NMR (MeOD) δ: 7.79˜7.74 (m, 3H), 7.67˜7.62 (m, 3H), 7.50 (s, 1H), 7.37˜7.22 (m, 6H), 6.78˜6.75 (m, 2H), 4.57˜4.55 (m, 1H), 3.78˜3.61 (m, 4H), 2.24˜1.99 (m, 4H).
Examples 180-189b
Compounds of Examples 180-189b were prepared in a similar manner as described in Example 179.
Example Structure MW Name
180
Figure US11053243-20210706-C00481
 		557.701 N-(4-{5-[6-(dimethylamino)-4- methylpyridin-3-yl]-1H-indol-2- yl}phenyl)-1-(phenylacetyl)-L- prolinamide
181
Figure US11053243-20210706-C00482
 		555.704 N-{4-[5-(1-benzothiophen-3-yl)- 1H-indol-2-yl]phenyl}-1- (phenylacetyl)-L-prolinamide
182
Figure US11053243-20210706-C00483
 		579.708 N-{4-[5-(1-benzyl-1H-pyrazol-4- yl)-1H-indol-2-yl]phenyl}-1- (phenylacetyl)-L-prolinamide
183
Figure US11053243-20210706-C00484
 		557.655 N-{4-[5-(2,3-dihydro-1,4- benzodioxin-6-yl)-1H-indol-2- yl]phenyl}-1-(phenylacetyl)-L- prolinamide
184
Figure US11053243-20210706-C00485
 		550.666 1-(phenylacetyl)-N-{4-[5- (quinolin-8-yl)-1H-indol-2- yl]phenyl}-L-prolinamide
185
Figure US11053243-20210706-C00486
 		505.644 1-(phenylacetyl)-N-{4-[5- (thiophen-3-yl)-1H-indol-2- yl]phenyl}-L-prolinamide
186
Figure US11053243-20210706-C00487
 		563.662 tert-butyl {(1S)-2-[(2S)-2-{[4-(5- cyano-1H-indol-2-yl)phenyl] carbamoyl}pyrrolidin-1-yl]-2- oxo-1-phenylethyl}carbamate
187
Figure US11053243-20210706-C00488
 		879.037 propan-2-yl [(1R)-2-oxo-1- phenyl-2-{(2S)-2-[4-(2-{4- [({(2S)-1-[(2R)-2-phenyl-2- {[(propan-2-yloxy)carbonyl] amino}acetyl]pyrrolidin-2- yl}carbonyl)amino]phenyl}-1H- indol-5-yl)-1H-imidazol-2-yl] pyrrolidin-1-yl}ethyl]carbamate
188
Figure US11053243-20210706-C00489
 		606.687 propan-2-yl {(1R)-2-[(2S)-2-(5- {2-[4-(acetylamino)phenyl]-1H- indol-5-yl}-1,3,4-oxadiazol-2- yl)pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
189
Figure US11053243-20210706-C00490
 		576.704 N-{4-[5-(5-{(2S)-1-[(2R)-2- (diethylamino)-2- phenylacetyl]pyrrolidin-2-yl}- 1,3,4-oxadiazol-2-yl)-1H-indol- 2-yl]phenyl}acetamide
189a
Figure US11053243-20210706-C00491
 		806.9 methyl [(2S)-1-{(2S)-2-[5-(10- {2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]- 1H-imidazol-5-yl}indolo[1,2-c] [1,3]benzoxazin-3-yl)-1H- imidazol-2-yl]pyrrolidin-1-yl}-3- methyl-1-oxobutan-2- yl]carbamate
189b
Figure US11053243-20210706-C00492
 		824.9 methyl [(2S)-1-{(2S)-2-[5-(12- fluoro-10-{2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]- 1H-imidazol-5-yl}indolo[1,2- c]][1,3]benzoxazin-3-yl)-1H- imidazol-2-yl]pyrrolidin-1-yl}-3- methyl-1-oxobutan-2- yl]carbamate
Example 189b (Alternative Procedure: Methyl [(2S)-1{(2S)-2-[5-(12-fluoro-10-{2-[(2S)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}indolo[1,2-c][1,3]benzoxazin-3-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate
Figure US11053243-20210706-C00493
Step 1
Figure US11053243-20210706-C00494
To a solution of compound 3-bromophenol (51 g, 0.3 mol) and Et3N (36 g, 0.36 mol) in 500 mL of DCM was added dropwise acetyl chloride (26 g, 0.33 mol) in an ice-water bath. The mixture was stirred at RT for 30 minutes. The mixture was washed with 1 N HCl, saturated Na2CO3 and brine, dried over Na2SO4 and concentrated in vacuo to give a oil (62 g).
Step 2
Figure US11053243-20210706-C00495
AlCl3 (40 g, 0.3 mol) was slowly added to the product from step 1 (21.5 g, 0.1 mol) in an ice-water bath. The mixture was stirred at 140° C. for 2 hours. After cooling to 60-70° C., the mixture was slowly poured into an ice water. The resulting solution was extracted with DCM. The combined organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography to give the desired compound (14 g). MS (ESI) m/e (M+H+): 214.
Step 3
Figure US11053243-20210706-C00496
A mixture of the ketone obtained in step 2 (4.2 g, 20 mmol) and 4-bromophenyl hydrazine hydrochloride (4.4 g, 20 mmol) in AcOH and EtOH (1:10, 100 mL) was heated to reflux for 6 hours. The solvent was removed in vacuo to give a solid, which was used in the next step without further purification (9.2 g crude). MS (ESI) m/e (M+H+): 383.
Step 4
Figure US11053243-20210706-C00497
A mixture of product from step 3 (9.2 g) in PPA was heated to 80° C. for 2 hours. After cooling to RT, the mixture was poured into ice water. The resulting solution was extracted with DCM. The combined organic phases were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography to give the desired indole (4.8 g). MS (ESI) m/e (M+H+): 368.
Step 5
Figure US11053243-20210706-C00498
To a mixture of the indole from step 4 (6 g, 16.3 mmol) in DMSO/CH3CN (1:1, 24 mL) was added SELECTFLUOR® (5.8 g, 16.3 mmol) in portion at RT. The mixture was stirred for an additional 1 hour at RT, and the mixture was purified by HPLC to give a solid (1.0 g). MS (ESI) m/e (M+H+): 386.
Step 6
Figure US11053243-20210706-C00499
A mixture of the compound from step 5 (650 mg, 1.63 mmol), CH2Br2 (1.5 g, 8.62 mmol) and K2CO3 (1.2 g, 8.7 mmol) in DMF (32.5 mL) was stirred for 5 hours at 80° C. Then the mixture was evaporated in vacuo. The residue was diluted with EA and water. The organic layer was separated, dried over Na2SO4 and concentrated in vacuo to give a solid, which was directly used to next step without further purification (610 mg). MS (ESI) m/e (M+H+): 396.
Step 7
Figure US11053243-20210706-C00500
To a solution of the product from step 6 (1 mmol) in 1,4-dioxane was added bis pinacol borate (1.1 mmol) and Pd(dppf)Cl2 (0.02 mmol) and KOAc (2 mmol). The reaction mixture was stirred under N2 and heated to 110° C. for 3 hours. After that, the solvent was removed under vacuum, and the residue was purified by column chromatography to afford the product. MS (ESI) m/e (M+H+): 492.
Step 8
Figure US11053243-20210706-C00501
A suspension of the boronate from above (2 mmol), tert-butyl 2-(2-bromo-1H-imidazol-5-yl) pyrrolidine-1-carboxylate (2.4 mmol), Pd(dppf) Cl2 (200 mg), Na2CO3 (3 mmol) and in THF/H2O (10:1, 33 mL) was refluxed at 75° C. overnight under N2 protection. The mixture was cooled and filtered, and the filtrate was washed with water (50 mL) and extracted with EtOAc (100 mL), washed with brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by column chromatography to afford the desired compound. MS (ESI) m/e (M+H+): 710.
Step 9
Figure US11053243-20210706-C00502
The protected proline from above (1.3 mmol) was added to HCl/CH3OH (10 mL, 3M). The mixture was stirred at RT for 2-3 hours before the mixture was concentrated to give the crude product, which was used in the next step without further purification. MS (ESI) m/e (M+H+): 510
Step 10
Figure US11053243-20210706-C00503
To a mixture of the crude product from step 9 (1.0 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (2.0 mmol) and DIPEA (8 mmol) in CH3CN (10 mL) was added BOP (2.2 mmol). The resulting mixture was stirred at RT. After LCMS showed the starting material to be consumed, the mixture was filtered, and the filtrate was purified by HPLC to give the desired compound as a white solid. MS (ESI) m/e (M+H+): 825. 1H NMR (MeOD): δ 7.83-7.85 (m, 3H), 7.72 (s, 1H), 7.53 (s, 2H), 7.46-7.48 (m, 1H), 7.42 (s, 1H), 5.92 (s, 2H), 5.20-5.22 (m, 2H), 4.20-4.23 (m, 2H), 4.06-4.09 (m, 2H), 3.86-3.88 (m, 2H), 3.61 (s, 6H), 2.50-2.52 (m, 2H), 1.96-2.20 (m, 8H), 0.90-0.98 (m, 12H).
Example 190: (2S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]-N-(2-{5-[({(2S)-1-[(2R)-2-(dimethylamino)-2-phenylacetyl]pyrrolidin-2-yl}carbonyl)amino]-1,3-benzoxazol-2-yl}-1H-indol-5-yl)pyrrolidine-2-carboxamide
Figure US11053243-20210706-C00504
Step 1
Figure US11053243-20210706-C00505
To a solution of imidazole (13.6 g, 0.2 mol) in 1 L of DCM was added BrCN (7.4 g, 66 mmol), and the mixture was heated at reflux for 30 minutes. The mixture was cooled to RT, and the white precipitate removed by filtration, and the filtrate concentrated to 100 mL then cooled to 0° C. for 2 days. The crystallized solid was filtered and washed with cold DCM, then dried in vacuo to give the desired product (8.8 g) as a white solid.
Step 2
Figure US11053243-20210706-C00506
A solution containing the product from step 1 (8.36 g, 54.2 mmol) and 2-amino-4-nitrophenol (8.74 g, 54.2 mmol) in anhydrous THF (200 mL) was allowed to reflux under N2 for 14 hours. The mixture was cooled to RT, filtered, and the precipitate was washed with THF (cold) then dried in vacuo to afford the desired product (9.0 g), as a yellow solid. MS (ESI) m/e (M+H+): 180. 1H NMR (DMSO) δ: 7.85˜7.96 (m, 3H), 7.52 (d, J=8.8 Hz, 1H).
Step 3
Figure US11053243-20210706-C00507
To a suspension of the product from step 2 (3.58 g, 20 mmol) in acetonitrile (300 mL) was added CuBr2 (8.96 g, 40 mmol). The solution became dark green and t-butyl nitrite (4.12 g, 40 mmol) was added RT over 5 minutes, whereupon the mixture heated at 45° C. for 2 hours. The reaction mixture was poured into water (800 mL) and DCM (800 mL), and the phases were separated. The aqueous phase was extracted with DCM (3×800 mL), dried with Na2SO4 and evaporated to afford the crude product. Purification by column chromatography afforded the desired product. MS (ESI) m/e (M+H+): 243/245. 1H NMR (DMSO) δ: 8.71 (s, 1H), 8.42 (d, J=9.2 Hz, 1H), 8.10 (d, J=9.2 Hz, 1H).
Step 4
Figure US11053243-20210706-C00508
The mixture of compound from step 3 above (603 mg, 2.5 mmol), the indole boronic acid from Example 42 (1.0 g, 2.75 mmol), Pd(dppf)Cl2 (183 mg, 0.25 mmol), Na2CO3 (530 mg, 5.0 mmol) in 5 mL dioxane-H2O (5:1) was heated to reflux under N2 atmosphere overnight. When reaction was complete, the mixture was poured into water and extracted with DCM. The organic phase was dried over Na2SO4 and concentrated, and the residue was purified to give compound the desired product. MS (ESI) m/e (M+H+): 596.
Step 5
Figure US11053243-20210706-C00509
The product from step 4 (596 mg, 1.0 mmol) was dissolved in EtOAc and treated with Pd/C (100 mg, 20%). Then, the mixture was stirred at RT overnight under H2 atmosphere. When the reaction was complete, the Pd/C was filtered off, and the resulting solution was concentrated to give the crude product MS (ESI) m/e (M+H+): 565. This material was covered with 5 mL of 3M HCl, and the mixture was stirred at RT for 2 hours. Evaporation of the solvent afforded the desired product, which was used directly without further purification. MS (ESI) m/e (M+H+): 265.
Figure US11053243-20210706-C00510
Step 6
The compound was coupled using the procedure similar to that which was described in Example 40 starting from 265 mg (1.0 mmol) of the product from step 5. 1H NMR (MeOD) δ: 8.12 (s, 1H), 7.97 (d, J=2 Hz, 1H), 7.30˜7.70 (m, 15H), 5.30˜5.35 (m, 2H), 4.51˜4.60 (m, 2H), 3.85˜3.95 (m, 2H), 3.15˜3.25 (m, 2H), 3.06 (s, 3H), 2.54 (s, 6H), 1.80˜2.30 (m, 8H). MS (ESI) m/e (M+H+): 781.
Example 191: 1-[(2R)-2-(diethylamino)-2-phenylacetyl]-N-{2-[4-(5-{(2S)-1-[(2R)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl}-1,3,4-oxadiazol-2-yl)phenyl]-1H-indol-5-yl}-L-prolinamide
Figure US11053243-20210706-C00511
Step 1
Figure US11053243-20210706-C00512
To a solution of N-Cbz-L-Pro (14.9 g, 0.06 mol) and TEA (8.08 g, 0.08 mol) in 100 mL of DCM added dropwise isopropyl chloroformate (8.05 g, 0.066 mol) at 0° C. After addition, the solution was continued to stir for 1 hour before the hydrazide (13.0 g, 0.05 mol) was added, and the mixture was continued to stir for another 1 hour. The solvent was evaporated in vacuo, and the residue was recrystallized from EtOH to give a white solid (22.1 g). 1H NMR (DMSO) δ: 10.47 (s, 1H), 10.03 (s, 1H), 7.86 (d, J=8.0 Hz, 2H), 7.62 (d, J=8.0 Hz, 2H), 7.31˜7.61 (m, 5H), 4.91˜5.14 (m, 2H), 4.26˜4.35 (m, 1H), 3.30˜3.4 (m, 2H), 1.95˜2.19 (s, 4H). MS (ESI) m/e (M+H+): 494.
Step 2
Figure US11053243-20210706-C00513
To a solution of the product from step 1 (2.1 g, 4.26 mmol), DIPEA (2.3 mL, 17.7 mmol) and PPh3 (1.71 g, 6.5 mmol) in 20 mL of MeCN was added hexchloroethane (1.41 g, 5.97 mmol), and the mixture was stirred at RT for 1.5 hours. The solvent was evaporated, and the residue was purified by chromatography to give a white solid (1.75 g). MS (ESI) m/e (M+H+): 494.
Step 3
Figure US11053243-20210706-C00514
A mixture of the product from step 2 above (494 mg, 1.0 mmol), indole boronic acid from Example 42 (377 mg, 1.0 mmol), Pd(dppf)Cl2 (73 mg, 0.10 mmol), Na2CO3 (318 mg, 3.0 mmol), THF (25 mL) and H2O (5 mL) was refluxed under N2 overnight. The mixture was poured into water and extracted with CH2Cl2. The organic phase was combined, dried over Na2SO4 and filtered to give the desired compound, which was used directly in the next step. MS (ESI) m/e (M+H+): 680.
Step 4
Figure US11053243-20210706-C00515
Following the procedure described in Example 99, steps 4-7, the oxadiazole from step 3 above was converted to the desired product. 1H NMR (MeOD) δ: 8.09 (d, J=8.8 Hz, 2H), 7.99 (d, J=8.8 Hz, 2H), 7.83 (s, 1H), 7.66˜7.68 (m, 4H), 7.55˜7.58 (m, 6H), 7.38˜7.40 (m, 1H), 7.22˜7.24 (m, 1H), 6.98 (s, 1H), 5.39 (s, 1H), 5.37˜5.39 (m, 2H), 4.52˜4.54 (m, 1H), 4.12˜4.14 (m, 1H), 3.94˜3.96 (m, 1H), 3.10˜3.41 (m, 8H), 2.72˜2.76 (m, 2H), 1.84˜2.24 (m, 8H), 1.34˜1.41 (m, 6H), 1.16˜1.19 (m, 6H). MS (ESI) m/e (M+H+): 821.
Example 192: Methyl {(2S)-1-[(2S)-2-{5-[4-(5-{2-[(2S)-1-{(2S)-2-[(methoxy-carbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-1-benzofuran-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
Figure US11053243-20210706-C00516
Step 1
Figure US11053243-20210706-C00517
A 2 L, 3-necked round bottomed flask equipped with an overhead stir and a N2 inlet was charged with a solution of oxalyl chloride (130 mL, 0.26 mol) in DCM (250 mL). The solution was cooled to −78° C., and a solution of DMSO (20 mL, 0.28 mol) in DCM (30 mL) was added dropwise. After 30 minutes, a solution of (S)—N-Boc-prolinol (40 g, 0.20 mol) in DCM (200 mL) was added dropwise. After 30 minutes, TEA (140 mL, 1.00 mol) was added to the solution, and the flask was transferred to an ice/water bath and stirred for another 30 minutes. The reaction mixture was diluted with DCM (200 mL) and washed successively with H2O, 1M HCl, saturated NaHCO3, and brine. The DCM layer was dried over Na2SO4, filtered, and concentrated to afford crude (S)-2-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester (40 g) as an oil, which was used without further purification.
Step 2
Figure US11053243-20210706-C00518
Glyoxal (2.0 mL of 40% in water) was added dropwise over 11 minutes to a methanol solution of NH4OH (32 mL) and (S)-Boc-prolinal (8.564 g, 42.98 mmol) and stirred at ambient temperature for 19 hours. The volatile components were removed in vacuo, and the residue was purified by a flash silica gel chromatography (EtOAc) followed by a recrystallization (EtOAc) to provide the desired compound as a white fluffy solid (4.43 g). 1H NMR (DMSO) δ: 11.68, 11.59 (br s, 1H), 6.94 (s, 1H), 6.76 (s, 1H), 4.76 (m, 1H), 3.48 (m, 1H), 3.35-3.29 (m, 1H), 2.23-1.73 (m, 4H), 1.39/1.15 (s, 9H). MS (ESI) m/e (M+H+): 238.
Figure US11053243-20210706-C00519
Step 3
To a suspension of the compound from step 2 (140 g, 0.59 mol) in THF (2000 ml) was added NBS (200 g, 1.1 mol). The mixture was stirred at RT under N2 protection overnight before the solvent was removed, and the residue was purified by chromatography on silica gel to give 230 g of the desired dibromo compound. MS (ESI) m/e (M+H+): 396.
Step 4
Figure US11053243-20210706-C00520
To a suspension of compound from step 3 (230 g, 0.58 mol) in EtOH/H2O (3000 ml) was added Na2SO3 (733 g, 5.8 mol). The resulting mixture was stirred under reflux overnight. After cooling to RT, the mixture was extracted by DCM and concentrated under vacuum. The resulting residue was purified by chromatography on silica gel to give the desired bromo imidazole target. MS (ESI) m/e (M+H+): 317.
Figure US11053243-20210706-C00521
Step 5
To a stirred solution of ethyl 4-bromophenylacetate (50 g, 205.8 mmol) in CCl4 (500 mL) was added NBS (38 g, 214.7 mmol), then 48% aqueous HBr (4 drops). After the addition, the solution was stirred overnight at 80° C. under argon. Then the reaction was cooled to RT, filtered, and concentrated. The resulting oil was directly used the next step.
Step 6
Figure US11053243-20210706-C00522
To a solution of the compound from step 5 (2 g, 6.2 mmol) in DMF (20 mL) was added 5-bromosalicylaldehyde (1.21 g, 6.0 mmol) and Cs2CO3 (2 g, 12.3 mmol) under N2 protection. The resulting suspension was stirred for 5 hours at 160° C., then cooled and treated with water. The resulting precipitate was filtered, and the filtrate cake was dried in vacuo to give the desired compound, which was used directly in next step.
Step 7
Figure US11053243-20210706-C00523
A suspension of the product from step 6 above (4.43 g, 12.58 mmol), bis(pincolato)diboron (8.31 g, 32.72 mmol), AcOK (3.72 g, 37.7 mmol) and Pd(dppf)Cl2 (921 mg, 1.26 mmol) in dioxane (100 mL) was heated to reflux for 4 hours under N2. The mixture was concentrated, the residue was partitioned between H2O and DCM, and the aqueous phase was extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, concentrated. The residue was purified by chromatography on silica gel to afford the desired compound (5 g).
Step 8
Figure US11053243-20210706-C00524
A suspension of the product from step 4 (5 mmol), the boronate ester from step 7 (2 mmol), Pd(dppf)Cl2 (146 mg, 0.2 mmol), and Na2CO3 (636 mg, 6 mmol) were refluxed in THF/H2O (10:1, 33 mL) overnight under N2 protection. The mixture was cooled and filtered, and the filtrate was washed with water (50 mL) then extracted with EtOAc (100 mL), washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated and the resulting residue was purified by column chromatography (PE/EA=8:1>5:1) to afford the desired compound. MS (ESI) m/z (M+H)+:641).
Step 9
Figure US11053243-20210706-C00525
The product from step 8 (1.3 mmol) was added into 3M HCl/CH3OH (20 mL) and the mixture was stirred at RT for 2 to 3 hours. The mixture was concentrated, and the crude product was used directly in the next step without further purification. MS (ESI) m/z (M+H)+: 441.
Step 10
Figure US11053243-20210706-C00526
To a mixture of the product from step 9 (1 mmol), N-Moc-L-valine (2.1 mmol) and DIPEA (0.4 mL) in DMF (3 mL) was added BOP reagent (2.2 mmol). The resulting mixture was stirred at RT for 16 hours. The solution was subjected directly to RPLC to afford the desired compound. 1H NMR (MeOD) δ: 7.7-8.1 (m, 10H), 7.4 (m, 1H), 5.3 (m, 2H), 4.3 (m, 2H), 4.1 (d, J=4.8 Hz, 2H), 3.9 (m, 2H), 3.7 (m, 6H), 2.6 (d, J=4.8 Hz, 2H), 2.0-2.4 (m, 8H), 1.3-1.4 (m, 2H), 0.9-1.0 (m, 12H). MS (ESI) m/z (M+H)+: 780.
Examples 193-202
Compounds of Examples 193-202 were prepared in a similar manner as described in Example 192.
Ex-
ample Structure 1H NMR M + 1 Name
193
Figure US11053243-20210706-C00527
 		(MeOD) δ: 7.2-8.1 (m, 20 H), 5.2-5.6 (m, 4 H), 3.9- 4.2 (m, 2 H), 3.1 (m, 2 H), 2.6 (m, 8 H), 1.9-2.5 (m, 8 H), 1.0-1.5 (m, 12 H). 844 (2R)-2-(diethylamino)-1- [(2S)-2-(5-{4-[5-(2-{(2S)- 1-[(2R)-2-(diethylamino)- 2-phenylacetyl]pyrrolidin- 2-yl}-1H-imidazol-5-yl)-1- benzofuran-2-yl]phenyl}- 1H-imidazol-2-yl) pyrrolidin-1-yl]-2- phenylethanone
194
Figure US11053243-20210706-C00528
 		(MeOD) δ: 8.0-8.1 (m, 3 H), 7.7-7.9 (m, 6 H), 7.4 (d, J = 2.4 Hz, 1 H), 5.3 (d, J = 5.6 Hz, 2 H), 4.1 (m, 2 H), 3.9 (m, 4 H), 3.7 (m, 6 H), 2.5-2.6 (m, 2 H), 2.1- 2.3 (m, 6 H), 1.1-1.2 (m, 2 H), 0.4-0.6 (m, 9 H). 775 Methyl {(1S)-1- cyclopropyl-2-[(2S)-2-{5- [4-(5-{2-[(2S)-1-{(2S)-2- cyclopropyl-2- [(methoxycarbonyl)amino] acetyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}-1- benzofuran-2-yl)phenyl]- 1H-imidazol-2- yl}pyrrolidin-1-yl]-2- oxoethyl}carbamate
195
Figure US11053243-20210706-C00529
 		(MeOD) δ: 7.7-8.1 (m, 9 H), 7.4(m, 16 H), 5.3-5.4 (m, 2 H), 3.5-4.1 (m, 12 H), 2.6 (d, J = 4.8 Hz, 26 H), 2.2 (d, J = 4.8 Hz, 6 H), 1.1-1.2 (m, 2 H), 0.4- 0.7 (m, 8 H). 775 Methyl {(1R)-1- cyclopropyl-2-[(2S)-2-{5- [4-(5-{2-[(2S)-1-{(2R)- 2-cyclopropyl-2- [(methoxycarbonyl)amino] acetyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}-1- benzofuran-2-yl)phenyl]- 1H-imidazol- 2-yl}pyrrolidin-1- yl]-2-oxoethyl}carbamate
196
Figure US11053243-20210706-C00530
 		(MeOD) δ: 7.8-7.9 (m, 5 H), 7.1-7.6 (m, 5 H), 5.6- 5.7 (m, 1 H), 5.2 (d, J = 4.8 Hz, 1 H), 4.0-4.2 (m, 3 H), 3.6-3.8 (m, 8 H), 2.0-2.5 (m, 10 H), 1.6 (d, J = 4.8 Hz, 1 H), 1.3 (m, 1 H), 0.8-1.1 (m, 11 H), 0.4 (m, 26 H). 780 Methyl {(2R)-1-[(2S)-2- {5-[2-(4-{2-[(2S)-1- {(2R)-2- [(methoxycarbonyl) amino]-3-methylbutanoyl} pyrrolidin-2-yl]-1H- imidazol-5-yl}phenyl)-1- benzofuran-5-yl]-1H- imidazol-2-yl}pyrrolidin- 1-yl]-3-methyl-1- oxobutan-2-yl}carbamate
197
Figure US11053243-20210706-C00531
 		(MeOD), δ 8.10(d, J = 4 Hz, 2 H), 8.01(s, 1 H), 7.94(s, 1 H) 7.87(d, J = 2 Hz, 2 H), 7.84(m, 1 H), 7.73(d, J = 4 Hz, 1 H), 7.44(m, 1 H), 5.25(m, 2 H), 4.33(m, 2 H), 4.16(m, 2 H), 3.89(m, 2 H), 3.67(s, 6 H), 2.58(m, 2 H), 2.20(m, 6 H), 0.97(m, 18 H) 806 Methyl {(2S)-1-[(2S)-2- {5-[4-(5-{2-[(2S)-1-{(2S)- 2-[(methoxycarbonyl) amino]-3,3- dimethylbutanoyl} pyrrolidin-2-yl]-1H- imidazol-5-yl}-1- benzofuran-2-yl) phenyl]-1H-imidazol-2- yl}pyrrolidin-1-yl]-3,3- dimethyl-1-oxobutan-2-
yl}carbamate
198
Figure US11053243-20210706-C00532
 		(MeOD) δ: 7.6-8.1 (m, 9 H), 7.3-7.5 (m, 11 H), 7.2 (m, 1 H), 5.4-5.5 (m, 2 H), 5.3 (m, 2 H), 4.1 (d, J = 4.8 Hz, 2 H), 3.7 (d, J = 2.4 Hz, 6 H), 1.9-2.4 (m, 8 H) 848 Methyl {(1R)-2-[(2S)-2- {5-[4-(5-{2-[(2S)-1- {(2R)-2- [(methoxycarbonyl) amino]-2- phenylacetyl}pyrrolidin- 2-yl]-1H-imidazol-4- yl}-1-benzofuran-2- yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-2-
oxo-1-phenylethyl}
carbamate
199
Figure US11053243-20210706-C00533
 		(MeOD) δ 8.08(d, J = 4 Hz, 2 H), 8.04(s, 1 H), 7.89(d, 3 H), 7.78(m, 1 H), 7.77 (m, 2 H), 7.42(m, 1 H), 5.34(t, J = 4 Hz, 2 H), 4.42(d, J = 4 Hz, 2 H), 4.10(s, 2 H), 3.82(m, 2 H), 3.79(m, 3 H), 3.64(s, 3 H), 2.57(m, 2 H), 2.20(m, 6 H), 1.88(m, 2 H), 1.48(m, 2 806 Methyl {(2S,3R)-1- [(2S)-2-(5-{2-[4-(2- {(2S)-1-[N- (methoxycarbonyl)-L- alloisoleucyl]pyrrolidin- 2-yl}-1H-imidazol-5-yl) phenyl]-1-benzofuran-5- yl}-1H-imidazol-2- yl)pyrrolidin-1-yl]-3- methyl-1-oxopentan-2- yl}carbamate
H), 1.32(m, 2 H),
0.97(m, 12 H).
200
Figure US11053243-20210706-C00534
 		(MeOD) δ: 7.6-8.1 (m, 9 H), 7.4 (m, 6 H), 5.4 (m, 2 H), 4.6 (m, 2 H), 3.5-4.1 (m, 13 H), 2.5-2.7 (m, 6 H), 2.3 (m, 5 H). 755 Methyl {(2S)-3-hydroxy- 1-[(2S)-2-{5-[4-(5-{2- [(2S)-1-{(2S)-3-hydroxy- 2-[(methoxycarbonyl) amino]propanoyl} pyrrolidin-2-yl]-1H- imidazol-5-yl}-1- benzofuran-2-yl)phenyl]- 1H-imidazol-2-yl} pyrrolidin-1-yl]-1- oxopropan-2-yl}carbamate
201
Figure US11053243-20210706-C00535
 		(MeOD), δ 8.04(d, J = 4 Hz, 2 H) 7.97(s, 1H), 7.84(d, J = 2 Hz, 2 H), 7.81(m, 1 H), 7.76(m, 1 H), 7.64(d, J = 4 Hz, 2 H), 7.38(m, 1 H), 5.29(m, 2 H), 4.49(m, 2 H), 4.15(m, 2 H), 3.97(m, 1 H), 3.92(m, 1 H), 3.66(m, 6 H), 2.63(m, 1 H), 2.60(m, 1 H), 2.54(m, 2 H), 2.16- 783 Methyl {(2S,3R)-3- hydroxy-1-[(2S)-2-{5-[4- (5-{2-[(2S)-1-{(2S,3R)- 3-hydroxy-2- [(methoxycarbonyl) amino]butanoyl} pyrrolidin-2-yl]- 1H-imidazol-5-yl}-1- benzofuran-2-yl)phenyl]- 1H-imidazol-2-yl} pyrrolidin-1-yl]-1-
2.22(m, 6 H), 1.16 (d, J = oxobutan-2-yl}carbamate
2 Hz, 6 H).
202
Figure US11053243-20210706-C00536
 		(MeOD), δ 8.05(d, J = 4 Hz, 2 H), 7.97(s, 1 H), 7.84(d, 1 H), 7.81(d, J = 2 Hz, 2 H), 7.76(m, 1 H), 7.64(d, J = 4 Hz, 2 H), 7.39(m, 1 H), 5.25(m, 2 H), 4.45(m, 2 H), 4.03(m, 2 H), 3.84(m, 2 H), 3.85(m, 2 H), 3.64(s, 6 H), 2.55(m, 2 H), 2.22(m, 6 H), 1.70(m, 2 H), 806 Methyl {(2S)-1- [(2S)-2-{5-[4-(5- {2-[(2S)-1-{(2S)-2- [(methoxycarbonyl) amino]-4- methylpentanoyl} pyrrolidin-2-yl]-1H- imidazol-5-yl}-1- benzofuran-2-yl) phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-
1.51(m, 4 H), 0.98 (m, 12 yl]-4-methyl-1-
H) oxopentan-2-
yl}carbamate
Example 203: Methyl {(2S)-1-[(2S)-2-{5-[3-fluoro-4-(5-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-1-benzofuran-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
Figure US11053243-20210706-C00537
Step 1
Figure US11053243-20210706-C00538
To a solution of 5-bromobenzofuran (3.9 g, 20 mmol) in dry THF (30 mL) cooled to −78° C. under N2-protected LDA (prepared from n-BuLi and iPr2NH in THF (˜30 mmol)) was slowly added. The mixture was stirred at the same temperature for 30 minutes, then triisopropylborate (5.64 g, 30 mmol) was added to the mixture. The mixture was allowed to warm to RT and stirred for 2 hours. The mixture was then quenched with 1N HCl to pH=3 and extracted with EtOAc. The combined organic phases were combined, dried and filtered. The filtrate was concentrated to afford the desired product (4.3 g). MS (ESI) m/e (M+H+): 241.
Step 2
Figure US11053243-20210706-C00539
A suspension of the boronic acid from step 1 (1.44 mg, 6.0 mmol), 2-fluoro-4-iodobromobenzene (1.8 g, 6.0 mmol), Pd(dppf)Cl2 (600 mg), Na2CO3 (954 mg, 9.0 mmol) and in THF/H2O (9:1, 100 mL) was refluxed at 75° C. overnight under N2 protection. The mixture was cooled and filtered. The filtrate was washed with water (150 mL) and extracted with EtOAc (200 mL), washed with brine and dried over anhydrous sodium sulfate. The solution was evaporated and the residue was purified by column chromatography (PE/EA=8:1>5:1) to afford the desired compound. MS (ESI) m/e (M+H+): 370.
Step 3
Figure US11053243-20210706-C00540
To a solution of the product from step 2 (1.85 g, 5 mmol), bis(pinacolato)diboron (2.54 g, 10 mmol) and Pd(dppf)Cl2 (80 mg) and KOAc (0.98 g, 10 mmol) were dissolved in 1,4-dioxane (30 mL), and the reaction mixture was heated at 110° C. for 16 hours. The solvent was evaporated, and the residue was purified by column chromatography with silica gel elution with PE to afford the desired product as white solid (1.95 g). MS (ESI) m/e (M+H+): 465.
Step 4
Figure US11053243-20210706-C00541
A suspension of the bromoimidazole from Example 192 (5 mmol), the boronate ester from step 3 (2 mmol), Pd(dppf)Cl2 (146 mg, 0.2 mmol) and Na2CO3 (636 mg, 6 mmol) was refluxed in THF/H2O (10:1, 33 mL) overnight under N2 protection. The mixture was cooled and filtered, and the filtrate was washed with water (50 mL) and extracted with EtOAc (100 mL), washed with brine and dried over anhydrous sodium sulfate. The solution was concentrated, and the resulting residue was purified by column chromatography (PE/EtOAc=8:1) to afford the desired compound. MS (ESI) m/e (M+H+): 683.
Step 5
Figure US11053243-20210706-C00542
The product from step 4 (682 mg, 1.0 mmol) was treated with 3M HCl/CH3OH (10 mL) and the mixture was stirred at RT for 3 hours. The reaction mixture was concentrated, and the crude product was used directly in the next step without further purification. MS (ESI) m/e (M+H+): 483.
Step 6
Figure US11053243-20210706-C00543
To a mixture of the product from step 5 (482 mg, 1.0 mmol), N-Moc-L-valine (2.1 mmol) and DIPEA (0.4 mL) in DMF (3 mL) was added BOP reagent (977 mg, 2.2 mmol). The resulting mixture was stirred at RT for 16 hours. The solution was subjected directly to RPLC to afford the desired compound as white solid (40 mg). 1H NMR (MeOD) δ: 7.99 (s, 1H), 7.89-7.80 (m, 5H), 7.72-7.67 (m, 2H), 7.47 (s, 1H), 5.27-5.22 (m, 2H), 4.22 (d, 2H), 4.09 (d, 2H), 3.89-3.84 (m, 2H), 3.64 (s, 6H), 2.55-2.02 (m, 10H), 0.92 (d, 6H), 0.88 (d, 6H). MS (ESI) m/e (M+H+): 797.
Examples 204-212
Compounds of Examples 204-212 were prepared in a similar manner as described in Example 203.
Ex-
ample Structure M + 1 Name
204
Figure US11053243-20210706-C00544
 		866 Methyl {(1R)-2-[(2S)-2-{5-[3-fluoro-4-(5-{2- [(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2-yl]-1H-imidazol-5- yl}-1-benzofuran-2-yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
205
Figure US11053243-20210706-C00545
 		797 Methyl {(2S)-1-[(2S)-2-{5-[3-fluoro-4-(5-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}-1-benzofuran-2-yl)phenyl]- 1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl- 1-oxobutan-2-yl}carbamate
206
Figure US11053243-20210706-C00546
 		816 Methyl {(2S)-1-[(2S)-2-{5-[2-(2,6-difluoro-4- {2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]- 3-methylbutanoyl}pyrrolidin-2-yl]- 1H-imidazol-5-yl}phenyl)-1-benzofuran-5- yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3- methyl-1-oxobutan-2-yl}carbamate
207
Figure US11053243-20210706-C00547
 		878 Methyl {(1R)-2-[(2S)-2-{5-[3-methoxy-4-(5- {2-[(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]- 2-phenylacetyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}-1-benzofuran-2-yl)phenyl]- 1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
208
Figure US11053243-20210706-C00548
 		814 Methyl {(2S)-1-[(2S)-2-{5-[2-(2-chloro-4-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-4-yl}phenyl)-1-benzofuran-5-yl]- 1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl- 1-oxobutan-2-yl}carbamate
209
Figure US11053243-20210706-C00549
 		873 Methyl {(1R)-2-[(2S)-2-{4-[3-cyano-4-(5-{2- [(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2-yl]-1H-imidazol-5- yl}-1-benzofuran-2-yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-2-oxo-1- phenylethyl}carbamate
210
Figure US11053243-20210706-C00550
 		794 Methyl {(2S)-1-[(2S)-2-{5-[2-(4-{2-[(2S)-1- {(2S)-2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-4-yl}-2-methylphenyl)-1- benzofuran-5-yl]-1H-imidazol-2- yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2- yl}carbamate
211
Figure US11053243-20210706-C00551
 		Methyl [(1S)-2-[(2S)-2-(5-{3-fluoro-4-[5-(2- {(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-2- (tetrahydro-2H-pyran-4-yl)acetyl]pyrrolidin- 2-yl}-1H-imidazol-5-yl)-1-benzofuran-2- yl]phenyl}-1H-imidazol-2-yl)pyrrolidin-1-yl]- 2-oxo-1-(tetrahydro-2H-pyran-4- yl)ethyl]carbamate
212
Figure US11053243-20210706-C00552
 		832 Methyl {(2S)-1-[(2S)-2-{4-[3-fluoro-4-(5-{2- [(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2- phenylacetyl}pyrrolidin-2-yl]-1H-imidazol-5- yl}-1-benzofuran-2-yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2- yl}carbamate
Example 213: Methyl {(1R)-2-[(2S)-2-{5-[4-(5-{2-[(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,3-benzoxazol-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate
Figure US11053243-20210706-C00553
Step 1
Figure US11053243-20210706-C00554
4-Bromobenzoic acid (20 g, 0.1 mol) and 2-amino-4-bromophenol (18.8 g, 0.1 mol) were added into polyphosphoric acid (250 mL), and the mixture was stirred at 140° C. for 90 minutes. After cooling in an ice-bath, the reaction mixture was diluted with water (4000 mL) and neutralized with NaOH. The resulting solid was filtered off and dried to afford the desired benzoxazole. MS (ESI) m/e (M+H+): 354.
Step 2
Figure US11053243-20210706-C00555
A suspension of the product from step 1 above (10.6 g, 30 mmol), bis(pinacolato)diboron (30.3 g, 120 mmol), KOAc (7.6 g, 78 mmol) and Pd(dppf)Cl2 (1.1 g, 1.5 mmol) in dioxane (300 ml) was stirred at 100° C. under N2 protection overnight. The reaction mixture was cooled and concentrated, then chromatographed on silica gel gave the product compound. MS (ESI) m/e (M+H+): 366.
Step 3
Figure US11053243-20210706-C00556
A suspension of the product from step 2 (1.2 g, 2.6 mmol), bromoimidazole from Example 192 (2 g, 6.3 mmol), Na2CO3 (1.3 g, 12 mmol) and Pd(dppf)Cl2 (220 mg, 0.3 mmol) in THF/H2O (36 ml) was stirred at 100° C. under N2 protection overnight. The reaction mixture was concentrated and purified by chromatography on silica gel to give the desired compound. MS (ESI) m/e (M+H+): 666.
Step 4
Figure US11053243-20210706-C00557
A solution of the product from step 3 (400 mg, 0.6 mmol) in HCl/MeOH (20 ml) was stirred at ambient temperature for 3 hours, then concentrated and dried under high vacuum to give to desired product. MS (ESI) m/e (M+H+): 466.
Step 5
Figure US11053243-20210706-C00558
To a mixture of the product from step 4 (233 mg, 0.5 mmol), N-Moc-D-Phg (1.1 mmol) and DIPEA (0.2 mL) in DMF (3 mL) was added BOP reagent (488 mg, 1.1 mmol). The resulting mixture was stirred at RT for 16 hours before the solution was subjected directly to RPLC to afford the desired compound. 1H NMR (MeOD) δ: 8.4 (d, J=8.4 Hz, 2H), 8.2 (s, 1H), 8.0 (m, 3H), 7.9 (m, 3H), 7.5-7.4 (m, 10H), 5.5 (s, 2H), 5.3 (m, 2H), 4.1-4.0 (m, 2H), 3.6 (d, J=2.8 Hz, 6H), 3.3 (m, 1H), 3.3-3.1 (m, 1H), 2.5-2.3 (m, 2H), 2.2-2.1 (m, 4H), 2.0 (m, 2H). MS (ESI) m/e (M+H+): 780.
Examples 214-215
Compounds of Examples 214-215 were prepared in a similar manner as described in Example 213.
Example Structure 1H NMR M + 1 Name
214
Figure US11053243-20210706-C00559
 		(MeOD) δ: 8.4 (d, J = 8.4 Hz, 2 H), 8.1 (s, 1 H), 7.9 (m, 3 H), 7.8 (m, 2 H), 7.7 (m, 1 H), 5.3 (m, 2 H), 4.2 (m, 2 H), 4.1-4.0 (m, 2 H), 3.9-3.8 (m, 2 H), 3.6 (s, 2 H), 2.6 (m, 2 H), 2.3 (m, 2 H), 2.2 (m, 4 H), 2.0 (m, 2 H), 0.9 (m, 12 H). 848 Methyl {(2S)-1-[(2S)-2- {5-[2-(4-{2-[(2S)-1-{(2S)- 2-[(methoxycarbonyl) amino]-3- methylbutanoyl} pyrrolidin-2-yl]-1H- imidazol-5-yl}phenyl)- 1,3-benzoxazol-5-yl]-1H- imidazol-2-yl}pyrrolidin- 1-yl]-3-methyl-1- oxobutan-2-yl}carbamate
215
Figure US11053243-20210706-C00560
 		(MeOD) δ: 8.4 (d, J = 6.8 Hz, 2 H), 8.2-8.1 (s, 1 H), 8.0 (m, 3 H), 7.9-7.8 (m, 3 H), 5.3 (m, 2 H), 4.1-4.0 (m, 2 H), 4.0 (m, 2 H), 3.9-3.8 (m 2 H), 3.7 (m, 6 H), 2.6 (m, 2 H), 2.4-2.1 (m, 6 H), 1.3- 1.1 (m, 2 H), 0.7-0.6 (m, 3 H), 0.6-0.5 (m, 3 H), 0.4 (m, 2 H). 776 Methyl {(1R)-1- cyclopropyl-2-[(2S)-2-{5- [4-(5-{2-[(2S)-1-{(2R)-2- cyclopropyl-2- [(methoxycarbonyl) amino]acetyl} pyrrolidin- 2-yl]-1H-imidazol-5-yl}- 1,3-benzoxazol-2- yl)phenyl]-1H-imidazol- 2-yl}pyrrolidin-1-yl]-2- oxoethyl}carbamate
Examples 216-227
Compounds of Examples 216-227 were prepared in a similar manner as described in Example 189b (Alternative Procedure).
Example Structure M + 1 Name
216
Figure US11053243-20210706-C00561
 		875 dimethyl (indolo[1,2- c][1,3]benzoxazine-3,10-diylbis{1H- imidazole-5,2-diyl(2S)pyrrolidine- 2,1-diyl[(1R)-2-oxo-1-phenylethane- 2,1-diyl]})biscarbamate
217
Figure US11053243-20210706-C00562
 		821 methyl [(2S)-1-{(2S)-2-[5-(11-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-6,7- dihydroindolo[1,2-d][1,4] benzoxazepin-3-yl)-1H-imidazol-2- yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
218
Figure US11053243-20210706-C00563
 		835 methyl [(2S)-1-{(2S)-2-[5-(3-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-6,6- dimethylindolo[1,2-c][1,3] benzoxazin-10-yl)-1H-imidazol-2- yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
219
Figure US11053243-20210706-C00564
 		839 methyl [(2S)-1-{(2S)-2-[5-(12-fluoro- 10-{2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- [(methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}-6-methylindolo[1,2- c][1,2]benzoxazin-3-yl)-1H-imidazol- 2-yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
220
Figure US11053243-20210706-C00565
 		804 methyl [(2S)-1-{(2S)-2-[5-(3-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}indolo[1,2- c]quinazolin-10-yl)-1H-imidazol-2- yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
221
Figure US11053243-20210706-C00566
 		835 methyl [(2S)-1-{(2S)-2-[5-(12-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-7,8-dihydro- 6H-indolo[1,2-e][1,5]benzoxazocin- 3-yl)-1H-imidazol-2-yl]pyrrolidin-1- yl}-3-methyl-1-oxobutan-2- yl]carbamate
222
Figure US11053243-20210706-C00567
 		820 methyl [(2S)-1-{(2S)-2-[5-(3-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-6-oxo-5,6- dihydroindolo[1,2-c]quinazolin-10- yl)-1H-imidazol-2-yl]pyrrolidin-1- yl}-3-methyl-1-oxobutan-2- yl]carbamate
223
Figure US11053243-20210706-C00568
 		883 methyl [(2S)-1-{(2S)-2-[5-(10-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-6- phenylindolo[1,2-c][1,3]benzoxazin- 3-yl)-1H-imidazol-2-yl]pyrrolidin-1- yl}-3-methyl-1-oxobutan-2- yl]carbamate
224
Figure US11053243-20210706-C00569
 		818 methyl [(2S)-1-{(2S)-2-[5-(3-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}-6- methylindolo[1,2-c]quinazolin-10- yl)-1H-imidazol-2-yl]pyrrolidin-1- yl}-3-methyl-1-oxobutan-2- yl]carbamate
225
Figure US11053243-20210706-C00570
 		875.1 methyl [(2S)-1-{(2S)-2-[5-(10′-{2- [(2S)-1-{(2S)-2-[(methoxycarbonyl) amino]-3-methylbutanoyl}pyrrolidin- 2-yl]-1H-imidazol-5-yl}spiro [cyclohexane-1,6′-indolo[1,2- c][1,3]benzoxazin]-3′-yl)-1H- imidazol-2-yl]pyrrolidin-1-yl}-3- methyl-1-oxobutan-2-yl]carbamate
226
Figure US11053243-20210706-C00571
 		842 methyl [(2S)-1-{(2S)-2-[5-(1,12- difluoro-10-{2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}indolo[1,2- c][1,3]benzoxazin-3-yl)-1H-imidazol- 2-yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
227
Figure US11053243-20210706-C00572
 		832 methyl [(2S)-1-{(2S)-2-[5-(12-cyano- 10-{2-[(2S)-1-{(2S)-2- [(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-1H- imidazol-5-yl}indolo[1,2- c][1,3]benzoxazin-3-yl)-1H-imidazol- 2-yl]pyrrolidin-1-yl}-3-methyl-1- oxobutan-2-yl]carbamate
Example 228 Measuring Compound Inhibitory Potency
Measurement of inhibition by compounds was performed using the HCV replicon system. Several different replicons encoding different HCV genotypes or mutations were used. In addition, potency measurements were made using different formats of the replicon assay, including different ways of measurements and different plating formats. See Jan M. Vrolijk et al., A replicons-based bioassay for the measurement of interferons in patients with chronic hepatitis C, 110 J. VIROLOGICAL METHODS 201 (2003); Steven S. Carroll et al., Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs, 278(14) J. BIOLOGICAL CHEMISTRY 11979 (2003). However, the underlying principles are common to all of these determinations, and are outlined below.
Stable neomycin phosphotransferase encoding replicon-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. In some cases, the cell lines encoded a luciferase:Neor fusion and could be assayed either directly by determination of RNA copy number, or indirectly through measurement of the luciferase activity.
To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate format for manual operation, or a 384-well plate in an automated assay. Replicon cells and compound were incubated for 24 to 72 hours. At the end of the assay, cells are washed free of media and compound and then lysed. Luciferase activity was measured using a conventional luciferase assay. EC50 determinations were calculated as a percent of a DMSO control by fitting the data to a four parameter fit function.
The activity table below provides representative data illustrating observed activity against genotype 1b.
Activity Table
Example EC50 (nM)
 2 9
 6 200
 14 10
 15 0.045
 19 25
 26 0.063
 30 26
 39 0.24
 40 0.026
 41 0.05
 42 14
 45 0.02
 49 0.072
 58 0.97
 60 0.13
 62 0.067
 72 0.17
 94 0.006
 95 0.01
 96 0.015
 99 0.038
100 0.031
101 0.5
102 8.3
103 5.7
105 0.08
107 0.04
116 0.065
119 0.013
125 0.016
129 0.7
130 0.05
131 17
137 0.009
138 8.5
144 0.036
155 0.9
158 0.5
159 0.002
169 0.004
178 317
186 0.015
189a 0.15
189b 0.001
190 0.067
191 0.02
192 0.002
193 0.05
203 0.004
213 0.009
It will be appreciated that various of the above-discussed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. It will also be appreciated that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein, also intended to be encompassed by the following claims, may be subsequently made by those skilled in the art.

Claims (12)

What is claimed is:
1. A compound having structural formula (I):
Figure US11053243-20210706-C00573
and/or a pharmaceutically acceptable salt thereof, wherein:
Figure US11053243-20210706-C00574
is chosen from the group consisting of 9-membered bicyclic aryl ring systems that contain from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and that are substituted on C or N atoms by u substituents R1,
each R1 is independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —(CH2)0-6C(O)R3, —CO2R3a, —C(O)N(R3a)2, —SR3a, —S(O)R3a, —S(O2)R3a, —(CH2)0-6N(R3a)2, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)R3, —N(R3a)COR3a, —N(R3a)C(O)N(R3a), C1-6alkyl, C3-8carbocycle containing from 0 to 3 heteroatoms chosen from N, O and S, and phenyl, and the C1-6alkyl, C3-8carbocycle and phenyl are substituted by from 0 to 3 substitutents independently chosen from the group consisting of hydrogen, halogen, —OR3a, —CN, —CO2R3a, —C(O)N(R3a)2, —N(R3a)2, —N(R3a)CO2R3a, —SR3a, —S(O)R3a, —S(O2)R3a, —N(R3a)SO2R3a, —N(R3a)CO2R3a, —N(R3a)C(O)N(R3a), C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, and C3-8cycloalkyl,
u is from 0 to 4,
each R3 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —OH, —O—C1-6alkyl and C3-8cycloalkyl, and
each R3a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
Figure US11053243-20210706-C00575
is a group chosen from 8- to 10-membered bicyclic ring systems, containing from 0 to 4 heteroatoms independently chosen from the group consisting of N, O and S, and substituted on C or N atoms by v substituents R2,
each R2 is independently chosen from the group consisting of hydrogen, halogen, —OR4a, —CN, —CO2R4a, —C(O)R4a, —C(O)N(R4a)2, —N(R4a)2, —N(R4a)COR4, —N(R4a)CO2R4a, —N(R4a)C(O)N(R4a), —N(R4a)SO2R4a, —SR4a, —S(O)R4a, —S(O2)R4a, C1-6alkyl substituted by from 0 to 4 R4 and C3-8cycloalkyl substituted by from 0 to 4 R4,
v is from 0 to 4,
each R4 is independently chosen from the group consisting of hydrogen, —OH, C1-6alkyl and C3-8cycloalkyl;
each R4a is independently chosen from the group consisting of hydrogen, C1-6alkyl and C3-8cycloalkyl;
such that said
Figure US11053243-20210706-C00576
and said
Figure US11053243-20210706-C00577
are taken together with one said substituent R1 and one said substituent R2 to form a 5- to 9-membered carbocyclic ring system represented by a group chosen from the group consisting of:
Figure US11053243-20210706-C00578
where
W is chosen from the group consisting of —(CH2)1-3—, —(CH2)0-2NH(CH2)0-2—, —(CH2)0-2N(C1-6alkyl)(CH2)0-2—, —(CH2)0-2O(CH2)0-2— and —(CH2)0-2C(O)(CH2)0-2—, where W is substituted by from 0 to 4 Rw, where each Rw is independently selected from C1-6alkyl and C3-8cycloalkyl;
each D is a group independently chosen from the group consisting of:
a single bond, or —N(R5)C(O)—
each R5 is hydrogen, and C1-6alkyl and
each E is a group independently chosen from the group consisting of:
a single bond, or
(c) a pyrrolidinyl derivative chosen from the group consisting of:
Figure US11053243-20210706-C00579
I is a bivalent group chosen from —C(O)—, and —CO2—,
each R8a is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8a may be taken together to form oxo,
each R8b is independently chosen from the group consisting of hydrogen, halogen, —OH, —OC1-6alkyl and C1-6alkyl, or two R8b may be taken together to form oxo,
each R8c is independently chosen from the group consisting of hydrogen and C1-6alkyl,
or any two groups selected from R8a, R8b and R8c may be taken together to form a spiro-bicyclic or bridged bicyclic ring;
each R9 is independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl, —S—C1-6alkyl, —NH—C1-6alkyl and —NHC(O)—C1-6alkyl,
each R7 is independently chosen from the group consisting of hydrogen, C1-6alkyl and phenyl, and the C1-6alkyl and phenyl are substituted by from 0 to 3 substituents independently chosen from the group consisting of hydrogen, halogen, C1-6alkyl, —O—C1-6alkyl and —S—C1-6alkyl; and
each G is independently chosen from the group consisting of:
hydrogen, and C1-6alkyl having 0 to 4 substituents R11,
each R11 is independently chosen from the group consisting of:
—N(R10)2,
(o) aryl ring systems G′ chosen from the group consisting of:
5- to 7-membered monocyclic ring systems and;
each R10 is independently chosen from the group consisting of
hydrogen,
C1-6alkyl,
—C(O)R14,
—CO2R14, and
3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S,
each R14 is independently chosen from the group consisting of hydrogen, C1-6alkyl, —(CH2)0-3C3-8cycloalkyl and phenyl.
2. The compound according to claim 1, wherein W is chosen from the group consisting of —CH2—, —NH—, —N(C1-6alkyl)-, —C(O)—, —CH2NH—, —CH2N(C1-6alkyl)-, —CH2CH2—, —C(O)CH2—, —CH2C(O)—, —CH2O—, —CH2CH2CH2—, —C(O)CH2CH2—, —CH2C(O)CH2—, —CH2OCH2—, —CH2CH2C(O)—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2N(C1-6alkyl)-, —CH2NHCH2—, —CH2N(C1-6alkyl)CH2—, —NHCH2CH2—, and —N(C1-6alkyl)CH2CH2—.
3. The compound according to claim 1, wherein each E is
Figure US11053243-20210706-C00580
4. The compound according to claim 1, wherein each G is independently chosen from the group consisting of:
(a) C1-6alkyl having 0 to 4 substituents R11,
(b) 3- to 8-membered carbocycles containing from 0 to 3 heteroatoms independently chosen from the group consisting of N, O and S, and having from 0 to 3 substitutents R10 on N or C atoms; and
(c) aryl ring systems G′ chosen from the group consisting of:
(i) 5- to 7-membered monocyclic ring systems.
5. The compound according to claim 1, wherein each G is independently chosen from the group consisting of
hydrogen, or
(c) C1-5alkyl having 1 to 3 substituents R11.
6. The compound according to claim 5, wherein each G is independently chosen from the group consisting of C1-4alkyl having 1 to 2 substituents R11, wherein each R11 is independently chosen from the group consisting of —NH2, —NCH3H, —N(CH3)2, and phenyl.
7. The compound according to claim 1, wherein
W is chosen from the group consisting of —(CH2)1-3—, —(CH2)0-2NH(CH2)0-2—, —(CH2)0-2N(C1-6alkyl)(CH2)0-2—, —(CH2)0-2O(CH2)0-2— and —(CH2)0-2C(O)(CH2)0-2—, where W is substituted by from 0 to 4 Rw, where each Rw is independently selected from C1-6alkyl and C3-8cycloalkyl; and
each R1 is hydrogen, or halogen,
wherein each D is independently chosen from the group consisting of a single bond, and —NR5C(O)—, where
R5 is hydrogen,
wherein each E is independently chosen from the group consisting of a single bond,
Figure US11053243-20210706-C00581
where one of R8a and R8b is —OH or fluorine;
wherein each G is independently chosen from the group consisting of hydrogen or C1-5 alkyl.
8. A pharmaceutical composition comprising an effective amount of the compound according to claim 1, and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition according to claim 8, further comprising a second therapeutic agent selected from the group consisting of HCV antiviral agents, immunomodulators, and anti-infective agents.
10. The pharmaceutical composition according to claim 9, wherein said second therapeutic agent is selected from the group consisting of HCV protease inhibitors and HCV NSSB polymerase inhibitors.
11. A method of treating a patient infected with HCV comprising the step of administering a compound according to claim 1, in an amount effective to infection by HCV in a subject in need thereof.
12. A method of treating a patient infected with HCV comprising the step of administering a compound according to claim 1, in an amount effective to inhibit HCV viral replication and/or viral production.
US16/829,878 2009-03-27 2020-03-25 Inhibitors of hepatitis C virus replication Active US11053243B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/829,878 US11053243B2 (en) 2009-03-27 2020-03-25 Inhibitors of hepatitis C virus replication
US17/324,799 US20220356182A1 (en) 2009-03-27 2021-05-19 Inhibitors of hepatitis c virus replication

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US16395809P 2009-03-27 2009-03-27
US24731809P 2009-09-30 2009-09-30
PCT/US2010/028653 WO2010111483A1 (en) 2009-03-27 2010-03-25 Inhibitors of hepatitis c virus replication
US201113260684A 2011-12-19 2011-12-19
US14/473,117 US9090661B2 (en) 2009-03-27 2014-08-29 Inhibitors of hepatitis C virus replication
US14/711,345 US20150246917A1 (en) 2009-03-27 2015-05-13 Inhibitors of hepatitis c virus replication
US15/272,669 US20170008906A1 (en) 2009-03-27 2016-09-22 Inhibitors of hepatitis c virus replication
US15/800,172 US20190127365A1 (en) 2017-11-01 2017-11-01 Inhibitors of hepatitis c virus replication
US16/829,878 US11053243B2 (en) 2009-03-27 2020-03-25 Inhibitors of hepatitis C virus replication

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/800,172 Continuation US20190127365A1 (en) 2009-03-27 2017-11-01 Inhibitors of hepatitis c virus replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/324,799 Continuation US20220356182A1 (en) 2009-03-27 2021-05-19 Inhibitors of hepatitis c virus replication

Publications (2)

Publication Number Publication Date
US20200262836A1 US20200262836A1 (en) 2020-08-20
US11053243B2 true US11053243B2 (en) 2021-07-06

Family

ID=66245222

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/800,172 Abandoned US20190127365A1 (en) 2009-03-27 2017-11-01 Inhibitors of hepatitis c virus replication
US16/829,878 Active US11053243B2 (en) 2009-03-27 2020-03-25 Inhibitors of hepatitis C virus replication

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/800,172 Abandoned US20190127365A1 (en) 2009-03-27 2017-11-01 Inhibitors of hepatitis c virus replication

Country Status (1)

Country Link
US (2) US20190127365A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066335T2 (en) 2018-10-05 2024-07-28 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101591A (en) 1996-09-27 1998-04-21 Eisai Co Ltd Preventing and therapeutic agent for viral infectious disease
WO2003010140A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
US20060019974A1 (en) 2000-09-20 2006-01-26 Werner Mederski 4-Amino-quinazolines
EP1719773A1 (en) 2004-02-24 2006-11-08 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US20060258682A1 (en) 2005-05-16 2006-11-16 Yun Liao Benzofuran compounds
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2007009120A2 (en) 2005-07-14 2007-01-18 Irm Llc Heterotetracyclic compounds as tpo mimetics
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20070110708A1 (en) 2003-07-10 2007-05-17 Miller David J Silicon compounds and their use
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US20070185175A1 (en) 2005-08-01 2007-08-09 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US20080299075A1 (en) 2006-08-11 2008-12-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN101336248A (en) 2005-12-16 2008-12-31 国家健康医学研究所 Novel compounds which interact with PEA-15
US20090004111A1 (en) 2005-02-28 2009-01-01 The Rockefeller University Structure of the Hepatitis C Ns5a Protein
US20090042860A1 (en) 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
WO2009102325A1 (en) 2008-02-13 2009-08-20 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US7662809B2 (en) 2004-10-26 2010-02-16 Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2010041687A1 (en) 2008-10-09 2010-04-15 コニカミノルタホールディングス株式会社 Organic photoelectric conversion element, solar cell, and optical sensor array
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010111483A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US20100316607A1 (en) 2009-06-16 2010-12-16 Yat Sun Or Hepatitis c virus inhibitors
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
US20110130361A1 (en) 2007-08-09 2011-06-02 Jonathan Grimm Silicon derivatives as histone deacetylase inhibitors
US7973040B2 (en) 2008-07-22 2011-07-05 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
US20110224211A1 (en) 2008-11-28 2011-09-15 Frank Ulrich Schmitz Anti-Viral Compounds, Compositions, And Methods Of Use
US20110223134A1 (en) 2010-03-09 2011-09-15 Anilkumar Gopinadhan Nair Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US20120040962A1 (en) 2009-03-27 2012-02-16 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
US20120083448A1 (en) 2009-03-27 2012-04-05 Van Andel Research Institute Parathyroid Hormone Peptides And Parathyroid Hormone-Related Protein Peptides And Methods Of Use
WO2012041014A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012050850A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US20130164258A1 (en) 2009-05-29 2013-06-27 Kevin X. Chen Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C
US20140170111A1 (en) 2010-09-29 2014-06-19 Merck Sharp & Dohmn Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US20140199264A1 (en) 2011-03-17 2014-07-17 Craig A. Coburn Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10101591A (en) 1996-09-27 1998-04-21 Eisai Co Ltd Preventing and therapeutic agent for viral infectious disease
US20060019974A1 (en) 2000-09-20 2006-01-26 Werner Mederski 4-Amino-quinazolines
WO2003010140A2 (en) 2001-07-25 2003-02-06 Boehringer Ingelheim (Canada) Ltd. Hepatitis c virus polymerase inhibitors with heterobicyclic structure
US20070110708A1 (en) 2003-07-10 2007-05-17 Miller David J Silicon compounds and their use
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
EP1719773A1 (en) 2004-02-24 2006-11-08 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7662809B2 (en) 2004-10-26 2010-02-16 Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US20090004111A1 (en) 2005-02-28 2009-01-01 The Rockefeller University Structure of the Hepatitis C Ns5a Protein
US20060258682A1 (en) 2005-05-16 2006-11-16 Yun Liao Benzofuran compounds
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2007009120A2 (en) 2005-07-14 2007-01-18 Irm Llc Heterotetracyclic compounds as tpo mimetics
US20070185175A1 (en) 2005-08-01 2007-08-09 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CN101336248A (en) 2005-12-16 2008-12-31 国家健康医学研究所 Novel compounds which interact with PEA-15
US20080299075A1 (en) 2006-08-11 2008-12-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20090042860A1 (en) 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20110130361A1 (en) 2007-08-09 2011-06-02 Jonathan Grimm Silicon derivatives as histone deacetylase inhibitors
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
WO2009102325A1 (en) 2008-02-13 2009-08-20 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US8080654B2 (en) 2008-07-22 2011-12-20 Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
US7973040B2 (en) 2008-07-22 2011-07-05 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
WO2010041687A1 (en) 2008-10-09 2010-04-15 コニカミノルタホールディングス株式会社 Organic photoelectric conversion element, solar cell, and optical sensor array
US20110224211A1 (en) 2008-11-28 2011-09-15 Frank Ulrich Schmitz Anti-Viral Compounds, Compositions, And Methods Of Use
WO2010065674A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010111483A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US8871759B2 (en) 2009-03-27 2014-10-28 Merck Sharp & Dohme Corp. Inhibitors of hepatitis C virus replication
US20120040962A1 (en) 2009-03-27 2012-02-16 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
US20120083448A1 (en) 2009-03-27 2012-04-05 Van Andel Research Institute Parathyroid Hormone Peptides And Parathyroid Hormone-Related Protein Peptides And Methods Of Use
US9090661B2 (en) 2009-03-27 2015-07-28 Merck Sharp & Dohme Corp. Inhibitors of hepatitis C virus replication
US20130164258A1 (en) 2009-05-29 2013-06-27 Kevin X. Chen Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C
US20100316607A1 (en) 2009-06-16 2010-12-16 Yat Sun Or Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US20110223134A1 (en) 2010-03-09 2011-09-15 Anilkumar Gopinadhan Nair Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012041014A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
US20140170111A1 (en) 2010-09-29 2014-06-19 Merck Sharp & Dohmn Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US20130280214A1 (en) 2010-09-29 2013-10-24 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012050850A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
US20140199264A1 (en) 2011-03-17 2014-07-17 Craig A. Coburn Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Alper, P.B., et al., "Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the trombopioetin (Tpo) receptor", Bioorganic and Medicinal Chem. Lett., 2008, vol. 18, pp. 5255-5258.
Caplus Accession No. 1980:471599.
Caplus Accession No. 2009:295362 (JP2009-054809).
CAR RN 1025830-17-4, STN Entry, Jun. 5, 2008.
CN1474815—English Abstract—Corresponding to US Application No. US2006/0019974.
Marsilje, T.H., et al., "Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold", Bioorganic and Medicinal Chem. Lett., 2008, vol. 18, pp. 5255-5258.
U.S. Appl. No. 13/260,684, filed Dec. 19, 2011.
U.S. Appl. No. 14/473,117, filed Aug. 29, 2014.
U.S. Appl. No. 14/711,345, filed May 13, 2015.
U.S. Appl. No. 15/272,699, filed Sep. 22, 2016.
U.S. Appl. No. 15/800,172, filed Nov. 1, 2017.
Wilson, et al., "Tunable DNA Photocleavage by an Acridine-Imidazole Conjugate", Inorganic Chemistry, 2005, vol. 44, No. 18, pp. 6159-6173.

Also Published As

Publication number Publication date
US20190127365A1 (en) 2019-05-02
US20200262836A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US9090661B2 (en) Inhibitors of hepatitis C virus replication
EP1718608B1 (en) Viral polymerase inhibitors
MX2011010113A (en) Method for preparing cha-type molecular sieves using novel structure directing agents.
JP2012510525A (en) Inhibitor of HCVNS5A
US11053243B2 (en) Inhibitors of hepatitis C virus replication
US20220356182A1 (en) Inhibitors of hepatitis c virus replication
AU2014200550A1 (en) Inhibitors of hepatitis C virus replication
AU2012202711A1 (en) Viral polymerase inhibitors

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: MERCK SHARP & DOHME CORP, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COBURN, CRAIG A.;LUDMERER, STEVEN W.;LIU, KUN;SIGNING DATES FROM 20110607 TO 20110714;REEL/FRAME:053160/0742

Owner name: MERCK SHARP & DOHME CORP, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WUXI APPTEC (SHANGHAI) CO., LTD.;REEL/FRAME:053160/0985

Effective date: 20110609

Owner name: WUXI APPTEC (SHANGHAI) CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, HAO;SOLL, RICHARD;ZHONG, BIN;AND OTHERS;REEL/FRAME:053161/0537

Effective date: 20170425

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: MERCK SHARP & DOHME LLC, NEW JERSEY

Free format text: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:061102/0145

Effective date: 20220407